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Abstract 
Enzymes have been the subject of numerous studies and have been extensively used to catalyse 
difficult chemical reactions. By extension, artificial metalloenzymes that bridge the gap between 
organometallic catalysis and enzymatic catalysis are attracting increasing attention in the scientific 
community due to their optimization potential by chemical and genetic methods. The active site of 
such artificial systems are based on the versatility of organometallic complexes, whereas the 
molecular scaffold, that provides the enantioselectivity as in natural enzymes, generates the 
second coordination sphere. The first part of this thesis presents new artificial metallohydrolases 
incorporating Ce(IV) as the active catalyst. The interest in this new class is motivated by the 
possibility to create new highly selective artificial nucleases for novel biomedical applications. The 
use of chiral substrates mimicking DNA or RNA coupled with colorimetric assay techniques allows 
developing high throughput screening methods to identify novel active and selective artificial 
metalloenzymes. The knowledge acquired by the creation of novel artificial hydrolases allows 
transposing the technology to a new class of artificial metalloenzymes such transfer 
hydrogenases. The second part of this thesis presents the incorporation of catalytically active 
biotinylated complexes within streptavidin, creating artificial metalloenzymes for the transfer 
hydrogenation of prochiral ketones. The optimization of the second coordination sphere, based on 
a crystal structure of the active hybrid catalyst and successive rounds of saturation mutagenesis at 
selected positions termed “designed evolution”, afforded highly active and selective catalysts for 
the reduction of challenging ketone substrates. The well-defined active site of the hybrid catalysts 
can be redesigned for the reduction of novel substrates such as imines to create the first example 
of an artificial imine reductase.  
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Résumé 
Les enzymes sont d’excellents catalyseurs qui ont fait l’objet de nombreuses études et qui ont été 
extensivement utilisées dans l’accélération de réactions chimiques difficiles. Par extension, les 
métalloenzymes artificielles qui tirent avantage de la catalyse organométallique et enzymatique 
attirent de plus en plus l’attention de la communauté scientifique de par leur excellent potentiel 
d’optimisation donné par leur diversité chimique et biologique. Le site actif de ces systèmes 
artificiels est basé sur la versatilité du complexe organométallique alors que l’échafaudage 
moléculaire fournit l’énantioselectivité à travers la seconde sphère de coordination, comme chez 
les enzymes naturelles. La première partie de la thèse présente de nouvelles hydrolases artificielle 
incorporant un Ce(IV) comme catalyseur actif. L’usage de substrat chiraux imitant l’ADN ou l’ARN 
couplé à des techniques d’analyse colorimétriques permet de développer des méthodes de 
criblage à haut débit pour identifier des nouvelles métallohydrolases artificielles actives et 
sélectives. Les connaissances accumulées par la création de nouvelles hydrolases artificielles 
permettent de transposer la technologie à une nouvelle classe de métalloenzymes artificielles 
telles que les transferts hydrogénases. La deuxième partie de la thèse présente l’incorporation de 
complexes biotinylés actifs au sein de la streptavidine engendrant une métalloenzyme artificielle 
pour le transfert hydrogénant de cétones prochirales. L’optimisation de la seconde sphère de 
coordination basée sur la structure cristalline du catalyseur hybride actif et des cycles de 
mutagénèse par saturation à des positions sélectionnées permet le design d’un protocole 
d’évolution pour générer des catalyseurs hautement actifs et sélectifs pour la réduction de 
substrats difficiles. Le site actif bien défini du catalyseur hybride peut être ré-optimisé pour la 
réduction de nouveaux substrats tels que les imines. Ceci permet d’obtenir le premier exemple 
d’une imine réductase artificielle. 
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«Douter de tout ou tout croire sont deux solutions également commodes, qui l’une et l’autre nous 
dispensent de réfléchir » 
 
            Henri Pointcarré 
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Chapter 1: Introduction 
1. General introduction to catalysis[1] 
Catalysis stems from the Greek meaning, “down and loosen”. Barzelius coined the term catalysis 
in 1836, proposing that beside the “affinity force”, a new force is operative that he termed the 
“catalytic force”. At that time, affinity was known as a driving force but there was no understanding 
at the molecular level of reaction rates. However, catalysis has already been exploited thousands 
years before in the fermentation process. In the Middle Ages, sulfuric acid was produced by 
burning sulfur with nitric acid in humid air without knowing that nitric acid catalyzed the reaction. At 
the end of the eighteenth century, the decomposition of several substances by metal oxides was 
described by different scientists. In 1834, Faraday proposed that reactants have to absorb 
simultaneously on the surface of a compound to react but didn’t give further explanations. Finally 
Ostwald proposed that a catalyst does not influence the thermodynamic equilibrium of reactants 
and products but affects the rate of chemical reactions. Ostwald won the Nobel Prize in chemistry 
in 1909 for his work. 
A catalyst is an entity, which is able to accelerate a chemical reaction by decreasing the energy of 
its transition state. The catalyst is not chemically changed at the end of the reaction and can be 
recovered and reused for other cycles. Catalysis plays a major role in many chemical processes 
such as plastic production, organic synthesis of fine chemicals, medicine applications, energy 
production or environmental protection. Some famous catalytic processes were described and 
used extensively in industry such as: 
- The Haber-Bosch chemical process that transforms nitrogen into ammonia[2] using iron oxide as 
a catalyst. Fritz Haber received the Nobel Prize in chemistry in 1918 and Carl Bosch in 1931 for 
the discovery of this process and its optimization. 
Introduction 
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- The Fisher-Tropsch chemical process that transforms carbon monoxide and hydrogen into 
hydrocarbons using iron or cobalt as catalyst.[3] 
- The three way catalyst used to purify car exhausts by oxydoreduction reactions using a so-called 
catalytic converter containing platinum metals as catalysts.[4] 
Catalysis has been a major research area for decades and major efforts have been invested in this 
context to understand the molecular mechanism of such reactions. The Nobel Prize in chemistry 
was awarded to Noyori, Sharpless and Knowles in 2001, to Chauvin, Grubbs and Schrock in 2005 
and to Heck, Negishi and Suzuki in 2010 for their research on catalytic systems, thus 
demonstrating that the field is still of great importance in chemistry and able to generate major 
discoveries used to solve scientific current problems. 
1.2 Catalyst performances[5] 
Catalysts participate in chemical reactions by changing the kinetics, while the overall 
thermodynamics are the same. The following factors can explain the effect of a catalyst on the 
reaction: 
1) Stabilization of the transition state 
2) Decrease of the entropy of the reactants by interactions that force their proximity and by 
favorable spatial orientation 
3) Selective enhancement of one specific pathway over the competing undesired ones. 
Different types of catalysts are presented in literature: homogeneous catalysts, heterogeneous 
catalysts and enzymatic catalysts. 
1.2.1 Enzymes[5] 
Enzymes are a class of macromolecules (see figure 1) that bind small molecules and affect 
reactions (see figure 1). In an enzymatic reaction, a complex between the substrate and the 
Introduction 
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enzyme is formed [ES], this [ES] complex passes through a transition state (ΔG≠cat, figure 2) and 
converts to the enzyme product complex [EP] and finally to the free enzyme and free product. 
From the formulation of the reaction sequence, a rate law can be derived. In enzyme catalysis the 
first rate law that described the process was Michaelis and Menten’s law in 1913; the 
corresponding mechanism is therefore named the Michaelis-Menten mechanism. 
 
 
 
 
 
 
Figure 1 Reaction sequence 
 
Enzyme Kinetics from binding and catalysis: 
 
 
In the first step, the enzyme (E) and the substrate (S) associate in a rapid and reversible 
equilibrium to obtain an enzyme-substrate complex (ES) with a dissociation constant called Ks. A 
reaction occurs in the second step to obtain the product with a rate constant k2. 
Substrate
Enzyme = [E] Enzyme + substrate = [ES] Enzyme + products = [EP] Enzyme = [E]
Products
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Figure 2 Free enthalpy reaction coordinate diagram for an enzyme reaction. 
 
Other intermediates can take place in this reaction to form for example an enzyme-product 
complex. An apparent dissociation constant can be defined called KM that represents the overall 
dissociation constant of all the enzyme-bound species. In the Michaelis-Menten equation, only an 
ES complex is involved and the binding step is considered to be fast therefore k2 is assimilated as 
kcat (the overall catalytic rate) and in this situation KM = KS. (See equation 1) 
 
(Equation 1) 
             
The activity of the enzyme is determined by the value of kcat (moles of converted substrate per 
mole of catalyst per unit of time). kcat/KM is called the catalytic efficiency and describes the 
specificity of the enzyme for competing substrates and thus its general synthetic utility. Both high 
activity and low product inhibition must be optimised for applications in catalytic processes. Finally, 
two important parameters for a catalyst is the turnover over number (TON) which is the number of 
Enzyme + Substrate 
Uncatalyzed transition state
Enzyme + Product
ΔG≠uncatΔG≠cat
Reaction coordinate
En
er
gy
Catalysed transition state
ΔΔG≠
ΔΔG≠ = ΔGuncat≠  - ΔG≠cat
ΔG≠cat= free enthalpy of  activation 
of catalyzed reaction
ΔG≠uncat= free enthalpy of  activation 
of uncatalyzed reaction
ΔGr
ΔGr= free enthalpy of reaction
  
! 
v (initial reaction rate) =
E[ ]
0
S[ ]kcat
KM + S[ ]
E + S ES E + P
KM kcat
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moles of product per mole of catalyst before its inactivation (representative of the product 
inhibition) and the turnover number frequency (TOF) that represents the number of moles of 
product per mole of catalyst per hour. Both parameters must be as high as possible to obtain a 
good catalyst. 
1.2.2 Homogeneous catalysis 
Homogeneous catalysis is a sequence of reactions that involves a catalyst in the same phase as 
the reactants. Most commonly, a homogeneous catalyst is dissolved in a solvent with the 
reactants. Homogeneous asymmetric catalysis refers to the introduction of an asymmetric center 
in the prochiral substrate after reaction with the asymmetric catalyst.[6] 
There are two types of homogeneous asymmetric catalysts: 
- organometallic catalysts 
- organocatalysts 
The first type has found most applications in enantioselective synthesis.[7] A complementary 
method, which has attracted renewed interest in recent years, is enantioselective organocatalysis, 
in which the reaction is mediated by a small chiral organic molecule.[8a] 
 
Homogeneous catalysis by transition metal complexes was extensively studied since the 1940’s. 
G. Wilkinson provided a major contribution to the field with alkene hydrogenation using rhodium-
based catalysts and this discovery had a major impact on the synthesis of organic compounds.[8b] 
Later on, Knowles[9] and Horner[10] modified Wilkinson’s catalyst for the asymmetric hydrogenation 
of prochiral enamines. An important contribution was introduced when Kagan and Dang described 
DIOP, a biphosphine ligand bearing the chirality within the carbon skeleton for the asymmetric 
hydrogenation of dehydroamino acids.[11] In addition, Knowles made a significant discovery with 
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the C2-symmetric chelating P*-stereogenic biphosphine DIPAMP employed with Rh(I) for the 
industrial production of L-DOPA involved in the treatment of Parkinson’s disease.[12] In the 1990’s, 
the next breakthrough was Ru(II)-BINAP introduced by Noyori for the asymmetric hydrogenation of 
prochiral olefins and keto groups to produce enantiomerically enriched compounds with excellent 
enantioselectivity.[13] Finally, K.B. Sharpless developed chiral catalysts for asymmetric oxidation 
reactions.[14] R. Noyori, W.S. Knowles and K.B. Sharpless received the Nobel Prize in 2001 for 
their work on enantioselective catalysis.[15] 
1.2.3 Heterogeneous catalysis 
Heterogeneous catalysis concerns catalysis where the phase of the catalyst differs from that of the 
reactants. Many different phases can be exploited such as solid, liquid, gas phases but also 
immiscible liquids. Most of the heterogeneous catalysts are solids and react with liquid or gases. 
The reactants diffuse to the catalyst surface and react with it through the formation of a chemical 
bond. After the reaction, the products desorb from the surface and diffuse away. Heterogeneous 
catalysis is involved in important industrial chemical processes and energy production and has 
earned Nobel prizes to Fritz Haber in 1918, Carl Bosch 1931, Irving Langmuir in 1932, and 
Gerhard Ertl in 2007 (and few others).[6] 
1.2.4 Artificial metalloenzymes 
In the past decades, enantiomerically pure compounds have been obtained using different 
approaches: homogeneous catalysis with transition metal catalysis, organocatalysis or 
biocatalysis.[16] In this context, each field has evolved separately but efforts have been made to 
bridge the gap between these three domains. Artificial metalloenzymes are becoming of interest as 
they take the best features from the mentioned fields of catalysis. They consist of a hybrid catalyst 
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in which a catalytically active transition metal complex is incorporated into a host 
biomacromolecule, typically a protein[17] or DNA.[18] 
 
It is widely assumed that the catalytic activity and selectivity of the transiton metal catalyst is 
almost exclusively controlled by the first coordination sphere provided by the chelating ligand. In 
contrast, enzymatic catalysis is known for its second coordination sphere interactions through 
hydrogen bonding or hydrophobic interactions. This provides a valuable contribution to activity and 
selectivity by complementing the transition state of the catalytic center.[19] Various approaches can 
be followed to create active and selective artificial metalloenzymes. One approach is the de novo 
design of such catalysts. It is based on the formation of a polypeptide not correlated to any natural 
protein. It would lead the possibility to obtain high activity and enantioselectivity from the start. One 
example of this system is the formation of alpha helical bundles used to mimic artificial heme 
proteins.[20] However the system suffers from poor knowledge of protein folding. 
 
In contrast to the de novo design, some other systems have been developed such as creating 
active sites in existing native biomolecular scaffolds, like proteins or DNA. It presents the 
advantage of thermodynamic stability and tolerance to mutagenesis of the biomolecule.[21] 
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Three key parameters for the formation of a highly efficient artificial metalloenzyme are: the 
transition metal containing cofactor, the biomolecular scaffold and the mode of attachment of the 
cofactor. The choice of the transition metal catalyst is guided by the desired catalytic activity. 
Futhermore, this activity must be orthogonal to the catalytic activity of the scaffold itself. The 
catalyst must also be tolerant to water as enzymes are active in water.[19, 22] 
 
Chemical properties of the scaffold such as pH tolerance, temperature stability and resistance to 
organic solvents are crucial to obtain a robust artificial metalloenzyme. Furthermore, it is important 
to choose between an existing active site or a new active site created in the protein. The existing 
active site presents the advantage of being well defined and therefore can be re-engineered to 
optimize the performances of the catalytic system. The best example of such an artificial enzyme 
is the pioneer work of Wilson and Whitesides.[23] Avidin was used as a proteic scaffold because of 
its strong affinity for biotin and therefore for the biotinylated catalyst. In its deep pocket, both 
catalyst and substrate can be accommodated and the reaction outcome is partially dictated by the 
second coordination sphere around the catalyst given by the protein. However the system is 
limited by the need of a cavity able to accomodate both the catalyst and the substrate. Many 
systems were obtained with such an approach and some of the best examples are Avidin[23], 
Streptavidin[22a], Bovine Serum Albumin (BSA)[24] and apo-myoglobin.[25] All of them achieved good 
to high enantioselectivity. Some other Scaffolds like papaïn[26], cutinase[27], carbonic anhydrase[28] 
and tHisf as well.[29] 
The alternative to active site redesign is to create a new active site in an existing biomolecular 
scaffold. The advantage of this approach is to extend the number of scaffolds that can be used. 
Some famous examples were given by the Roelfes-Feringa’s system[31] in which the active site is 
created near the DNA groove by binding a transition metal complex to DNA. In this situation the 
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second coordination sphere is provided by the DNA allowing production of one enantiomer of the 
product. 
 
Finally, a particular category of artificial metalloenzyme are proteins with a large vacant space e. g. 
the iron storage protein ferritin. The space allows the incorporation of metallic nanoparticles. In this 
context, the protein-encapsulated nanoparticles have been investigated for their catalytic 
properties. In this approach, the enantioselectivity is not necessarily important, as the hybrid 
system works more as a container or a reactor to grow nanoparticles of a certain size and shape 
that could be important for catalysis. Furthermore, the pores of the protein cage can be used to 
discriminate against substrates of different sizes.[32] 
1.2.5 Anchoring strategies 
In order to ensure the localization of the metal catalyst on the host scaffold, three strategies have 
been followed (see figure 3). The first is non-covalent and is based on anchoring through supra-
molecular interactions. The second approach relies on covalent anchoring. The supra-molecular 
approach is based on strong and highly specific non-covalent interactions between biopolymers 
and small molecules or possibly ligands/inhibitors to generate artificial enzymes.[17] The perfect 
example of such a system is the biotin-streptavidin technology.[33] The third anchoring strategy is 
closely related to supramolecular anchoring but involves dative bonds, which refers to coordination 
between the catalytic metal ion and functionalities presented by the scaffold. Artificial 
metalloenzyme based on Iron or Manganese corrole in serum albumin[34] or Cr(III) Schiff base into 
apomyoglobin[25] are examples of this anchoring approach. These systems are used for 
enantioselective sulfoxidation and the metal-moiety presents the advantage of being precisely 
positioned in the scaffold. 
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a)               b)            c) 
 
 
Figure 3 Anchoring strategies:  supramolecular a) dative b) covalent c). M represents the 
catalytically active moiety. 
 
The last strategy that can be envisaged is covalent anchoring. This method is based on the 
seminal work of Kaiser[35] where a cystein was used as the anchoring site. It allows site-selective 
anchoring. The system presents the advantage of having a precisely localized complex in the 
scaffold but it suffers from evolution limitation involving chemical modifications and non-trivial 
purification steps. 
2. The biotin-streptavidin technology as a supramolecular anchoring strategy 
The choice of a supramolecular anchor is important to create new artificial metalloenzymes. In this 
context, supramolecular anchoring seems to be more promising than the other systems because it 
allows separate variations, which can be further combined to generate consequent diversity. In 
addition, no chemical modification is needed after the incorporation of the catalyst precursor, 
ensuring the integrity of the catalytic moiety. As described previously, a strong interaction is 
M MXS
a) c)b)
First coordination sphere Second coordination sphere
M
Introduction 
Chapter 1 
     
24 
needed between the catalytic moiety and the scaffold. In this respect the biotin-streptavidin couple 
is a robust system to create artificial metalloenzymes with a high affinity between biotin or the 
biotinylated catalyst and (strep)avidin.[36] 
2.1 Biotin-streptavidin affinity 
The affinity constant of biotin for streptavidin is one of the strongest non-covalent interactions 
known in nature (Ka= 1.7⋅1015 M-1 for avidin and Ka = 2.5⋅1013 M-1 for Sav).[37] Derivatized 
biotinylated conjugates have a strong affinity for the protein even if slightly lower than biotin.[38] 
2.2 Stability 
Streptavidin has an excellent stability in the range of several minutes at 110°C (tetramer with 4 eq. 
of biotin), and an extreme resistance to pH variations (the denaturation of streptavidin requires 6M 
guanidinium chloride at pH = 1.5). The tetramer containing biotin is also resistant to high 
concentrations of organic solvants like ethanol (at 50% concentration) and to the presence of 
surfactants such as sodium dodecyl sulfate (SDS).[39] 
2.3 Protein expression 
Avidin[40] and streptavidin[38a, 40-41] can both be produced as recombinant proteins with high yields 
(about 200 mg per liter of E.coli culture for streptavidin). In addition, the two expressed proteins 
are easy to purify by affinity chromatography with immobilized iminobiotin. 
2.4 Structural and functional informations 
The exceptional properties of avidin and streptavidin are the reason for the wide interest of the 
scientific community for these proteins. The biotin (strep)-avidin system has been the subject of 
numerous practical applications and is an interesting model system for studying the affinity of 
macromolecules for small ligands. Many avidin and streptavidin variants, some including biotin 
Introduction 
Chapter 1 
     
25 
inside the binding pocket have been crystallized. Knowledge of the three dimensional structure of 
both avidin and streptavidin allows the comparison of their binding features towards biotin in more 
detail. Both proteins fold in an eight-stranded antiparallel β-barrel and their quaternary structure is 
composed of four identical barrels. Futhermore, each subunit of the protein has a single biotin-
binding site (see figure 4). X-ray data has revealed that the residues responsible for the strong 
affinity are divided in two groups: the hydrophilic and the hydrophobic amino acids.[42] 
 
 
Figure 4 Streptavidin monomer (blue) binding biotin (ball and stick). Amino acids involved in biotin 
binding are displayed as sticks (Trp-120 not shown). PDB 1MK5. 
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2.5 Hydrophobic interactions of biotin⊂(strep)avidin 
In avidin the residues responsible for the hydrophobic interactions of the amino acids with biotin 
are Trp-70, Phe-72, Phe-79, and Trp-97 from one monomer and Trp-110 from the adjacent 
monomer. Whereas in streptavidin (see figure 4 and 5b), these amino acids are Trp-79, Trp-92, 
Trp-108 from one monomer and Trp-120 from the adjacent monomer.[42b, 42e] 
2.5 Hydrophilic interactions of biotin ⊂  (strep)avidin 
For avidin (see figure 5a), three amino acid residues are involved in hydrophilic interactions: Asn-
12, Ser-16 and Tyr-33. Each of them forms a hydrogen bond with the ureido oxygen of biotin. In 
addition, the ureido nitrogens of biotin are involved in hydrogen bond interactions with Thr-35 and 
Asn-118 while the sulfur of biotin interacts with Thr-77. The carboxylate of biotin forms five 
hydrogen bonds, with one oxygen of the carboxylate interacting with Ala-39, Thr-40 and Thr-38. 
The other oxygen is involved in hydrogen bonding with Ser-73 and Ser-75. The pattern of 
hydrogen bonding of biotin into streptavidin is similar to avidin. The oxygen of the ureido group is 
forming three hydrogen bonds with Asn-23, Ser-27 and Tyr-43. The ring nitrogen forms a hydrogen 
bond with Ser-45 and Asp-128. The biotin sulfur is interacting through a hydrogen bond with Thr-
90. Finally, the carboxylate oxygens of the biotin valeric acid moiety form two hydrogen bonds, one 
with Asn-49 and the other with Ser-88.[42b, 42e] 
2.6 Hydrogen bonding pattern in the loop L3,4 
In avidin (see figure 5a), the loop L3,4 is three amino acids longer than the corresponding loop in 
streptavidin (residues 36-44 in avidin and 45-50 in streptavidin). In the apoproteins, the loop L3,4 
in both avidin and streptavidin has an opened disordered conformation. When biotin is added to 
the apoprotein, the loop closes. The difference in length of the loop is the reason the hydrogen-
bonding network is different with the carboxylic part of biotin. It is also believed that the presence 
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of Phe-72 and three additional hydrogen bonds are the reason of the stronger binding affinity of 
biotin to avidin in comparison with Streptavidin.[7a, 43] 
 
a)  Avidin binding pocket with amino acids interactions around biotin 
 
 
 
 
 
 
 
 
 
b)  Streptavidin binding pocket with amino acids interactions around biotin 
 
 
 
 
 
 
 
 
 
Figure 5 First coordination sphere hydrogen bonding of biotin ⊂ avidin and biotin ⊂ streptavidin. 
3. Biological and chemical diversity 
The chemogenetic approach[44] of artificial metalloenzymes has the potential for providing hybrid 
catalysts “made to order”. The biological diversity is provided by the scaffold library based on 
proteins or DNA whereas the chemical diversity is provided by a catalyst library further anchored 
into the scaffold e. g. biotin-(strep)avidin system. Combination of the two libraries forms a hybrid 
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catalyst collection that can be screened for a specific reaction. The good one can be further 
improved for activity or selectivity. 
The optimization of artificial metalloenzymes developed with biotin-streptavidin technology in the 
Ward group relies on the so-called “designed evolution”.[45] (see figure 6). 
 
Designed evolution incorporates rational decisions on scaffolds the corresponding elements, 
followed by rounds of screening to improve those elements that cannot be predicted.[46, 47] 
 
The success of designed evolution protocols depends on two important decisions when applied to 
hybrid metalloenzymes. First, the appropriate homogeneous catalyst and second, the 2nd robust 
scaffold providing a well defined coordination sphere: e. g. avidin or streptavidin.[48] 
 
If a crystal structure of the hybrid catalyst is available, amino acid close to the metal center (less 
than 10 Ångströms) can be selected and mutated to identify variants yielding good conversion and 
enantioselectivities towards a given substrate.[49] In this sense, the crystal structure guides the 
screening to identify rapidly the best variants (see figure 6). 
In addition, all the results combined give an insight on the reaction mechanism and therefore allow 
the optimization of the second coordination sphere around the catalyst leading to genetic 
evolutionary approaches. (see figure 6) 
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Figure 6 Designed evolution of an artificial metalloenzyme for asymmetric catalysis based on the 
biotin-(strept)avidin technology. 
4. Enantioselectivity and chirality 
The term “chiral” is used to describe an object that is not superimposable on its mirror image (see 
figure 7). By extension, in chemistry, “chiral” describes a molecule that is not superimposable to its 
mirror image. Chirality is a property of matter that can be found in biological systems from small 
molecules such as carbohydrates, amino acids and lipids to the layout of the entire organism. 
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Since life is based on chiral molecules, understanding and creating enantioselective processes is 
one of the most fascinating areas in organic chemistry.[6] 
 
 
 
 
 
 
 
 
Figure 7 Pair of enantiomers of amino acids not superimposable on each other. 
 
Chiral compounds have gained attention in many domains such as the pharmaceutical industry, 
biochemicals, pesticides, aroma and flavour compounds, dyes and pigments, polymers, and liquid 
crystals and others (see figure 8). 
 
 
 
 
 
 
Figure 8 The two enantiomers of menthol display different tastes: the (+)-enantiomer has a sweet, 
fresh, minty, strong cooling effect taste while the (-)-enantiomer has a dusty, vegetable, less minty, 
less cooling taste. 
 
A 1:1 mixture of two enantiomeres of a chiral compound is called a racemic mixture. The ratio 
between both enantiomers can be quantified with spectroscopic (NMR), polarimetric or 
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chromatographic techniques where the excess of one enantiomer over the other is given by the 
enantiomeric excess, ee (see equation 3) 
 
       (equation 2) 
 
Different strategies can be exploited for the preparation of enantiopure compounds:[50] 
 
1) Chemical modification of “chiral pool” molecules such as natural enantiopure molecules (amino 
acids, sugars, alkaloids, terpenes). 
2) Resolution techniques (separation of diastereoisomers, enzymatic resolution). 
3) Dynamic kinetic resolution allowing the transformation of a racemic starting material into a 
single enantiomer. 
4.1 Enantioselectivity of homogeneous catalysts 
Many non-biological metals have been used in synthetic chemistry as homogeneous catalysts. 
One of the best example is given by Wilkinson’s catalyst [RhCl(PPh3)3] for the hydrogenation of 
olefins[8b] or the derived work of William S. Knowles for asymmetric hydrogenation.[9] 
Knowles’ discovery showed that transition metals could be placed within a chiral environment 
provided by enantiopure ligands to carry out asymmetric catalysis. 
 
Many examples of asymmetric metal-catalysis have been given since the seminal work of 
Knowles. Some of the best examples are Noyori’s Ru(II) Ts-DPEN derived complexes for the 
asymmetric transfer hydrogenation of ketones and imines[51] or Sharpless’s work on the 
asymmetric dihydroxylation of alkenes[52] and asymmetric epoxydation of allylic alcohols.[53] 
  
! 
ee =
R[ ] " S[ ]
R[ ] + S[ ]
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4.2 Enantioselectivity of enzymes 
In addition to enantioselective homogeneous catalysts, enzymes are a class of macromolecules 
that catalyse some of the most difficult biological reactions. A fundamental difference of enzymes 
compared to homogeneous catalysts is the presence of a well-defined second coordination sphere 
around the metal center providing improved efficiency and enantioselection. Furthermore, the 
presence of a narrow channel guides the substrate to the reaction center ensuring high 
enantioselectivity, which is particularly difficult to master in homogeneous catalysis (see figure 
9).[54] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Comparison of enzyme versus homogeneous catalysts 
 
A homogeneous catalyst can be modulated by changing the metal or the ligand in metal complex 
thus enhancing its performance. Enzymes can also be optimized with different techniques to 
improve their enantioselective properties. The approach is called in vitro evolution of 
enantioselective enzymes or “directed evolution”.[55] 
Chiral ligand 
scaffold
Metal
Active site
Protein scaffold
Selectivity channel
Enzyme Homogeneous catalyst
Substrate Substrate
Introduction 
Chapter 1 
     
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Directed evolution of an enantioselective enzyme 
 
Directed evolution comprises an appropriate combination of gene mutagenesis and expression 
coupled with an efficient high throughput screening (HTS) system for evaluating enantioselectivity 
(enantiomeric excess assay). Cycles of evolution processes are called “Darwinistic“ processes 
(see figure 10). The generation of a large library of different enzymes can be done by error-prone 
mutagenesis, saturation mutagenesis or DNA-shuffling. An example of such an evolution protocol 
was applied to a lipase where the catalytic properties were enhanced with such processes (see 
figure 11), allowing kinetic resolution of a chiral ester with an enantiodiscrimination factor higher 
than 51 (E value).[56] 
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Figure 11 Kinetic resolution of a racemic mixture of chiral esters with lipase-variants 
 
Notwithstanding recent progress in explaining the mechanism and selectivity of enzymes, It is 
difficult to routinely design or evolve enzymes that satisfy all requirements for a specific reaction. 
The challenge lies in the immenseness of biomolecular space, in the intrinsic constraints of 
biological molecules (such as a limited array of reactive groups) and in the added difficulty of 
controlling several characteristics simultaneously (for example, finding an enzyme with high 
thermal stability and high catalytic activity for the generation of an enantioenriched product).[57] 
These challenges are likely to slow the success of enzyme design and evolution. An alternative 
approach that can be exploited is the construction of hybrid catalysts obtained by the combination 
of a non biological catalyst entity and a biomolecular scaffold to generate an artificial 
metalloenzyme.[57] 
4.3 Enantioselectivity of artificial metalloenzymes 
The artificial metalloenzymes developed in the Ward group based on biotin-(strept)avidin have 
demonstrated that the chemogenetic fine tuning of the second coordination sphere can have 
dramatic effects on activity and selectivity.  
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Figure 12 Ligands and substrates used in the Ward group 
 
The first published example is the hydrogenation of acetamidoacrylic acid using diphosphine 
rhodium complexes [Rh(Biot-4ortho-1)COD]+ (5, figure 12) that yielded 94% ee in favor of the (R)-
enantiomer by using a streptavidin isoform (S122G).[40]  
A second example is the transfer hydrogenation of prochiral ketones using a biotinylated Ru-piano 
stool such as the [η6-(p-Cymene)Ru(Biot-p-L)] (4) that afforded the (R)-enantiomer with the 
S112A streptavidin variant with a 91 % ee with p-methylacetophenone (2) whereas [η6-
(benzene)Ru(Biot-p-L)] ⊂ S112T variant afforded the (S)-enantiomer (55%) with p-
bromoacetophenone (3).[58] 
In addition to reduction reactions, oxidation reactions can also be optimized using the modulation 
of a biological scaffold through mutagenesis. Vanadyl-loaded streptavidin was successfully used 
for enantioselective sulfoxidation. The WT Sav afforded a 86% ee ((R)-enantiomer) using t-
BuOOH as oxydant and VOSO4 as vanadium source (cyclohexyl(methyl)sulfane as substrate, 1) 
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whereas the Aviloop with VOSO4 afforded a 90% ee ((R)-enantiomer) in the same catalytic 
conditions (cyclohexyl(methyl)sulfane as substrate, 1).[33] 
These examples demonstrate that genetic optimization is a powerful tool to improve or invert the 
enantioselectivity of artificial metalloenzymes. Hence, all entries provided by each hybrid variant 
allow insight on the reaction mechanism making wiser choices for the “designed evolution”. 
5. Comparison natural enzymes with artificial metalloenzymes 
Natural and artificial metalloenzymes can be compared through their reaction scope. 
5.1 Enzymes classification 
Nomenclature of enzymes was first proposed in 1992.[59] In this context, natural enzymes are 
classified according to the committee of the international union of biochemistry and molecular 
biology and are divided into 6 classes given by an E.C. number (see figure 13): 
1. Oxidoreductases (EC 1) 
2. Transferases (EC 2) 
3. Hydrolases (EC 3) 
4. Lyases (EC 4) 
5. Isomerases (EC 5) 
6. Ligases (EC 6) 
 
Each class of enzyme is further divided into subclasses, depending on the reaction type, cofactor, 
substrate type, etc.  
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Figure 13 Enzymes classification  
 
5.2 Artificial enzyme classification 
Despite increasing descriptions of different types of artificial metalloenzymes, to date no 
classification has been proposed. The natural enzymes classification could be extended to artificial 
metalloenzymes. The same classes can be conserved and applied to artificial enzymes. Table 1 
classifies and reviews some of the best artificial metalloenzymes as well as natural enzymes for 
comparison based on the enzyme nomenclature. It is interesting to mention that no artificial lyase 
has been described. Difficulties in such a classification relies on major differences between 
artificial systems and natural enzymes e. g. the type of anchoring strategy is not taken into 
consideration. Furthermore some sub-classes do not exist for the moment in the nomenclature 
such as chemical acceptors for the oxidoreductases but are replaced as suggested by a 99 
(meaning: other). It is interesting to mention that streptavidin as a host is involved in 4 of the six 
1. OxIdoreductases
5. Isomerases 3. Hydrolases
2. Transferases6. Ligases
Enzymes
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classes of enzymes as artificial metalloenzymes. This supports the versatility of the scaffold and 
the anchoring strategy to create artificial metalloenzymes. 
 
Table 1 Comparison between artificial metalloenzymes based on biotin-streptavidin technology 
and natural enzymes 
 
Enzyme 
type 
Reaction 
type 
Enzyme  
name 
Metal-
complex 
Biomolecule 
host Anchoring E.C. number Ref. 
1. Oxydoreductases 
Artificial Hydrogenation Hydrogenase Rh-Biotin Streptavidin Supramole
cular 
1.12.99 [20, 23, 
36, 40, 
60] 
Artificial Hydrogenation Hydrogenase Rh Papain Covalent 1.12.99 [26b, 
49a, 61] 
Artificial Hydrogenation Hydrogenase Rh-
diphosphine 
Antibody Supramole
cular 
1.12.99 [62] 
Artificial Hydrogenation Hydrogenase Pd Apo-ferritin Supramole
cular 
1.12.99 [63] 
Artificial Transfer 
hydrogenation 
Transfer 
hydrogenase 
Ru, Ir, Rh-
Biotin 
Streptavidin Supramole
cular 
1.12.99 [33] 
Artificial Oxydation Alcohol 
oxydase 
Ru, Ir, Rh-
Biotin 
Streptavidin Supramole
cular 
1.1.99 [22a] 
 Oxydation Alcohol 
oxydase 
Zn-Cu 
exchange 
Carboxypeptida
se 
Dative 1.1.99 [64] 
Artificial Sulfoxidation Sulfoxidase V Streptavidin Dative 1.8.99 [33] 
Artificial Sulfoxidation Sulfoxidase Mn, Fe-
corrole 
BSA Dative 1.8.99 [34] 
Artificial Sulfoxidation Sulfoxidase Cr, Mn-Schiff 
base 
Myoglobine Covalent 1.8.99 [32a, 
32c, 65] 
Artificial Sulfoxidation Sulfoxidase MO4n-: 
M=V,Mo,Re,
Se,W 
Hydrolases, 
ferritin 
Dative 1.8.99 [66] 
Artificial Dihydroxylatio
n 
Dihydroxylase OsO4 Streptavidin Dative 1.14.99 Sub
mitte
d 
Artificial Dihydroxylatio
n 
Dihydroxylase OsO4 BSA Dative 1.14.99 [24] 
Artificial Epoxydation Epoxydase Mn-Schiff 
base 
Papain Covalent 1.14.99 [61a] 
Artificial Epoxydation Epoxydase Zn-Mn 
exchange 
Carbonic 
anhydrase 
Dative 1.14.99 [28, 67] 
Artificial Peroxydation Peroxidase Se Subtilisin Covalent 1.11.1 [68] 
Artificial Peroxydation Peroxidase Fe-
phophycene 
Myoglobin Dative 1.11.1 [69] 
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Artificial Peroxydation Peroxidase Fe-hemin DNA-RNA Supramole
cular 
1.11.1 [70] 
Natural Meerwein-
Pondorrf-
Verley 
reduction 
Alcoholdehydr
o genase 
Zn   1.1.1.1 [71] 
Natural Epoxydation 
Squalene 
epoxydase 
-   1.14.99.7 [72] 
Natural Oppenauer 
oxidation 
Alcohol 
dehydrogenas
e 
Zn   1.1.1.1 [71] 
Natural Hydroxylation Phenylalanine 
hydroxylase 
Fe   1.14.16.1 [73] 
Natural Peroxidation Cytochrome C 
Peroxidase 
Fe   1.11.1.9 [74] 
Natural Sulfoxidation Sulfite 
oxydase 
Mo   1.8.3.1 [75] 
 
2. Transferases 
Artificial Transfer Acyl transferase Se Subtilisin Covalent 2.3 [76] 
Artificial Transfer Transaminase Cu-
pyridoxamine 
Ribonuclease S Supramole
cular 
2.3 [77] 
Natural Transfer Methyltransferas
e 
   2.1.1.1 [78] 
Natural Transfer Acyltransferase
e 
   2.3.1.1 [79] 
3. Hydrolases 
Artificial Phosphodies
ter hydrolysis 
Phosphodiester
ase 
Ce-HXTA Streptavidin Supramole
cular 
3.1.4 This 
work 
Artificial Hydrolysis Esterase and 
amidase 
Cu-
phenantrolin
e 
Adipocyte lipid-
binding protein 
Covalent 3.1.4 and 
3.4.13 
[80] 
Artificial Hydrolysis Endonucleases Cu-
phenantrolin
e 
DNA-binding 
proteins 
Covalent 3.1.4 [81] 
Artificial 
Hydrolysis Endonucleases Zn Peptide 
fragement with 
Rh intercalator 
Covalent 3.1.4 [82] 
Artificial Hydrolysis Endonucleases Eu, Ce,Cu Helix-Turn-
Helix/Ca-binding 
motif 
Covalent 3.1.4 [83] 
Artificial Hydrolysis Endonucleases Ce Zinc finger 
protein 
Covalent 3.1.4 [84] 
Artificial Hydrolysis Nucleases Zr Peptide nucleic 
acid 
Covalent 3.1.21 [85] 
Artificial Hydrolysis Nucleases Ce Complementary 
peptide nucleic 
acid 
 3.1.21 [86] 
Natural Hydrolysis Phosphodiester
ase 
Zn, Fe   3.1.4.3 [87] 
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Natural Hydrolysis Carboxylic ester 
Hydrolase 
Zn   3.1.1 [88] 
Natural Hydrolysis Amidase    3.5.1.4 [89] 
Natural Hydrolysis Exonuclease Mg   3.1.11-16 [90] 
Natural Hydrolysis Endonuclease Mn 
 
 3.1.21-31 [91] 
 
4. Lyase 
Natural  Decarboxylase    
4.1.1.1 
[92] 
Natural  Aldolase Zn   4.1.2.2 [93] 
Natural  Oxacide lyase    4.1.3.1 [94] 
 
5. Isomerase 
Artificial Isomerisation Isomerase Rh CA Covalent 5.2.1 [28] 
Natural Isomerisation Racemase    5.1.1.1 [95] 
Natural Isomerisation Isomerase    5.2.1.1 [96] 
 
6. Ligase 
Artificial Methatesis Methatesase Ru-Biotin Streptavidn Supramole
cular 
6.4.1 Not 
publi
shed 
Artificial Allylic 
alkylation 
Allylic alkylase Pd-Biotin Streptavidin Supramole
cular 
6.4.1 [97] 
Artificial Diels-Alder Diels-Alderase Cu-
phtalocyanin
e 
BSA Dativ 6.4.1 [26b] 
Artificial Diels-Alder Diels-Alderase Cu-bidentate 
diimines 
DNA Supramole
cular 
6.4.1 [18, 31, 
98] 
Artificial Hydroformylati
on 
Hydroformylas
e 
Rh HSA Dative 6.4.1 [99] 
Artificial Friedel Craft Friedel 
Craftase 
Cu DNA Covalent 6.4.1 [100] 
Artificial Allylic 
amination 
Allylic aminase Ir DNA Covalent 6.3.1 [101] 
Natural synthetase Tyrosine-tRNA 
ligase 
   6.1.1 [102] 
Natural synthetase Acetate- Coa 
ligase 
   6.2.1.1 [103] 
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6. Goal of thesis 
Artificial metalloenzymes based on biotin-streptavidin offer a new perspective for protein 
engineering by combining chemical and genetic modifications to create new activities and to fine-
tune the selectivity. The object of this thesis is the development of efficient hybrid catalysts for 
challenging hydrolysis and reduction reactions (see figure 13). Hence, the work is divided in two 
parts, dealing with two different reactions: phosphate transfer, and transfer hydrogenation of 
carbonyl and imine compounds. The first part relies on the discovery of a selective artificial 
metalloenzyme for the hydrolysis of a chiral RNA mimic substrate (hydrolase). The goal of the 
following studies is the implementation of a high throughput screening protocol for the identification 
of an active and selective artificial metallohydrolases. The second part deals with the 
implementation of a robust protocol for the chemogenetic optimization of an artificial transfer 
hydrogenases (Oxydoreductase). This project started in a previous PhD thesis in Thomas Ward’s 
laboratory (PhD thesis of Dr. Anca Pordea) and aimed to exploit the influence of the second 
coordination sphere to create an artificial keto-reductase for the reduction of challenging 
substrates, such as dialkylketones. This concept was further extended to create the first artificial 
imine reductase. 
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« Le plus beau sentiment du monde, c'est le sens du mystère. Celui qui n'a jamais connu cette 
émotion, ses yeux sont fermés » 
 
        Albert Einstein 
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Chapter 2: Artificial phosphate transferases 
1. Abstract 
Introduction of a biotinylated Ce(IV) complex within streptavidin affords an artificial 
metallohydrolase. Combining both chemical and genetic optimization strategies allows the 
improvement of both the activity and the selectivity of the hybrid catalyst for the phosphate 
transfer of enantiopure 2-hydroxypropyl-para-nitrophenylphosphate (HPNP), a model 
phosphodiester (kobs/kuncat> 50 and estimated E > 65 (R) and -27 (S)). 
2. Introduction 
Creating new artificial hydrolases is of particular interest especially for selective DNA and RNA 
cleavage.[1] Phosphodiester bonds are remarkably stable with a half-life of ca. 130 000 years.[2] In 
natural nucleases, the stability of the negatively charged backbone of nucleic acid molecules 
towards nucleophilic attack is overcome through coordination to Lewis acid metals (Zn(II), Ca(II), 
Mg(II), Fe(II)). These metals activate both the P–O bond for cleavage and the nucleophilicity of 
coordinated water.[1a] Lanthanide ions, which are hard Lewis acids with high coordination numbers 
and fast ligand exchange rates are ideally suited to mimick the reactivity of these biological metal 
cofactors.[1a, 3]  
Many catalysts for the hydrolysis of phosphodiester substrates have been developed by mimicking 
enzymes found in nature such as alkaline phosphatase and purple acid phosphatase (see figure 
1).[4] Alkaline phosphatase bears a dinuclear zinc center whereas purple acid phosphatase 
possesses a dinuclear iron center.  
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   Purple acid phosphatase       Alkaline phosphatase 
 
  
 
Figure 1 Close up view of the active sites of purple acid phosphatase and alkaline phosphatase. 
Both bear a dinuclear metal center (iron or zinc) coordinated by histidines, aspartate and 
glutamate. Coordination of a tyrosine to the metal center (Tyr-55) in purple acid phosphatase 
generates a charge transfer transition yielding a purple color to the enzyme. For alkaline 
phosphatase, an arginine presents the substrate to the metal center via Coulomb interactions and 
a serine acts as a transient nucleophile towards the phosphorus atom of the substrate. 
 
To mimic these natural enzymes, chemists have developed a variety of catalysts able to perform 
phosphodiester hydrolysis on model substrates such as HPNP (2-hydroxypropyl-para-
nitrophenylphosphate) or BNPP (bis-nitrophenylphosphate) (see figure 2), single stranded DNA 
(ss-DNA), double stranded DNA (ds-DNA) or supercoiled DNA (plasmid). The hydrolysis of 
phosphodiesters was investigated with lanthanide salts, mono and dinuclear metal complexes. 
Some of the best catalysts are reviewed in the next paragraphs. 
The trivalent lanthanides ions[3b] accelerate the hydrolysis of DNA under saturation kinetics 
conditions up to kcat = 1.0 · 10-4 s-1. Ce(IV) is a 20 to 1000 times more efficient than any other 
trivalent lanthanide. It displays comparable efficiency toward ss-DNA and ds-DNA.[5] However, 
His-222
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His-195Tyr-187
His-92
Asn-91
His-412
His-331
Arg-166
Ser-102
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aqueous lanthanides salts are toxic. To overcome this problem, stable and highly active 
complexes needs to be developed. Theses hydrolytic complexes are divided in two groups: the 
mononuclear complexes and the dinuclear complexes. 
 
 
 
 
 
 
 
Figure 2 Schematic representation of BNPP and HPNP 
 
A few mononuclear complexes were described as artificial nucleases. The Co(III) complex of the 
polyamine ligand TAMEN (3) cleaves plasmid DNA with a kcat = 5 · 10-5 s-1 , in this case the 
cleavage is hydrolytic.[6] Fuji and co-workers reported a TACH/Cu(II)[7] (4, figure 3) complex 
promoting the hydrolytic cleavage of plasmid DNA. Saturation kinetic were observed with a kcat = 
1.2 · 10-3 s-1. Such reactivity ranks among the highest to date for mononuclear complexes. 
 
In addition to mononuclear complexes, dinuclear complexes were described for the cleavage of 
phosphodiesters and DNA cleavage. In 1996, Schneider and co-workers described a 30-
membered azacrown macrocyle able to bind to Eu(III) or Pr(III) ions[3b] (6). These complexes 
promoted plasmid DNA nicking with a kcat = 2.8 · 10-4 s-1. More effective are the dinuclear Er(III) 
complexes of a Schiff base containing macrocycles (7) reported by Zhu and coworkers[8] able to 
hydrolyse plasmid DNA with a maximum rate constant of kcat = 1.1 · 10-3 s-1. A few complexes 
mimicking the active site of purple acid phosphatase incorporating a dinuclear iron center were 
described. An example is given by Liu and co-workers that developed an Iron/DTPB[9] complex (8) 
able to cleave supercoiled DNA with a kcat = 2.1 · 10-3 s-1 which is the best system to date for the 
O
P
O
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O2N O2N
O
P
O
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hydrolytic cleavage of DNA. Very few bimetallic systems based on zinc and copper have been 
described: Scrimin and coworkers developed a binuclear Zn(II)-binding heptapeptide[10] able to 
cleave plasmid DNA with a kcat = 1.1 · 10-5 s-1. Finally, a very efficient dicerium complex composed 
of a polyaminocarboxylate ligand HXTA (5) was reported by Que and coworkers.[2] The catalyst 
displays an acceleration of kcat = 1.4 · 10-4 s-1 for the cleavage of ds-DNA.  
 
Mononuclear and dinuclear complexes present a good acceleration towards model substrates 
such as BNPP, HPNP (see figure 2) or DNA-substrates. In contrast, all of them suffer from product 
inhibition and therefore most of the time the turnover number of the catalyst is not mentioned or is 
very small.[11] In addition, not all kinetic parameters (kcat/kuncat, KM, Vmax, kcat/KM) are clearly 
reported in the literature for each catalyst. This renders difficult the comparison between all 
systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Some of the most efficient metal-ligand combinations for DNA hydrolysis 
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Anchoring artificial hydrolases to a macromolecular scaffold (protein or DNA) provide a second 
coordination sphere around the organometallic complex thus mimicking natural enzymes. The 
second coordination sphere may ameliorate the turnover number and or the selectivity of the 
catalyst. Some of the best examples of catalysts comprising a second coordination sphere are 
reviewed below.  
Hollfelder et al.[11-12] have developed a highly active polymer system called “synzymes” for the 
hydrolysis of HPNP. The system works with or without metal. It consists of a derivatization of 
polyethylene imine (PEI) with alkyl (C2-C12) benzyl and guanidinium groups (see figure 4). The 
system without metal gives rise to catalysts with a rate acceleration (kcat/kuncat) of up to 104 for 
intramolecular transesterification of HPNP. The synzymes exhibit saturation kinetics (KM = 250 µM, 
kcat = 0.5 min-1) and up to 2340 turnovers per polymer molecule. Addition of a metal (especially 
zinc) to the polymers creates metal containing synzymes and accelerate the phosphate transfer by 
108 (kcat/kuncat) with a KM in the range of 2.5 to 8 mM, the kcat of the system increases to 0.09 s-1. In 
the metal coordinated synzymes, the polymer around the metal can be viewed as a second 
coordination sphere thus mimicking the active site of a natural enzyme. 
 
 
 
 
 
 
 
 
 
Phosphate Transfer 
Chapter 2 
     
51 
 
 
Figure 4 HPNP transesterification reaction a) b) Derivatization scheme to modify PEI to give 
“synzymes”. Polymer amine groups reacted (in DMF, 30°C) with varying amounts of (i) praxadine 
(1H-pyrazole-1-carboximide hydrochloride) and (ii) iodoalkanes (C2-C12) or benzylbromide b) 
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Another example is the work of Komiyama et al.[13] They used an artificial restriction DNA cutter 
(ARCUT) composed of Ce(IV)/EDTA complex (molecular scissors) in combination with pseudo-
complementary PNA (pcPNA) strands (see figure 5). The PNA strands are highly selective towards 
specific sequences of DNA thus allowing recognition in vivo. 
 
 
 
Figure 5 Schematic diagram of site-specific cleavage of double-stranded DNA by ARCUT. By 
adding two pcPNA strands (blue line) to double-stranded DNA (black line), ss-DNA portions (red 
lines) are formed within the invasion complex. These single-stranded portions are selectively 
hydrolysed by Ce(IV)/EDTA complex (gray circles). 
Krämer et al.[14] described a family of PNA-metal chelators conjugates whose Zr(IV) complexes 
selectively cleave ss-DNA oligonucleotides (see fig 6). The use of a large excess of free Zr(IV), 
due to the low metal affinity for the ligand (TRIS) subunit led to substantial non-specific cleavage. 
However, the scission occurred with remarkable regiospecificity at the P-O3’ bond. 
 
 
 
 
 
 
Figure 6 Proposed model for hydrolytic DNA scission by PNA-Zr(IV) conjugate. 
Fig.2: Schematic diagram of site-specific cleavage of double-stranded DNA by ARCUT. By adding two pcPNA strands (blue 
line) to double-stranded DNA (black line), single-stranded portions (red lines) are formed within the invasion complex. These 
single-stranded portions are selectively hydrolysed by Ce(IV)/EDTA complex (gray circle).
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Barton and coworkers[15] have developed a mononuclear Zn(II)-binding peptide, tethered to a 
rhodium complex as a major groove intercalator (see figure 7). This system allows plasmid 
cleavage with a rate constant of kobs = 2.5 · 10-5 s-1 at pH = 6 and 37 °C. In contrast to the system 
described above, this system has a similar activity toward ds-DNA. 
  
Figure 7 Schematic illustration of intercalator-peptide conjugates. The conjugate combines DNA-
binding and reactive moieties: the rhodium intercalator binds in the major groove with high affinity 
and the tethered peptide binds divalent cations to promote hydrolysis of the phosphodiester 
linkage. 
Examples of selective bimetallic systems based on Cu(II) and Zn(II) with a good activity were 
reported by Scrimin and coworkers.[10, 16] (see figure 8). They have described a Zn(II)-binding 
heptapeptide wich cleaves plasmid DNA with a first order rate constant of kcat = 10-5 s-1 at pH = 7 
and 37°C. The peptide has a 310-helical conformation and the two chelating TACN moieties face 
each other at a distance of about 6 Å. The substrate is believed to interact with both metal centers 
thus mimicking artificial dinuclear nucleases. 
Design of a Synthetic Nuclease: DNA Hydrolysis by
a Zinc-Binding Peptide Tethered to a Rhodium
Intercalator
Marilena P. Fitzsimons and Jacqueline K. Barton*
DiVision of Chemistry and Chemical Engineering
California Institute of Technology
Pasadena, California 91125
ReceiVed September 30, 1996
The design of artificial nucleases represents an area of
substantial interest.1 While many reagents have been success-
fully applied to RNA hydrolysis,2 there have been fewer
successes with DNA3,4 due to its relatively high hydrolytic
stability.5 We have approached the problem of designing a
deoxyribonuclease by combining both DNA-binding and reac-
tive moieties: (i) a rhodium intercalator which binds in the major
groove with high affinity6 and (ii) a tethered metallopeptide
modeled after natural hydrolytic enzymes.7 Previous work in
our laboratory has shown that small peptides tethered to a
rhodium complex bind DNA with high site specificity governed
by the appended peptide.8 Here we extend this strategy to create
a synthetic endonuclease by incorporating zinc-promoted reac-
tivity into the tethered peptide.9
Figure 1 shows a schematic illustration of our metal-peptide
conjugate, Rh(phi)2bpy!-Peptide (Rh-P). A short peptide, Asp-
Pro-Asp-Glu-Leu-Glu-His-Ala-Ala-Lys-His-Glu-Ala-Ala-Ala-
Lys-CONH2, is tethered to Rh(phi)2bpy!, a sequence-neutral
intercalator, through a methylene linker derived from the
modified bipyridine ligand. Complexes of rhodium(III) which
contain a phenanthrenequinone diimine (phi) ligand bind in
the major groove of DNA (Kd < 10-6 M)6 and upon photoac-
tivation cleave DNA at the rhodium intercalation site.10 The
peptide tethered to the intercalator was designed de noVo on
the basis of the active sites of metal-containing hydrolases, well-
characterized metalloenzyme sites in which biopolymer hy-
drolysis occurs under mild conditions.7 Two histidines
were placed in positions 7 and 11 along the 16-residue peptide
to create a zinc coordination site on one face of a putative
R-helix. A glutamate was included at position 4, and glutamate-
lysine salt bridges as well as space-filling alanines were added
to encourage R-helicity.11 The coupling of the metallointerca-
lator to the peptide was carried out by methods described
earlier.12
The ability of Rh-P to coordinate metal ions was confirmed
by spectroscopy.13 Consistent with the coordination of one
metal ion to the two histidines, circular dichroism reveals that
maximum helical content of Rh-P is reached with stoichiometric
Zn2+ and decreases with additional metal ion.14 Upfield
shifts in the histidine resonances in 1H NMR spectra with
added Zn2+ also support coordination of one Zn2+ ion to the
peptide.15
In the presence of stoichiometric Zn2+, Rh-P is found to
convert supercoiled pBR322 DNA (I) to both the nicked (II)
and linear (III) forms (Figure 2). DNA cleavage is found to
depend on the presence of the rhodium complex, the tethered
peptide, and Zn2+. The efficiency of DNA cleavage is
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Figure 8 A Zn(II)-binding heptapeptide cleaves plasmid DNA with first order rate constant of  
10-5 s-1 at pH = 7 and 37 °C. 
 
To exploit dendrimers as scaffold, Scrimin et al. developed metallodendrimers as 
transphosphorylation catalysts.[16a] For this purpose, they functionalized a third generation DAB 
(polypropylene imine) dendrimers with triazacyclononane moieties. The metal loaded dendrimer 
cleaves HPNP with a kcat = 8.72 · 10-3 s-1 and a kobs = 1.55 · 10-2 s-1 (see figure 9). The 
triazacyclononane macrocycle is an excellent ligand for ions such as Zn(II) and Cu(II) and 
complexes and these metal ions are effective catalysts for the cleavage of phosphodiesters.  
 
 
 
 
 
Figure 9 DAB dendrimers able to perform catalysis on phosphodiester substrates. 
Following similar design principles, they developed a nanoparticle-based catalyst for 
phosphodiester and DNA hydrolysis.[16c] The catalyst was obtained by self-assembling multiple 
copies of a ligand bearing a thiol anchor on gold nanoparticules (see figure 10). High activity and a 
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new mode of action emerged from the multivalent nature of the catalyst. Zn(II) complexes of BAPA 
(bis(2-amino-pyridinyl-6-methyl)amine) relies on two Lewis acids for the activation of the substrate 
and on hydrogen bonding to achieve increased hydrolytic activity toward phosphate diester with a 
kobs of 3.6 · 10-5 s-1. 
BAPA 
not active      not active 
           not active       
o 
 
Figure 10 Nanoparticle-based catalyst for phosphodiester and DNA hydrolysis. The catalyst is 
obtained by self-assembling multiple copies of the thiolated ligand on the surface nanoparticules 
(MPGNs).  
 
Finally, Scrimin et al. studied the nuclease mechanism by exploring the role of proximal 
ammonium groups on phosphate diester cleavage (see figure 11). The hydrolytic activity of 
complexes based on the BAPA allowed easy investigation of the substituent effect.  
They designed new ligands (11) where an ammonium group is located behind the active 
nucleophile in the spirit of a Lysine group present in nucleases. The ammonium group helps the 
formation of the nucleophile and decrease the pKa by 2 orders of magnitude compared to ligand 
(10).  
The maximum reactivity shifted closer to physiological values and the reactivity is increased due to 
electrostatic effects exerted by positive charge stabilization of the transition state. The pKa 
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decrease appears also for ligand (12) but no charge interaction with the substrate was present. 
The catalytic efficiency is given for BNPP kcat/KM = 0.097 M-1 s-1 for complex (10) (see figure 11) 
compared to kcat/KM = 0.022 M-1 s-1 for complex (11) (see figure 11) and kcat/KM  = 0.0015 M-1 s-1 for 
(12). 
 
 
 
 
 
 
Figure 11 Ligands designed by Scrimin et al. with an ammonium group located behind the 
nucleophile reminiscent of the Lys group in nucleases. 
The reaction of HPNP (1) with metal complexes is an intramolecular transesterification where the 
nucleophile is the substrate’s hydroxyl groups. As a consequence, HPNP (1) reactivity is not 
affected by the activity (or even by the absence) of metal-bound nucleophiles and provided a good 
indication of the ability of the catalyst to stabilize the transition state. The catalytic efficiency is 
given for HPNP by kcat/KM = 0.26 M-1 s-1 for complex (10) (see figure 11) compared to kcat/KM = 
0.70 M-1 s-1 for complex (11) (see figure 11) and kcat/KM  = 0.22 M-1 s-1 for (12). 
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Sugiura and coworkers[17] have exploited the DNA binding affinity of zinc finger motifs to prepare a 
sequence selective DNA cleavage catalyst (see figure 12). They obtained zinc finger peptides with 
hydrolytic activity kcat/KM = 502 · 10-2 M-1 s-1. 
 
Linkage of these three zinc-finger mutants resulted in a system with high affinity for the DNA 
duplex containing a GC box (Kd = 85 nM). The cleavage is moderately efficient but the system has 
a good selectivity. 
 
 
 
Figure 12 Zinc finger peptide. Aminoacids bound to the zinc, cationic and anionic amino acids are 
denoted by bold black, red, and blue letters, respectively a) The three-tandem zinc finger protein 
for sequence selective ds DNA cleavage b). 
 
Finally, Franklin et al.[18] have designed a 33-mer peptide incorporating a DNA recognition 
sequence and a metal ion binding site (see figure 13). The peptide folds in a HTH motif where the 
two helices have been derived from the DNA binding engrailed homeodomain and the turn 
produces the calcium binding site of calmodulin. Addition of Ce(IV) or Eu(III) allows formation of a 
peptide bearing a lanthanide which maintains the tertiary structure. The complex allows cleavage 
of both plasmids and ds-DNA with reactivity similar to the free metal ion. The complex is 
regioselective while cleaving only the P-O3’ bonds and has a preference for T/C rich domains.  
Sequence-Selective and Hydrolytic Cleavage of DNA by Zinc Finger Mutants
Akiko Nomura and Yukio Sugiura*
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The molecules that can hydrolyze the DNA phosphoester at
specific positions are valuable tools in biotechnology, thus facilitat-
ing DNA manipulation in a variety of applications. Although many
naturally occurring nucleases have been utilized in the laboratory
for this purpose, designing artificial nucleases is one of the most
interesting current topics in the field of protein engineering because
artificial nucleases could expand a set of recognizable DNA
sequences beyond the limited sequences of currently available
nucleases. Most of the artificial nucleases so far reported have been
constructed by linking DNA binding moieties with DNA cleavage
moieties.1,2 For example, Ni(II)-peptide complexes1a,3 have been
attached as a DNA cutter at the terminus of DNA recognition
proteins or molecules.4 The other fascinating strategy for artificial
nucleases is to construct a hydrolytic active site in the DNA binding
peptides; for example, novel types of artificial nucleases have been
developed based on HTH and EF-hand DNA binding peptides by
introducing lanthanide ions in the original calcium binding site.5
We recently succeeded in constructing zinc finger peptides with
hydrolytic ability by mutating amino acid residues coordinated to
the zinc ion.6 Since zinc finger motifs have been known to bind to
the major groove of the DNA duplex in a sequence-specific
fashion,7 we expected that our zinc finger mutants would function
as a novel type of artificial nuclease with high sequence specificity
for DNA duplexes. In addition, DNA recognition by the zinc finger
motifs is expected to cover a wide rang of DNA sequences,
compared to restriction enzymes, because zinc finger motifs bind
to asymmetric sequences while the DNA sequences recognized by
the restriction enzymes must be palindromic. In this context, we
have studied the expansion of recognizable DNA sequences by zinc
finger motifs (e.g., nine-tandem zinc finger proteins that can bi
unusually longer DNA sequences8 or R-helix-exchanged zinc finger
peptides that can bind to A/T-rich sequences instead of the original
G/C-rich sequences).9 Furthermore, the efforts to realize the DNA
recognition of a wide variety of sequences by zinc finger motifs
have been also enthusiastically pursued by other groups.10 Aiming
to create peptide-based biochemical tools exhibiting a site-specific
DNA cleavage ability, in this study, we examined the ability of
the zinc finger mutant peptides for sequence-selective DNA
hydrolysis.
First of all, we examined the ability of a zinc finger mutant
zf(HHHH) (Zn‚1),6 whose sequence is based on the second finger
in the three-tandem zinc finger protein Sp1 (Figure 1a), to hydrolyze
bis(4-nitrophenyl) phosphate (BNP) as a model compound for
DNA.11 It was revealed that Zn‚1 catalyzed the hydrolysis of BNP
to afford 4-nitrophenolate and 4-nitrophenyl phosphate.12 The
estimated second-order rate constant, k, was notably higher than
that observed for the zinc-cyclen complex, known to be an
excellent functional model for hydrolytic zinc enzymes,11a-c,13 by
2 orders of magnitude under identical conditions (Table 1). This
result encouraged us to examine the DNA hydrolytic ability of Zn‚
1. We used a supercoiled plasmid DNA, pUC19GC, as a substrate
since pUC19GC contains a GC box to which Sp1 specifically
binds.14 DNA cleavage converts the supercoiled plasmid DNA (form
I) to the nicked circular form (form II) and then to the linear form
(form III). Despite the inactivated phosphoester, Zn‚1 converted
pUC19GC to form II but not to form III (Figure S1 of the
Supporting Information). The cleavage efficiency linearly increased
as the zinc concentration increased and reached a plateau at the
point of 1 equiv of zinc ion (Figure S2 of the Supporting
Information). These results emphasize that the zinc ion plays a
critical role in DNA hydrolysis.15 However, the hydrolytic reactivity
decreased along with an increase in the ionic strength (Figure 2),
which suggests that the positively charged zinc finger peptide binds
with the phosphate of DNA, rather than with the DNA bases, via
electrostatic interactions. The same hydrolytic efficiency of Zn‚1
for pUC19, which contains no GC box, as for pUC19GC indicates
nonselective binding of Zn‚1 with DNA (Figure S3 of the
Supporting Information).
Tandem alignment of zinc finger mutants, like the native Sp1,
should be a strategy to achieve selective binding at the GC box by
the zinc finger mutants because repeated zinc finger motifs show
a drastic enhancement in DNA affinity compared with that of a
single zinc finger motif.16 We already reported that a three-tandem
zinc finger protein (Zn‚2, Figure 1b), where two of the cysteine
ligands in each finger motif were replaced by histidine ligands,
retains a high affinity for the DNA duplex containing a GC box,
Figure 1. Zinc finger mutant peptide and protein. (a) The second zinc
finger mutant zf(HHHH) (Zn‚1). Ligands of the zinc ion, cationic amino
acids, and anionic amino acids are denoted by bold black, red, and blue
letters, respectively. (b) The three-tandem zinc finger protein (Zn‚2).
Table 1. BNP Hydrolysis Rate Constant, k, by the Zinc
Complexesa
catalyst k ! 10-5 (M-1 s-1)
Zn‚1 502 ( 24.5
apo-form of Zn‚1 65.0 ( 5.28
zinc-cyclen 7.58 ( 0.696
a The [catalyst] ) 10-20 mM, [BNP]0 ) 2-6 mM in 20 mM HEPES
buffer (pH 7.5) containing 0.1 M NaCl and 3.5% THF at 37 °C.
Figure 2. Ionic strength dependence of the plasmid DNA cleavage by Zn‚
1. The reactions were carried out at 37 °C for 96 h. [Zn‚1] 2 µM,
[pUC19GC] ) 57.4 nM (0.154 mM bp). Lane 1, 0 mM NaCl; lane 2, 3
mM NaCl; lane 3, 8 mM NaCl; lane 4, 18 mM NaCl; lane 5, 48 mM NaCl;
lane 6, 98 mM NaCl.
Published on Web 11/03/2004
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Figure 13 Computer-generated model of the interaction of chimeric peptides with DNA based on 
the HTH motif and EF-hand motifs from engrailed (red) and calmodulin (yellow), respectively. 
Crystal structure of engrailed homeodomain, cocrystallized with DNA 82HDD; gray and red ribbon, 
wit blue DNA and one EF-hand of calmoduline (1OSA; yellow ribbon, with coordinated Ca(II)), are 
overlaid to show the similarity of the folds. The peptides comprise α2 and α3 of engrailed and the 
Ca-binding loop of calmodulin. 
 
Characteristics of natural enzymes are often their high substrate selectivity, provided by a well-
defined second coordination sphere environment that can allow exquisite discrimination. It was 
anticipated that, thanks to its large biotin binding vestibule, streptavidin (Sav hereafter) may be 
well suited to accommodate biotinylated Lewis acids and thus provide a suitable host for the 
generation of artificial hydrolases. 
Fig.8: Computer-generated model of the  interaction of chimeric peptides 
with DNA based on the HTH and EF-hand motifs  from engrailed (red) and 
calmodulin (yellow), respectively. Crystal structures of engrailed 
homeodomain, cocrystallized with DNA 82HDD; gray and red ribbon, with 
blue DNA) and one EF-hand of calmoduline (1OSA; yellow ribbon, with 
coordinated Ca(II)), are overlaid to show the similarity of the folds. The 
pepties comprise !2 and !3 of engrailed and the Ca-binding loop of 
calmodulin.
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3. Aims of the chapter 
The aim of the chapter is the development of artificial phosphate transferase based on the biotin-
streptavidin technology. Whereas redox artificial metalloenzymes[19] (hydrogenation, transfer 
hydrogenation, oxidation) and ligases[19b] (allylic alkylation) have been previously described, this is 
the first report of an artificial phosphate transferase based on biotin-streptavidin technology. In the 
annex this concept is extended to the hydrolysis of i) insoluble chiral phosphodiester leading to 
phospholipases like activity and ii) biotinylated ss-DNA leading to artificial restriction enzymes. 
 4. Results and discussion 
To test the validity of this concept, enantiopure 2-hydroxypropyl-para-nitrophenylphosphate HPNP 
was selected as a substrate (see figure 14). Inspired by the report of Que[2] and Komiyama, 
Ce(IV)[5a, 13, 20] was selected as Lewis acid. There is ample evidence that, even in the presence of 
anionic donor atoms, these are powerful redox-innocent Lewis-acids capable of hydrolyzing model 
substrates, and single as well as double stranded DNA.[2] The synthesis of a series of biotinylated 
aminocarboxylic acids for coordination with Ce(IV) was carried out. The ligands are outlined in 
figure 15 (see experimental part).[21] 
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Figure 14 Artificial metallohydrolases based on the biotin-avidin technology. Incorporation of a 
biotinylated Ce(IV) complex within streptavidin yields an artificial phosphodiesterase. Optimization 
can be achieved either by varying the nature of the spacer (oval) or the ligand combined with site-
directed mutagenesis at select positions on the host protein.  
 
To gain insight on the localization of the biotinylated Lewis acid within streptavidin, docking studies 
were performed on {(Biot-HXTA)Ce2(µ-OAc)2}+ ⊂ Sav. (Hereafter, the symbol ⊂ is used for the 
incorporation of the biotinylated catalyst within Sav). For this purpose, the X-ray structure of 
{(HXTA)Fe2(µ-OAc)2}- (CSD refcode AJEKOP[22]) was derivatized with a biotin anchor and the 
{Fe2(µ-OAc)2}4+- fragment removed. The resulting biotinylated ligand Biot-HXTA-H5 was docked 
within Sav using the AutoDock4[23] program and the {Ce2(µ-OAc)2}6+ fragment was introduced, The 
resulting structure is depicted in figure 15b. 
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a)      b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Structure of biotinylated aminocarboxylic acids used in this study a); close up view of 
the docked structure of {(Biot-HXTA)Ce2(OAc)2}+ ⊂ Sav (only one complex displayed). Close-lying 
residues subjected to mutagenesis are highlighted in red b). 
 
This structure reveals that, despite the size of the dinuclear complex, up to four biotinylated 
moieties can occupy the four binding sites of tetrameric Sav. This was confirmed by a HABA 
displacement titration[24] demonstrating the incorporation of four equivalents of {(Biot-HXTA)Ce2}3+ 
(Fig.16b). To determine the optimal pH, the rate of hydrolysis of (rac)-HPNP was determined in the 
presence of {(Biot-HXTA)Ce2}3+ ⊂ Sav at 37 °C, Fig. 1b. All subsequent studies were performed at 
pH 7.0 in HEPES (100 mM). 
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Figure 16 HABA-displacement titration, suggesting the incorporation of four {(Biot-HXTA)Ce2}3+ 
within tetrameric streptavidin a) and initial rate (rac)-HPNP hydrolysis as a function of pH catalyzed 
by {(Biot-HXTA)Ce2}3+ ⊂ Sav b) 
?
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Based on the docked structure, positions S112, K121, and L124 were identified as close-lying and 
thus were subjected to site-directed mutagenesis to incorporate genetic diversity.  
 
Mutants V47G and P64G, wich had proven versatile in other artificial metalloenzymes, were also 
included in the screening effort. A library of 23 Sav isoforms was combined with six complexes 
prepared in situ from ligands Biot-2-IDA-H2, Biot-3-IDA-H2, Biot-HXTA-H5, Biot-4m-HXTA-H5, 
Biot-4p-HXTA-H5 and Biot-phen-HXTA-H5. This chemogenetic n·m diversity matrix was screened 
in the presence of enantiopure HPNP.  
 
The initial rates of hydrolysis (kobs) were conveniently monitored using a 96 well-plate reader by 
recording the absorbance at 405 nm, diagnostic for the formation of nitrophenolate and the 
corresponding product of the reaction (the cyclized phosphonate).  
 
Determination of the initial slopes for each catalyst ⊂ Sav isoform was carried out for both HPNP 
enantiomers in separate wells, thus yielding both kobs (Figure 17 a, Table 1) and the estimated E 
(ratio of kobs(R)/kobs(S), figure 17b, Table 2). From these data, the following trends for kobs were 
identified: 
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a) 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
Figure 17 Graphical summaries of the results for the hydrolysis of HPNP catalyzed by artificial 
metallohydrolases: Initial rates kobs for both HPNP enantiomers a) and estimated E b). 
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E > 
{(Biot-IDA-2)Ce}2+ ⊂ V47G (>65) 
{(Biot-IDA-3)Ce}2+ ⊂ V47G (>65) 
{(Biot-phen-HXTA)Ce2}3+ ⊂ L124V (>65) 
{(Biot-4m-HXTA)Ce2}3+ ⊂ S112N (>65) 
{(Biot-4p-HXTA)Ce2}3+ ⊂ S112N (>65) 
{(Biot-IDA-3)Ce}2+ ⊂ S112T (>65) 
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{(Biot-4m-HXTA)Ce2}3+
{(Biot-4p-HXTA)Ce2}3+
{(Biot-phen-HXTA)Ce2}3+
{(Biot-phen-HXTA)Ce2}3+ ⊂ S112D (>65) 
{(Biot-4m-HXTA)Ce2}3+ ⊂ S112H (>65) 
{(Biot-IDA-3)Ce}2+ ⊂ S112H (>65) 
{(Biot-IDA-2)Ce}2+ ⊂ S112D (>65) 
{(Biot-IDA-2)Ce}2+ ⊂ S112T (-15) 
{(Biot-IDA-2)Ce}2+ ⊂ S112N (-27) 
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Table 1 Numerical summary of selected initial rates kobs for the HPNP hydrolysis. 
Entry Ligand Sav 
kobs/kuncat 
(R)-HPNP 
kobs/kuncat 
(S)-HPNP 
1 {(Biot-4m-HXTA)Ce2}3+ – 8 8 
2 {(Biot-2-IDA)Ce}2+ S121G 25 18 
3 {(Biot-2-IDA)Ce}2+ S121F 26 27 
4 {(Biot-3-IDA)Ce}2+ S121G 23 20 
5 {(Biot-HXTA)Ce2}3+ S121F 43 32 
6 {(Biot-4m-HXTA)Ce2}3+ S121G 47 49 
7 {(Biot-4m-HXTA)Ce2}3+ S121R 21 42 
8 {(Biot-4m-HXTA)Ce2}3+ S124Y 45 49 
9 {(Biot-4p-HXTA)Ce2}3+ S121N 51 38 
10 {(Biot-phen-HXTA)Ce2}3+ WT 38 40 
11 {(Biot-phen-HXTA)Ce2}3+ S121G 47 55 
12 {(Biot-phen-HXTA)Ce2}3+ S121F 45 20 
 
i) Compared to the uncatalyzed reaction at pH 7.0, rate accelerations (kobs/kuncat) > 50 fold were 
obtained. Compared to the biotinylated catalyst alone, incorporation within Sav results in > 7 fold 
rate accelaration (Table 1 entries 1 vs. 2-12). This suggests that the host protein has a tunable 
impact on the hydrolysis rate of the resulting artificial metallohydrolases. 
ii) Mutation of S112 leads to a significant decrease in activity. We hypothesize that, in a biomimetic 
spirit, this serine may act as a transient nucleophile during hydrolysis. 
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iii) Dinuclear complexes derived from HXTA are more efficient (higher kobs) than mononuclear 
complexes bearing an IDA moiety (Table 1, entries 2-5 vs. 6-12) 
iv) Introduction of a spacer between the biotin anchor and HXTA contributes to the improvement of 
kobs, thus yielding the most proficient artificial hydrolases (Table 1 entry 5 vs. 6-12). 
v) Mutation at position K121 is most effective, yielding rate accelerations kobs/kuncat of up to 55-fold. 
Substitution of the positively charged lysine by a glycine (K121G) is most beneficial (Table 1 
entries 2,4,6,11).  
 
Table 2 Numerical summary of selected estimated E values (kobs(R)/kobs(S)) for the HPNP 
hydrolysis. 
Entry Ligand Prot estimated E 
1 {(Biot-2-IDA)Ce}2+ S112D >65 
2 {(Biot-2-IDA)Ce}2+ V47G >65 
3 {(Biot-2-IDA)Ce}2+ S112N -27 
4 {(Biot-2-IDA)Ce}2+ S112T -15 
5 {(Biot-3-IDA)Ce}2+ S112H >65 
6 {(Biot-3-IDA)Ce}2+ V47G >65 
7 {(Biot-4m-HXTA)Ce2}3+ S112H >65 
8 {(Biot-4m-HXTA)Ce2}3+ S112N >65 
9 {(Biot-4p-HXTA)Ce2}3+ S112N >65 
10 {(Biot-phen-HXTA)Ce2}3+ S112D >65 
11 {(Biot-phen-HXTA)Ce2}3+ L124V >65 
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Compared to the kobs data summarized above, the estimated E data (Table 2) reveal distinct 
trends: 
 
i) Both mononuclear, IDA and HXTA-derived metalloenzymes are equally effective for the 
preferential hydrolysis of one enantiomer of HPNP (Table 2 entries 1-4 vs. 5-10). 
ii) The hydrolysis of (R)-HPNP 1 is preferred in most cases. Only two combinations were identified 
which hydrolyze (S)-HPNP more efficiently (E -26 and -15 for {(Biot-2-IDA)Ce}2+ ⊂ S112N Sav and 
{(Biot-2-IDA)Ce}2+ ⊂ S112T Sav, respectively, Table 2, entries 2, 3). 
iii) Mutation of S112 by more potent nucleophiles at pH 7 (ie. S112H and S112D) has a positive 
impact on selectivity (Table 2, entries 1, 4, 5, 8). For example, mutation S112H displays higher 
kobs(R) with {(Biot-3-IDA)Ce}2+ (and with {(Biot-phen-HXTA)Ce2}3+) than equivalent combinations 
with other Sav mutants at this position. This rate acceleration for the (R)-HPNP gives rise to both 
high rates and high selectivity. These data lend support to docking studies, suggesting the 
proximity of position 112 to the biotinylated Lewis acids. 
As a representative and promising example, {(Biot-4m-HXTA)Ce2}3+ ⊂ K121G was subjected to 
Michaelis-Menten kinetic analysis, figure 18. For the recognized (R)-substrate, the KM values (2.34 
mM, (S)-HPNP 0.0091 mM) are comparable to natural enzymes, as well as some of the best man-
made catalysts.  
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Enzyme KM [mM] kcat [s-1] 
Purple acid phosphatase 1.25 470 
Alkaline phosphatase 90 80 
Metal-coordinated synzyme 16.7 0.00145 
Synzyme 1.25 0.00833 
{(Biot-4m-HXTA)Ce2} ⊂ K121G 2.34 0.000030 
 
Figure 18 Saturation kinetics plot for the hydrolysis of (R)-HPNP (measured : full circles; fitted : 
solid blue line) and (S)-HPNP (measured: red full squares; fitted : solid red line) catalyzed by 
{(Biot-4m-HXTA)Ce2}3+ ⊂ K121G a) and parameters for selected natural and artificial 
metallonucleases b.  
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5. Conclusion 
As was outlined in this work, the kobs values and kcat (3 · 10-5 s-1 and 1.41 · 10-6 s-1 for both HPNP 
enantiomers) can be improved by combining chemical and genetic diversity. Relying on this 
strategy, it was shown for the first time that promising selectivities towards two enantiomers could 
be achieved. 
6. Perspectives 
As demonstrated by Que and coworkers, {(HXTA)Ce2}3+ can hydrolyze ds-DNA. Incorporation of 
this fragment in a host protein offering extended contacts with DNA may allow selective hydrolytic 
cleavage of specific sequences. Current efforts are directed towards the recognition of oncogenic 
ds-DNA sequences using the strategy outlined above. 
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7. Experimental part 
7.1.Synthesis 
 
Synthesis of Biot-2-IDA 
 
 
A solution of ethylenediamine (490 µL, 7.43 mmol) was slowly 
added at 0 °C to a solution of activated biotin 5[25] (300 mg, 0.73 
mmol) in DMF (20 mL) containing Et3N (230 µL, 1.65 mmol). The 
mixture was stirred at RT for 2 days. The solvent was evaporated 
under reduced pressure. The residue was dissolved in hot MeOH (20 mL) and cooled overnight (5 
°C). The white precipitate was filtered, washed with cold MeOH and cold acetonitrile and dried 
under reduced pressure to afford amine 6 (Yield: 72%). 
 
1H NMR (400.00 MHz, [D6] DMSO, 20 °C): δ (ppm) = 1.25-1.67 (m, 6H, H7, H8, H9), 2.10 (m, 2H, 
H10), 2.59 (m, 1H, H1a), 2.79-2.86 (m, 3H, H1b, H13), 3.08-3.19 (m, 1H, H6), 3.23-3.28 (m, 2H, H12), 
4.13-4.16 (m, 1H, H5), 4.32 (m, 1H, H2), 6.40 (s, 1H, H3), 6.45 (s, 1H, H4), 8.03 (s, 1H, H11); 13C 
NMR (100.58 MHz, [D6] DMSO, 20 °C): δ (ppm) = 25.9, 28.9, 29.1, 36.0, 39.8, 40.0, 40.7, 56.3, 
60.1, 61.9, 163.6, 173.6 ; MS (ESI): ESI-MS for C12H22N4O2S (286.2 g/mol): 287.2 (100%) [M+H]+. 
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Mp ( °C)  211 (Dec.). 
 
Amine 6 (500 mg, 1.75 mmol) was dissolved in MeOH (60 
mL) and added to an aqueous solution of 2-bromoacetic acid 
(486 mg, 3.50 mmol, 9 mL) . The reaction was stirred for 2 h 
at 35 °C and NaOH (280 mg, 6.99 mmol dissolved in water 6 
mL) was added. The solution was stirred for 1 day at RT. The pale brown precipitate was filtered 
and dried under reduced pressure. The solid obtained was dissolved in MeOH, precipitated with 
ether and filtered to afford Biot-2-IDA-H2. (Yield: 87%). 
 
1H NMR (400.00 MHz, D2O, 20 °C): δ (ppm) = 1.29-1.69 (m, 6H, H7, H8, H9), 2.74 (m, 1H, H1a), 
2.97 (m, 1H, H1b), 3.13 (m, 1H, H6), 3.25-3.5 (m, 10H, H10, H12, H13, H14), 4.33-4.36 (m, 1H, H5), 
4.51-4.54 (m, 1H, H2) MS (ESI): ESI-MS for C16H26N4O6S (402.2 g/mol) : 401.2 (100%) [M-H]-. Mp 
( °C)  121. 
 
Synthesis of Biot-3-IDA 
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A solution of 1,3-propylenediamine  (490 µL, 5.87 mmol) was 
slowly added at 0°C to a solution of activated biotin 5[1] (300 mg, 
0.73 mmol) in DMF (20 mL) containing Et3N (230 µL, 1.65 
mmol). The mixture was stirred at RT for 2 days. The solvent 
was evaporated under reduced pressure. The residue was dissolved in hot MeOH (20 mL) and 
cooled overnight (5 °C). The white precipitate was filtered, washed with cold MeOH and cold 
acetonitrile and dried under reduced pressure to afford amine 7 (Yield: 72%). 
 
1H NMR (400.00 MHz, [D6] DMSO, 20 °C): δ (ppm) = 1.24-1.66 (m, 8H, H7,H8,H9,H14), 2.05 (t, 2H, 
H10), 2.56-2.65 (m, 1H, H1a), 2.80-2.85 (m, 1H, H1b), 3.00-3.12 (m, 5H, H6, H12, H13), 4.11-4.15 (m, 
1H, H5), 4.29-4.32 (m, 1H, H2), 6.36 (s, 1H, H3), 6.43 (s, 1H, H4) ; 13C NMR (100.58 Hz, [D6] 
DMSO, 20 °C): δ (ppm) = 24.4, 26.2, 28.9, 29.1, 30.2, 36.1, 37.1, 40.7, 56.3, 60.1, 61.9, 163.6, 
172.8 ; MS (ESI): ESI-MS for C13H24N4O2S (300.2 g/mol): 301.2 (100%) [M+H]+. Mp ( °C) 241 
(Dec.). 
 
Amine 7 (552 mg, 1.84 mmol) was dissolved in MeOH (60 
mL) and mixed with a solution of 2-bromoacetic acid (486 
mg, 3.5 mmol) in water (9 mL). The reaction was stirred for 2 
h at 35 °C and NaOH (280 mg, 6.99 mmol dissolved in water 
6 mL) was added. The solution was stirred for 1 day at RT. The pale brown precipitate was filtered 
and dried under reduced pressure. The solid obtained was dissolved in MeOH, precipitated with 
ether and filtered to afford Biot-3-IDA-H2 (Yield: 98%).  
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1H NMR (400.00 MHz, D2O, 20 °C): δ (ppm) = 1.25-1.9 (m, 6H, H7, H8, H9), 2.1-2.23 (m , 2H, H10), 
2.74 (m, 1H, H1a), 2.94 (m, 1H, H1b), 3.13-3.29 (m, 7H, H6, H12, H13, H14), 3.79-3.86 (m, 4H, H15), 
4.31-4.37 (m, 1H, H5), 4.52-4.55 (m, 1H ,H2) ; MS (ESI): ESI-MS for C17H28N4O6S (416.2 g/mol): 
415.5 (100%) [M-H]-. Mp ( °C)  77. 
 
Synthesis of Biot-HXTA 
 
 
 
 
Amine 8 (3.56 g, 22.10 mmol) was added to a solution of aqueous 
formaldehyde 37 % (0.66 g, 21.84 mmol) and MeOH (12 mL). After 
evaporation of the solvent, another portion of MeOH (12 mL) was 
added to the reaction mixture and the solvent was again evaporated. 4-nitrophenol (0.76 g, 5.46 
mmol) was added to the mixture and the solution was heated to 110 °C for 20 h. The slurry was 
dissolved in a minimal amount of dichloromethane and precipitated in an excess of ether. The 
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collected solid was filtered, washed with cold ether and dried under reduced pressure to afford the 
nitrophenol 9 (Yield: 19%). 
 
1H NMR (400.00 MHz, CDCl3, 20 °C): δ (ppm) = 3.59 (s, 8H, H3), 3.74 (s, 12H, H4), 4.04 (s, 4H, 
H2), 8.13 (s, 2H, H1.); 13C NMR (100.58 MHz, CDCl3, 20 °C): δ (ppm) = 171.5, 161.8, 140.4, 126.1, 
124.3, 55.6, 54.2, 52.1 ; MS (ESI): ESI-MS for C20H27N3O11 (485.2 g/mol): 486.1 (100%) [M+H]+ 
508.13 (10%) [M+Na]+. Mp ( °C)  125. 
An autoclave containing a suspension of Pd/C (5%, 36.32 mg) in 
MeOH (18 mL) was filled with p-nitrophenol 9 (100 mg, 0.21 
mmol). The autoclave was purged three times with nitrogen and 
filled with hydrogen (3 bars). The reaction was stirred at RT for 3 h, 
the pressure was carefully released and the suspension was filtered through a celite plug. The 
organic solvent was evaporated under reduced pressure to dryness to obtain the crude product, 
which was purified by flash chromatography (CH2Cl2/MeOH 3%) to yield aminophenol 10, a brown 
air sensitive sticky solid (Yield: 78%). 
 
1H NMR (400.00 MHz, CDCl3, 20 °C): δ (ppm) = 3.55 (s, 8H, H4), 3.71 (s, 12H, H5), 3.91 (s, 4H, 
H3), 5.32 (s, 1H, H6), 6.56 (s, 2H, H2) , 8.82 (s, 2H, H1); 13C NMR (100.58 MHz, CDCl3, 20 °C): δ 
(ppm) = 171.8, 148.7, 138.5, 123.8, 117.2, 54.2, 54.1, 51.9; MS (ESI): ESI-MS for C20H29N3O9 
(455.2 g/mol): 456.1 (10%) [M+H]+, 478.1 (100%) [M+Na]+. 
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To a suspension of biotin (96 mg, 0.39 mmol) in 
acetonitrile (10 mL) aminophenol 10 (177 mg, 
0.389 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine 
(CDMT) (72 mg, 0.41 mmol) were added. N-
methymorpholine (0.064 mL, 0.58 mmol) was then added 
at RT. The solution was stirred at RT for 24 h. The crude product was purified by flash 
chromatography (AcOEt/MeOH 8:1) to obtain 11 as a white solid. (Yield: 18%). 
 
1H NMR (400.00 MHz, CD3OD, 20 °C): δ (ppm) = 1.5-1.8 (m, 6H, H7, H8, H9), 2.38 (m, 2H, H10), 
2.73 (m, 1H, H1a), 2.95 (m, 1H, H1b), 3.25 (m, 1H, H6), 3.54 (s, 8H, H14), 3.69 (s, 12H, H15), 3.89 (s, 
4H, H13), 4.31 (m, 1H, H5), 4.49 (m, 1H, H2), 7.29 (s, 2H, H12) ; MS (ESI): ESI-MS for 
C30H43N5O11S (681.3 g/mol): 363.9 (100%) [M+2Na]2+. Mp ( °C)  95. 
 
A 10 mL flask was charged with tetraester 11 (42 mg, 
0.062 mmol) and a solution of KOH in EtOH (3 mL, 0.5 M) 
was added. After 15 min a precipitate had formed. The 
reaction mixture was stirred for 2 h, water (1.3 mL) was 
added to dissolve the precipitate and the reaction was 
stirred for an additional 2 h. The solution was acidified with HCl (1 mL, 2 M). The solvent was 
removed under reduced pressure and the residue was dissolved in MeOH and filtered. The solvent 
was removed in vacuo to afford the biotinylated ligand Biot-HXTA-H5 as a white powder (Yield: 
35%). 
 
7
NH 4
O
H 5
HN3
H2
S
H1b
H1a
H 6
8
9
10
O
H
N
11
12
12 OH
16
13
13
N
N
14
14
14
14
COOH
15
COOH
15
COOH
15
COOH
15
Biot-HXTA-H5
7
NH 4
O
H 5
HN3
H2
S
H1b
H
1a
H 6
8
9
10
O
H
N
11
12
12 OH 16
13
13
N
N
14
14
14
14
COOMe
15
COOMe
15
COOMe
15
COOMe
15
11
Phosphate Transfer 
Chapter 2 
     
76 
1H NMR (400.00 MHz, CD3OD, 20 °C): δ (ppm) = 1.17-1.77 (m, 6H, H7, H8, H9), 2.41 (m, 2H, H10), 
2.76 (m, 1H, H1a), 2.97 (m, 1H, H1b), 3.25 (m, 1H, H6), 4.24 (s, 4H, H13), 4.43 (m, 1H, H5), 4.61 (m, 
1H, H2), 4.67 (s, 8H, H14), 7.81 (s, 2H, H12) ; MS (ESI): ESI-MS for C26H35N5O11S (625.2 g/mol): 
624.3 (100%) [M-H]-. Mp ( °C)  271(Dec.). 
 
Synthesis of Biot-4m-HXTA 
 
 
 
 
Isobutyl chloroformate (0.32 mL, 2.47 mmol) was added to a 
solution of biotin (496 mg, 2.03 mmol) in DMF (40 mL) 
containing tri-N-butylamine (0.64 mL, 2.69 mmol). After 10 min 
at RT, the mixture was slowly added at 5 °C to a suspension 3-
aminobenzoic acid (561 mg, 4.1 mmol) in DMF (40 mL). After stirring at 5 °C for 2 h, the solvent 
was removed under reduced pressure and the crude precipitate was dissolved in warm aqueous 
EtOH (1:1, 36 mL total). The mixture was acidified with 2.0 M HCl to pH 2 and kept at 0 °C for 12 
h. The resulting precipitate was filtered, washed with water and dried under reduced pressure to 
afford 14 as a pale yellow powder (yield: 65%). 
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1H NMR (400 MHz, [D6] DMSO, 20 °C): δ (ppm) = 1.30-1.70 (m, 6H, H7, H8, H9), 2.34 (m, 2H, H10), 
2.61 (m, 1H, H1a), 2.83 (dd, 1H, H1b), 3.16 (m, 1H, H6), 4.16 (m, 1H, H5), 4.32 (m, 1H, H2), 6.38 (br, 
1H, H4), 6.46 (br, 1H, H3), 7.42 (m, 1H, H13), 7.61 (m, 1H, H12), 7.84 (m, 1H, H14), 8.25 (m, 1H, 
H15), 10.15 (br, 1H, H11), 12.80 (br, 1H; H16); 13C NMR (100.58 MHz, [D6] DMSO, 20 °C): δ (ppm) = 
25.9, 29.0, 29.1, 37.1, 40.7, 56.3, 60.1, 61.9, 120.6, 124, 124.6, 129.8, 132.1, 140.4, 163.6, 168.1, 
172.3; MS (ESI): ESI-MS for C17H21N3O4S (363.13  g/mol) : 362.2 [M-H]-. Mp ( °C) 288 (Dec.). 
 
To a suspension of carboxylic acid 14 (144, 
0.39 mmol) in acetonitrile (10 mL), amine 10 
(177 mg, 0.38 mmol), 2-chloro-4,6-dimethoxy-
1,3,5-triazine (72 mg, 0.41 mmol) and N-
methymorpholine (0.093 mL, 0.596 mmol) were added. The solution was stirred at RT for 24 h. 
The crude tetraester 15 was purified by flash chromatography (AcOEt/MeOH 8:1) to obtain 18 as a 
white solid (Yield: 12%). 
 
1H NMR (500.00 MHz, CD3OD, 20 °C): δ (ppm) = 1.47-1.94 (m, 6H, H7, H8, H9), 2.43 (m, 2H, H10), 
2.70 (d, 1H, H1a), 2.92 (m, 1H, H1b), 3.30 (m, 1H, H6), 3.57 (s, 8H, H19), 3.70 (m, 12H, H20), 3.93 (s, 
4H, H18), 4.31 (m, 1H, H5), 4.49 (m, 1H, H2), 7.44 (m, 3H, H17, H14), 7.61 (m, 1H, H15), 7.73 (m, 1H, 
H13), 8.08 (s, 1H, H16) ; MS (ESI): ESI-MS for C37H48N6O12S (800.3 g/mol): 822.8 (25%) [M+Na]+, 
801.0 (100%) [M+H]+. Mp ( °C) 87. 
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A 10 mL flask was charged with tetraester 15 
(50.4 mg, 0.067 mmol) and a solution of KOH in 
EtOH (3 mL, 0.5 M). After 15 min a precipitate 
was formed. The reaction mixture was stirred for 
2 h, water (1.3 mL) was added to dissolve the 
precipitate and the reaction was stirred for an additional 2 h. The solution was acidified with HCl 
(1 mL, 2 M). The solvent was removed under reduced pressure and the residue was dissolved in 
MeOH and filtered. The solvent was removed in vacuo to afford the biotinylated ligand Biot-4m-
HXTA-H5 as a white powder (Yield: 20%). 
1H NMR (500.00 MHz, CD3OD, 20 °C): δ (ppm) = 1.25-1.8 (m, 6H, H7, H8, H9), 2.47 (m, 2H, H10), 
2.75 (m, 1H, H1a), 2.97 (m, 1H, H1b), 3.27 (m, 1H, H6), 4.13 (s, 8H, H19), 4.36 (m, 1H, H5), 4.54 (s, 
1H, H2), 4.58 (s, 4H, H18), 7.49-7.69 (m, 3H, H12, H13, H14), 7.81 (s, 1H, H15), 8.25 (s, 2H, H17) ; MS 
(Maldi-TOF, neg) for C33H40N6O12S (744.2 g/mol): 742.7 (100%) [M-H]-. 
 
Synthesis of Biot-4p-HXTA 
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Isobutyl chloroformate (0.32 mL, 2.47 mmol) was added to a 
solution of biotin (496 mg, 2.03 mmol) in DMF (40 mL) 
containing tri-N-butylamine (0.64 mL, 2.69 mmol). After 10 min 
at RT, the mixture was slowly added at 5 °C to a suspension of 
4-aminobenzoic acid (561 mg, 4.1 mmol) in DMF (40 mL). After stirring at 5 °C for 2 h, the solvent 
was distilled under reduced pressure and the crude precipitate was dissolved in warm aqueous 
EtOH (1:1, 36 mL total). The mixture was acidified with 2.0 M HCl to pH 2 and kept at 0 °C for 12 
h. The precipitated product 12 was filtered, washed with water and dried under reduced pressure. 
(Yield: 74%). 
 
1H NMR (400.00 MHz, [D6] DMSO, 20 °C): δ (ppm) = 1.30-1.70 (m, 6H, H7, H8, H9), 2.36 (m, 2H, 
H10), 2.61 (m 1H; H1a), 2.84 (m, 1H, H1b), 3.13 (m, 1H, H6), 4.16 (m, 1H, H5), 4.32 (m, 1H, H2), 6.41 
(br, 1H, H4), 6.50 (br, 1H; H3), 7.72 (d, J = 8.8 Hz, 2H, H12), 7.89 (d, J = 8.8 Hz, 2H, H13), 10.20 (br, 
1H, H11), 12.68 (br, 1H, H14), 13C NMR (100.58 MHz, [D6] DMSO, 20 °C): δ (ppm) = 25.8, 28.9, 
29.1, 37.2, 40.7, 56.3, 60.1, 61.9, 119.1, 125.7, 131.2, 144.2, 163.7, 167.8, 172.6 ; MS (ESI): ESI-
MS for  C17H21N3O4S (363.13 g/mol): 386.13 (100%) [M+Na]+. Mp ( °C) 285 (Dec.). 
 
To a suspension of carboxylic acid 12 
(144 mg, 0.39 mmol) in acetonitrile (10 mL) 
aminophenol 10 (177 mg, 0.38 mmol), 2 chloro-
4,6-dimethoxy-1,3,5-triazine (72 mg, 0.596 
mmol) and N-methymorpholine (0.064 mL, 0.58 
mmol) were added to the suspension. The 
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resulting solution was stirred at RT for 24 h. The crude product was purified by flash 
chromatography (AcOEt/MeOH 8:1) to yield the tetraester 13 as white solid (Yield: 10 %). 
1H NMR (400.00 MHz, CD3OD, 20 °C): δ (ppm) = 1.5-1.8 (m, 6H, H7, H8, H9), 2.46 (m, 2H, H10), 
2.73 (m, 1H, H1a), 2.95 (m, 1H, H1b), 3.25 (m, 1H, H6), 3.60 (s, 8H, H17), 3.74 (s, 12H, H18), 3.96 (s, 
4H, H16), 4.35 (m, 1H, H5), 4.52 (m, 1H, H2), 7.45 (s, 2H, H15), 7.75 (d, J = 8.8 Hz, 2H, H13), 7.92 
(d, J = 8.7 Hz, 2H, H12); MS (ESI): ESI-MS for C37H48N6O12S (800.3 g/mol): 801.0 (100%) [M+H]+, 
822.8 (25%) [M+Na]+. 
 
A 10 mL flask was charged with tetraester 13 
(50.4 mg, 0.067 mmol) and a solution of KOH in 
EtOH (3 mL, 0.5 M) was added. After 15 min a 
precipitate formed. The reaction mixture was 
stirred for 2 h and water (1.3 mL) was added to 
dissolve the precipitate. The solution was stirred 
for an additional 2 h and the solution was acidified with HCl (1 mL, 2 M). The solvent was removed 
under reduced pressure, the residue was dissolved in MeOH and filtered. The solvent was 
removed in vacuo to afford the biotinylated ligand Biot-4p-HXTA-H5 as a white powder (Yield: 
23%). 
 
1H NMR (400.00 MHz, CD3OD, 20 °C): δ (ppm) = 1.36-1.77 (m, 6H, H7, H8, H9), 2.35 (m, 2H, H10), 
2.60-2.63 (m, 1H, H1a), 2.83-2.86 (m, 1H, H1b), 3.13 (m, 1H, H6), 3.93 (s, 8H, H19), 4.24 (m, 1H, 
H5), 4.38 (s, 4H, H18), 4.41 (m, 1H, H2), 7.61 (s, 2H, H17), 7.64-7.66 (d, J = 8.7 Hz, 2H, H13), 7.82-
7.84 (d, J = 8.7 Hz, 2H, H12) ; MS (Maldi-TOF, neg) for C33H40N6O12S (744.2 g/mol): 742.7 (100%) 
[M-H]-. 
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Synthesis of the Biot-phen-HXTA 
 
 
 
A 100 mL Schlenk flask was charged under nitrogen with 
degased acetonitrile (50 mL). Amine 10 (469 mg, 1.03 mmol), 
R-Boc-phenylalanine (275 mg, 1.28 mmol) and 2-chloro-4,6-
dimethoxy-1,3,5-triazine (199 mg, 1.13 mmol) were added. N-
methylmorpholine (0.28 mL, 2.54 mmol) was added dropwise 
and the red reaction mixture was stirred overnight. The solvent was removed under reduced 
pressure and the crude product was dissolved in MeOH and adsorbed on silica. Column 
chromatography (CH2Cl2/MeOH, gradient from 0.00-3.00% MeOH) yielded the Boc-protected 
amine 16 (Yield: 30 %) as a red oil. 
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1H NMR (400.00 MHz, CDCl3, 20 °C): δ (ppm) = 1.29 (s, 9H, H1), 2.30-2.74 (m, 2H, H4), 3.25 (s, 
16H, H12, H14), 3.36 (m, 1H, H3), 3.44 (s, 2H, H4), 3.62 (s, 8H, H13), 7.20-6.70 (m, 7H, H5, H6, H7, 
H8, H9, H11) ; MS (ESI): ESI-MS for C34H46N4O12 (702.31 g/mol): 703.1 (100%) [M+H]+, 724.9 
(20%) [M+Na]+, 740.8 (4%) [M+K]+. 
 
A 5 mL flask was charged with Boc-protected amine 16 (218.2 
mg, 0.31 mmol) and CH2Cl2 (0.5 mL). A solution of trifluoroacetic 
acid (0.46 mL, 6.05 mmol) and anisole (0.045 mL, 0.625 mmol) in 
CH2Cl2 (1 mL) was slowly added. The resulting dark red solution 
was stirred for 3.5 h at RT. The solvent was removed under 
reduced pressure to afford the crude amine 17 (Yield: 100%) as a red oil which was used without 
further purification. 
1H NMR (400.00 MHz, CDCl3, 20 °C): δ (ppm) = 3.51 (s, 12H, H13), 3.68 (s, 8H, H12), 4.32 (s, 4H, 
H11), 6.69-7.40 (m, 10H, H2,H3,H4,H5,H6,H7,H8,H10) ; MS (ESI): ESI-MS for C29H38N4O10 (602.3 
g/mol): 603.1 (100%) [M+H]+. 
 
A 50 mL Schlenk flask was charged with degased 
DMF (5 mL) and activated biotin 5[1] (127 mg, 0.31 
mmol). A solution of amine 17 (187 mg, 0.31 mmol) 
in DMF (20 mL) was added, the red solution was 
stirred and diisopropylethylamine (155 mg, 1.2 
mmol) was added. The reaction mixture was stirred for 40 h at RT and then at 60 °C for 3 h. The 
solvent was removed under reduced pressure and the brown crude product was dissolved in 
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MeOH and adsorbed on silica. The crude product was purified by preparative TLC (Solvent: AcOEt 
4/ MeOH 1) to afford pure tetraester 18 as a yellow solid (Yield: 8.25 %). 
 
1H NMR (500.00 MHz, CD3OD, 20 °C): δ = 1.44-1.76 (m, 6H, H7, H8, H9), 2.5 (m,, 2H, H10), 2.86 
(m, 1H, H1a), 2.90 (m, 1H, H1b), 3.25 (m, 3H, H12, H13), 3.25 (m, 1H, H6) 3.50 (s, 8H, H22), 3.66 (s, 
12H, H23), 3.81 (s, 4H, H21), 4.23-4.30 (m, 1H, H5), 4.40-4.50 (m, 1H, H2), 7.45 (m, 3H, H15, H16, 
H17), 7.61 (m, 1H, H14), 7.76 (m, 1H, H18), 8.1 (s, 2H, H20) ; MS (ESI): ESI-MS for C39H52N6O12S 
(828.3 g/mol): 829.5 (100%) [M+H]+, 851.4 (25%) [M+Na]+. Mp ( °C)  88.5. 
 
A 10 mL flask was charged with tetraester 18 (40 
mg, 0.053 mmol) and a solution of KOH in EtOH (3 
mL, 0.5 M) was added. After 15 min a precipitate 
formed. The reaction mixture was stirred for 2 h, 
water (1.3 mL) was added to dissolve the 
precipitate and the reaction stirred for an additional 2 h. The solution was acidified with HCl (1 mL, 
2 M). The solvent was removed under reduced pressure and the residue was dissolved in MeOH 
and filtered. The solvent was removed in vacuo to afford the biotinylated ligand Biot-phen-HXTA-
H5 as a white powder (Yield: 30%). 
 
1H NMR (400.00 MHz, CD3OD, 20 °C): δ (ppm) = 1.51-1.79 (m, 6H, H7, H8, H9), 2.26 (m, 2H, H10), 
2.71-2.74 (m, 1H, H1a), 2.91-3.12 (m, 1H, H1b), 3.18 (m, 1H, H6), 3.24 (m, 2H, H12), 4.14 (s, 8H, 
H21), 4.29 (m, 1H, H11), 4.52 (m, 1H, H5) 4.56 (s, 4H, H20), 4.70 (m, 1H, H2), 7.23-7.31 (m, 5H, H13, 
H14, H15, H16, H17), 7.63 (s, 2H, H19).; MS (Maldi-TOF, neg) for  C35H44N6O12S (772.3 g/mol): 770.7 
(100%) [M-H]-. Mp ( °C) 240 (Dec.). 
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Complexes: The formation of the {(Biot-spacer-HXTA)Ce2}3+ complex was conveniently 
monitored by the appearance of an absorption band at 472 nm upon addition of ceric ammonium 
nitrate to Biot-spacer-HXTA-H5 at pH 8 as described by Que for the non-biotinylated analogue.[2] 
7.2. Experimental procedure for catalysis 
 
The catalysis was performed in a 96 well plate and the reactions were monitored with a 
thermostatted Tecan Safire-2 plate reader. The following solutions were added to each well by 
means of a 12 channel pipette: 
i) biotinylated ligand (15 µL, 2.4 mM in HEPES 100 mM pH 7), ii) Ceric ammonium nitrate (15 µL, 
4.8 mM for the HXTA ligands in water and 2.4 mM for the IDA ligands). 
iii) streptavidin isoform (100 µL, 0.4 mM with 4 active sites in HEPES 100 mM pH 7). 
iv) enantiopure HPNP substrate (7.5 µL, 10 mM, in HEPES 100 mM pH 7).  
v) buffer (7.5 µL, HEPES 100 mM, pH 7). 
The hydrolysis of the substrate was monitored at 37 °C for 4.5 h at 405 nm. The initial rate for each 
reaction was calculated using the Magellan software. The estimated E was determined as the ratio 
of the slopes of the measured initial rates for both HPNP enantiomers. 
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Yellow dots = reaction mixtures 
Blue dots = empty wells 
 
Figure 19 Schematic representation of the catalytic setup (Selectivity is given by the Estimated E, 
ratio of the initial slopes for each enantiomer). 
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7.3 Summary of initial rates  
Values given in [mmole·h-1], NR : not determined 
 
Entry Protein Enantiomer Biot-2-IDA Biot-3-IDA Biot-HXTA Biot-4m-HXTA 
Biot-4p-
HXTA 
Biot-phen-
HXTA 
1 – (R)-HPNP 2.00E-08 1.83E-08 2.92E-08 3.82E-08 2.68E-08 3.97E-08 
2 – (S)-HPNP 1.30E-08 6.28E-09 0.00E+00 3.03E-08 6.46E-09 4.23E-08 
3 S112A (R)-HPNP 2.89E-09 1.05E-08 6.67E-08 1.03E-07 1.49E-10 6.11E-08 
4 S112A (S)-HPNP 4.39E-09 3.83E-10 7.07E-08 3.21E-08 7.25E-09 1.13E-07 
5 S112G (R)-HPNP 8.18E-10 3.30E-09 1.11E-08 4.08E-09 1.77E-09 1.01E-07 
6 S112G (S)-HPNP 1.05E-08 2.63E-08 7.03E-09 9.31E-09 3.95E-09 1.72E-07 
7 S112V (R)-HPNP 3.75E-09 5.53E-09 3.29E-09 1.32E-08 9.37E-09 1.50E-07 
8 S112V (S)-HPNP 1.04E-09 2.64E-10 3.81E-09 1.65E-08 5.87E-09 7.22E-08 
9 S112H (R)-HPNP 1.05E-08 4.63E-08 4.51E-08 1.09E-10 2.42E-09 1.33E-07 
10 S112H (S)-HPNP 1.22E-08 NR 1.24E-08 NR 3.89E-09 1.47E-07 
11 S112N (R)-HPNP 4.13E-10 8.20E-08 9.51E-09 1.51E-08 2.33E-08 7.19E-08 
12 S112N (S)-HPNP 1.09E-08 6.71E-09 5.93E-08 0.00E+00 0.00E+00 5.52E-08 
13 S112D (R)-HPNP NR 1.83E-07 2.89E-08 9.44E-08 1.54E-09 1.72E-07 
14 S112D (S)-HPNP 3.15E-08 1.55E-08 1.83E-07 9.17E-08 7.84E-09 0.00E+00 
15 S112K (R)-HPNP 2.35E-09 9.82E-09 3.56E-08 1.86E-08 1.40E-08 9.53E-08 
16 S112K (S)-HPNP 2.40E-09 2.40E-09 8.38E-08 1.05E-07 4.81E-09 1.84E-07 
17 S112T (R)-HPNP 1.17E-09 4.17E-08 2.17E-09 2.65E-08 1.97E-09 1.33E-07 
18 S112T (S)-HPNP 1.77E-08 0.00E+00 1.24E-08 1.11E-07 7.17E-09 5.28E-08 
19 WT (R)-HPNP 1.02E-07 8.84E-08 1.69E-07 2.14E-07 1.46E-07 1.69E-07 
20 WT (S)-HPNP 9.62E-08 9.38E-08 1.58E-07 2.13E-07 1.83E-07 1.76E-07 
21 K121G (R)-HPNP 1.10E-07 9.92E-08 1.65E-07 2.09E-07 1.90E-07 2.10E-07 
22 K121G (S)-HPNP 7.90E-08 9.09E-08 1.64E-07 2.16E-07 1.48E-07 2.43E-07 
23 K121H (R)-HPNP 1.08E-07 9.72E-08 1.72E-07 1.43E-07 2.18E-07 1.30E-07 
24 K121H (S)-HPNP 8.06E-08 1.13E-07 9.08E-08 1.94E-07 1.80E-07 1.81E-07 
25 K121N (R)-HPNP 8.33E-08 7.91E-08 1.56E-07 1.71E-07 1.78E-07 1.78E-07 
26 K121N (S)-HPNP 8.19E-08 7.79E-08 1.36E-07 2.09E-07 2.24E-07 1.15E-07 
27 K121R (R)-HPNP 8.78E-08 7.35E-08 1.49E-07 9.58E-08 1.68E-07 1.69E-07 
28 K121R (S)-HPNP 7.59E-08 9.00E-08 1.25E-07 1.86E-07 1.43E-07 1.37E-07 
29 K121F (R)-HPNP 1.25E-07 1.14E-07 1.87E-07 2.00E-07 2.03E-07 2.02E-07 
30 K121F (S)-HPNP 1.22E-07 1.19E-07 1.39E-07 1.21E-07 1.55E-07 8.74E-08 
31 K124G (R)-HPNP 8.16E-08 1.08E-07 9.61E-08 1.80E-07 6.84E-08 8.53E-08 
32 K124G (S)-HPNP 4.37E-08 8.06E-08 4.30E-08 1.16E-07 2.80E-08 7.02E-08 
33 K124V (R)-HPNP 5.08E-08 6.13E-08 4.19E-08 2.08E-08 3.96E-08 2.90E-08 
34 K124V (S)-HPNP 4.04E-08 4.50E-08 2.06E-08 2.38E-08 3.48E-08 NR 
35 K124K (R)-HPNP 7.22E-08 8.16E-08 1.53E-07 1.70E-07 1.70E-07 1.16E-07 
36 K124K (S)-HPNP 7.91E-08 6.32E-08 8.08E-08 1.80E-07 1.42E-07 1.25E-07 
37 K124Y (R)-HPNP 8.20E-08 8.89E-08 1.47E-07 1.96E-07 1.90E-07 1.09E-07 
38 K124Y (S)-HPNP 7.90E-08 9.09E-08 1.64E-07 2.16E-07 1.48E-07 2.43E-07 
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Duplicates: 
 
Entry Biotinylated complex Sav (R)-HPNP kobs/kuncat (S)-HPNP kobs/kuncat 
1 {(Biot-4m-HXTA)Ce2}3+ - 8 8 
2 {(Biot-4m-HXTA)Ce2}3+ - 8 8 
3 {(Biot-2-IDA)Ce}2+ K121G 29 20 
4 {(Biot-2-IDA)Ce}2+ K121G 25 18 
5 {(Biot-2-IDA)Ce}
2+ K121F 23 24 
6 {(Biot-2-IDA)Ce}
2+ K121F 28 28 
7 {(Biot-HXTA)Ce2}
3+ K121F 44 29 
8 {(Biot-HXTA)Ce2}
3+ K121F 43 32 
9 {(Biot-4m-HXTA)Ce2}
3+ L124Y 41 44 
10 {(Biot-4m-HXTA)Ce2}
3+ L124Y 45 49 
11 {(Biot-phen-HXTA)Ce2}
3+ WT 35 37 
12 {(Biot-phen-HXTA)Ce2}
3+ WT 38 40 
13 {(Biot-phen-HXTA)Ce2}
3+ K121G 52 60 
14 {(Biot-phen-HXTA)Ce2}3+ K121G 47 55 
15 {(Biot-phen-HXTA)Ce2}3+ K121F 52 19 
16 {(Biot-phen-HXTA)Ce2}3+ K121F 45 20 
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7.4 Estimated E values 
 
As described in[26] 
 
Entry Protein Biot-IDA-2 Biot-IDA-3 BiotHXTA 
Biot-4m-
HXTA Biot-4p-HXTA 
Biot-phen-
HXTA 
1 – 1 1 1 1 1 1 
2 112A 1.52 27.48 1.06 3.21 48.49 1.85 
3 112G 12.85 7.98 1.58 2.28 2.23 1.70 
4 112V 3.61 20.96 1.16 1.25 1.60 2.08 
5 112H 1.16 >65 3.64 >65 1.61 1.10 
6 112N 1.02 1.02 1.15 1.22 1.26 1.54 
7 112D >65 11.82 6.34 1.03 5.11 >65 
8 112K 1.02 4.10 2.35 5.65 2.90 1.00 
9 112T 15.15 >65 5.69 4.19 3.63 2.53 
10 WT 1.06 1.06 1.07 1.00 1.26 1.04 
11 121G 1.39 1.09 1.01 1.03 1.28 1.15 
12 121H 1.34 1.16 1.90 1.35 1.21 1.39 
13 121N 1.02 1.02 1.15 1.22 1.26 1.54 
14 121R 1.16 1.22 1.19 1.95 1.18 1.23 
15 121F 1.02 1.05 1.34 1.65 1.31 2.31 
16 124G 1.87 1.34 2.24 1.55 2.44 1.21 
17 124V 1.26 1.36 2.03 1.14 1.14 >65 
18 124K 1.10 1.29 1.89 1.06 1.20 1.08 
19 124Y 1.04 1.02 1.12 1.10 1.29 2.23 
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7.5 Turnover number 
 
 
Best conversion results per metalloenzyme 
 
Entry Metalloenzymes TON 
1 {(Biot-2-IDA)Ce}2+ ⊂ K121G 1.64 
2 {(Biot-3-IDA)Ce}2+ ⊂ K121G 1.61 
3 {(Biot-HXTA)Ce2}3+ ⊂ K121G 1.80 
4 {(Biot-4m-HXTA)Ce2}3+ ⊂ K121G 1.95 
5 {(Biot-4p-HXTA)Ce2}3+ ⊂ K121G 1.55 
6 {(Biot-phen-HXTA)Ce2}3+ ⊂ K121G 1.91 
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7.6 Michaelis-Menten kinetics 
 
The Michaelis-Menten experiment was performed in a 96 well plate and the reactions were 
monitored with a thermostatted Tecan Safire 2 plate reader. The following solutions were added to 
each well by means of a 12 channel pipette: 
i) Biot-4m-HXTA (15 µL, 2.4 mM in HEPES (100 mM, pH 7)). 
ii) Ceric ammonium nitrate (15 µL, 4.8 mM) in water. 
ii) K121G (100 µL, 0.4 mM with 4 active sites in HEPES (100 mM, pH 7)). 
iv) The enantiopure HPNP substrate (prepared according to the table as a 10-fold concentrated 
solution, in HEPES (100 mM pH 7)).  
v) Buffer (7.5 µLHEPES (100 mM, pH 7)). 
The hydrolysis of the substrate was monitored at 37 °C for 4.5 h at 405 nm. The initial rate for each 
reaction was calculated using the Magellan software. 
 
Results of the Michaelis-Menten kinetics  
 
Entry Substrate [mM] 
Artificial enzyme 
[mM] 
Initial rate (R)-
HPNP 
[mM s-1]·10-7 
Initial rate (S)-
HPNP 
[mM s-1]·10-7 
1 10.000 0.4 mM 7.0455 0.4203 
2 10.000 0.4 mM 6.0998 0.3141 
3 5.0000 0.4 mM 5.0100 0.1578 
4 5.0000 0.4 mM 4.6138 0.0584 
5 2.5000 0.4 mM 4.1840 0.7244 
6 2.5000 0.4 mM 3.8206 0.7078 
7 1.2500 0.4 mM 2.1560 0.7198 
8 1.2500 0.4 mM 2.0342 0.4193 
9 0.6250 0.4 mM 1.8055 0.4713 
10 0.6250 0.4 mM 1.6597 0.3799 
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11 0.3125 0.4 mM 1.6725 0.3549 
12 0.3125 0.4 mM 1.4038 0.0103 
13 0.1563 0.4 mM 0.9211 0.6491 
14 0.1563 0.4 mM 0.8197 0.5910 
15 0.0781 0.4 mM 0.3140 0.2238 
16 0.0781 0.4 mM 0.2118 0.1914 
17 0.0391 0.4 mM 1.0255 0.1742 
18 0.0391 0.4 mM 0.9481 0.1351 
19 0.0195 0.4 mM 0.2588 0.3451 
20 0.0195 0.4 mM 0.1087 0.3446 
 
Programme:  
 
 
 
Values given by Prism 5 for mac OS X, Version 5.0, December 21, 2009 
 
Michaelis-Menten (R)-HPNP (S)-HPNP 
 
 
 
 
  
Best-fit values   
Vmax 7.228e-007 3.392e-008 
KM 2.344 0.009141 
Std. Error   
Vmax 4.115e-008 5.077e-009 
KM 0.3504 0.01398 
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Chapter 3:  
Artificial Transfer Hydrogenases for the 
Enantioselective Reduction of Aryl  
Ketones and Cyclic Imines 
 
 
 
«Le mental intuitif est un don sacré et le mental rationnel est un serviteur fidèle. Nous avons créé 
une société qui honore le serviteur et a oublié le don» 
 
        Albert Einstein 
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Chapter 3: Artificial transfer hydrogenases for the enantioselective reduction of 
aryl ketones and cyclic imines 
1. Abstract 
The first part of the chapter describes the incorporation of biotinylated, “racemic” at metal three-
legged d6-piano stool complexes in streptavidin yielding enantioselective transfer hydrogenation 
artificial metalloenzymes for the reduction of ketones. In a previous screening step, S112A and 
S112K were identified, respectively, as the best (R) and (S)-selective streptavidin mutants for the 
reduction of acetophenone derivatives.  
 
The X-ray structure analysis of the S112K variant containing the [η6-(benzene)Ru(Biot-p-L)] 
confirmed the prediction that this mutated residue is close to the catalytic site, providing valuable 
structural insight into the “second coordination sphere” of the complex. The X-ray structure was 
used to identify two additionnal residues that are likely to influence catalysis: K121 and L124. 
 
To test this hypothesis, a second screening step was carried out in a panel of immobilized double 
mutants after saturation mutagenesis at positions K121 and L124, conserving the S112K and 
S112A mutations. The results of this screen for the reduction of ketones confirmed that K121X and 
L124X mutations can dramatically influence catalysis; further, these experiments showed that a 
combination of rational design and directed evolution, which was termed “designed evolution”, is a 
powerful means to fine-tune the selectivity of artificial metalloenzymes.  
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The second part of the chapter describes the incorporation of biotinylated racemic three-legged d6-
piano stool complexes into streptavidin yielding artificial metallohydrogenases for imine reduction. 
A library of biotinylated complexes was combined with a library of proteins resulting from saturation 
mutagenesis at position S112. This approach allowed the improvement of conversion and ee for 
the reduction of the drug-precursor 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline. The best 
artificial metalloenzyme with the S112A Sav isoform achieved 100% conversion and an ee of up to 
93% (R). Incorporation of the complex [η5-(Cp*)Ir(Biot-p-L)Cl] into the S112A Sav isoform lead to 
a 3-fold rate acceleration compared to the complex alone.  
 
The X-ray structure of the most selective artificial imine reductase allowed speculations on the 
reduction mechanism of a drug precursor (Salsolidine). Finally, streptavidin generated insoluble 
protein polymers cross-linked called CLEAs (Cross Linked Enzymes Aggregates) thus allowing a 
new protocol for immobilized artificial metalloenzymes for imine reduction. 
2. Introduction 
2.1 Transfer hydrogenation 
Transfer hydrogenation refers to the reduction of an unsaturated molecule using a hydrogen donor 
other than H2. Transfer hydrogenation (TH) is an alternative to hydrogenation processes and 
present many advantages: The reaction is easy to implement, takes place under mild conditions 
and does not use hazardous hydrogen gas.  
2.1.1 Ketone reduction 
Chiral alcohols are important intermediates in the synthesis of various high value-added 
chemicals.[1] One of the best routes to obtain such compounds is the asymmetric reduction of 
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carbonyl compounds. Chemical stereoselective reduction of carbonyl functionalities is a simple 
transformation but has been a challenge for synthetic chemists. The first example of transfer 
hydrogenation of carbonyl groups has been described with the Meerwein-Ponndorf-Verley (MPV) 
reduction discovered in 1925[2] but in the past decade an extensive development of highly active 
and selective catalysts for the reduction of carbon-heteroatom unsaturated bonds has been 
described.[3] A major breathrough in asymmetric transfer hydrogenation of carbonyl compounds 
was achieved with the work of Noyori et al. using d6 piano-stool ruthenium complexes formed with 
aminosulfonamide ligands such as Ts-DPEN (N-(p-toluenesulfonyl)-1,2-
diphenylethylenediamine).[4] 
2.1.2 Metal complexes 
A variety of metal complexes have been used in ATH of carbonyl compounds allowing high 
conversion and selectivities. Most of them bear bi-, tri-, or tetradentate ligands containing nitrogen, 
oxygen or phosphorus as coordinating atoms. A selection of some of the best ligands are given in 
figure 1.[3c, 5] The monotosylated (1 and 2) ligand [4, 5b, 6], the 1,2-amino alcohols (3 and 4)[3a, 7] and 
some phosphinoaxazolines derivatives[8] (5) give the best conversions and enantioselectivities. In 
addition, Reetz, recently, described the BINOL-derived disphosphonite ligand (8) with very large 
scope.[9] 
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Figure 1 Some of the most effective ligands for the ATH of ketones. 
 
Typical metal fragments associate with the bidentate monotosylated ligands (see figure 1, 1 and 2) 
to give half sandwich π-complexes such as Ru-Arene or Ir/Rh-cyclopentadienyl moities possessing 
an additional ligand, typically a halide (see figure 2). 
 
 
 
 
 
 
 
 
 
Figure 2 Schematic representation of Ru, Ir or Rh complexes as ATH catalysts precursors. 
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2.1.3 Hydrogen source 
The most common sources of hydrogen for ATH of ketones are isopropanol, azeotropic mixtures 
of isopronapol with triethylamine, formic acid or formate salts. Isopropanol is the most commonly 
used solvent and hydrogen donor, as it is cheap and easy to handle. The activation of the catalyst 
precursor is achieved by addition of a base to the hydrogen donor (e.g. potassium hydroxide).[3a, 10] 
Isopropanol is oxidized to acetone (a possible substrate for reduction). In consequence, the 
reduction of ketones in isopropanol is governed by the redox potential of the ketone/alcohol 
couple. The reversibility of the reaction constitutes a major limitation of the reductions with 
isopropanol.[3a] To circumvent this problem, formate salts or formic acid triethylamine mixtures 
have been used in an open system to drive the reaction to completion. The irreversible formation 
of CO2 (g) with generation of the metal hydride favours an irreversible reaction.[4] One limitation of 
the process is the decomposition of the catalyst in contact with high concentrations of formic 
acid.[3c] 
2.1.4 Mechanism 
The mechanism of transfer hydrogenation for either imine or ketone reduction is the same and is 
divided into two broad classes. The first is the MPV reduction by which a metal coordinates both 
substrate and hydrogen source and hydrogen transfer takes place via a six-membered transition 
state (see figure 3), the mechanism in called the “direct hydrogen pathway” and is observed when 
the metal cannot readily form a metal hydride.[11] 
 
 
Figure 3 Direct hydrogen pathway, the hydrogen transfer takes place via a six-membered 
transition state. 
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In contrast, the second is a “hydridic route” where a metal hydride is involved. Most of the time, 
metals such as Rh, Ru and Ir favor this mechanism due to their ability to form hydrides. The 
hydrititic route is further divided in two: the first is a dihydride mechanism and the second one is a 
monohydride mechanism. The monohydride mechanism contains two different subclasses: the 
inner sphere without ligand assistance and coordination of the substrate to the metal and the outer 
sphere with ligand assistance and no coordination of the substrate to the metal. Noyori’s Ru(II) Ts-
DPEN follows a monohydride mechanism with ligand assistance.[1, 10] (see figure 4) 
 
 
Ln = n ligand(s) coordinated to the metal, L = basic group on the ligand, M = Metal. 
Figure 4 Overview of the possible reduction pathways: the dihydride mechanism a) the 
monohydride mechanism with coordination of the substrate to the metal (inner sphere mechanism) 
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b) the monohydride mechanism without coordination of the substrate to the metal (outersphere 
mechanism) c). 
The proposed catalytic cycle[11d] for [Ru(p-Cymene)(R,R-TsDPEN)Cl] complex[1, 3a, 12] is depicted in 
figure 5. The true catalytic species is the 16 e- Ru complex B formed from the catalyst precursor A 
by elimination of HCl in the presence of a base. Deprotonation of the hydrogen donor leads to the 
18 e- Ru-hydride complex C. The hydride and the axial NH proton are transferred simultaneously 
from the 18 e- Ru complex to the substrate via a six membered ring transition state, to regenerate 
the 16 e- complex B.[11d] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Catalytic cycle for the transfer hydrogenation of on aromatic ketone using the [Ru(p-
Cymene)(R,R-TsDPEN)Cl]  and isopropanol as the hydrogen donor.[11d] 
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2.1.5 Enantioselection mechanism 
The enantioselectivity of the reaction presented in figure 6 is the result of a combination of steric 
and electronic factors.[1] From the trigonal planar 16 e- complex, the hydride species is formed, the 
chirality at the ruthenium is dictated by the enantiopure ligand to give one major diastereomer of 
the complex.[3a] The conformation of the five-membered ring formed by the chelating ligand and 
the ruthenium is defined by the bulky groups on the ligand (Phenyl groups in the case of Ts-DPEN) 
occupying pseudo-equatorial positions.[3a] The enantiodiscrimination between the two prochiral 
faces of the ketone is caused by chemical interactions between the capping arene and the aryl 
group of the ketone.[13] Computational studies have shown that the C-H•••π is contributing to the 
stabilization of the transition state and is the major factor governing the enantiodiscrimination.[1] In 
this context, the modulation of the capping arene influence the enandiscrimination process and 
increased C-H•••π interactions provide better enantiodiscriminations (see figure 6).[3c] 
 
 
 
 
 
 
 
 
 
 
Figure 6 Favored transition state (with C-H•••π interactions) and less favored transition state 
(without C-H•••π interactions). 
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2.1.6 Water compatible systems 
Recently, aquaeous transfer hydrogenation reactions of ketones were developed.[5b] For this 
purpose, water-soluble ligands bearing polar or ionic groups (e.g. sulfonic acids) were synthetized 
and used for aqueous transfer hydrogenation.[14] However, non-modified water-insoluble ligands 
were more active and enantioselective.[5b] To solve the problem of solubility of both the substrate 
and the catalyst, surfactants were added to the reaction mixture but in most of the case, the 
insolubility of the ketone did not affect the reaction rate.[5b] Finally, the reduction rates were 
considerably faster using HCOONa than the HCOOH/Et3N azeotrope or i-PrOH.[15] In this context, 
Xiao has showed that both the reaction rate and the enantioselectivity of aqueous transfer 
hydrogenation reactions critically depend on the pH.[16] 
2.1.7 Asymmetric transfer hydrogenation of non aromatic ketones 
Aryl alkyl ketones are reduced with excellent enantioselectivities. In contrast, dialkylketones are 
challenging to reduce due to the absence of the C-H•••π interaction between the capping arene 
and the aryl group of the substrate.[1, 13] Woggon et al. reported on a Ru(II) Ts-DPEN complex 
linked to a β-cyclodextrin.[17] This catalytic entity provides a hydrophobic cavity for aliphatic 
substrates. Tethered ligand-arene Ru complexes were also described for the selective reduction of 
cyclohexyl methyl ketone.[18] Ru phosphino-oxazolides were developed as an alternative for the 
reduction of dialkylketones.[8b, 19] 
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2.2. Imine reduction 
Enantiopure amines represent an important class of compounds as they find wide use in industry 
(pharmaceutical, agrochemical and flavor).[20] In this context, enzymatic, homogeneous catalysis 
and chemoenzymatic approaches offer complementary means for the preparation of such 
targets.[21] Artificial metalloenzymes complete these approaches and have received increasing 
attention in the past years. The Ward group has previously reported artificial metalloenzymes for 
ketone reduction via transfer hydrogenation inspired by Noyori and coworkers but not for cyclic 
imines.[22] 
 
2.2.1 Transfer hydrogenation (TH) and asymmetric Transfer Hydrogenation (ATH) of imines 
in organic solvents 
 
In 1987, it was reported that Ru3(CO)12 was able to catalyze the transfer hydrogenation (TH) of 
benzylideanilines in isopropanol. The isolated active catalyst was a trimetallic hydride.[23] A Few 
years later, in 1992, racemic imine reduction via [RuCl2(PPh3)][24] was reported by Bäckvall. X-ray 
analysis of the catalyst demonstrated a metal hydride complex and mechanistic studies showed 
that a monohydride mechanism without ligand-assistance was operative (see figure 4). Many 
catalysts were described to be efficient for the TH of imines and a good example is given by the 
highly effective Shvo diruthenium catalyst studied by Casey and Bäckvall (9).[11a, 25] The 
asymmetric transfer hydrogenation (ATH) of imines under very mild conditions (room temperature 
and no need of hydrogen gas) via the Ru(II) Ts-DPEN[26] (10) was reported by Noyori and 
coworkers in 1996 (see figure 7). An azeotropic mixture of formic acid, triethylamine were usually 
used as H2 source.  
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      9    10 
 
Figure 7 Some efficient catalysts for TH and ATH of imines. The Shvo catalyst dissociates in 
solution thereby forming the catalytically active mononuclear species a) Noyori’s Ru(II) Ts-DPEN, 
an active catalyst working via a ligand-assisted monohydride mechanism b). 
 
Ru(II) Ts-DPEN also allowed the reduction of cyclic imines bearing an alkyl and a benzyl groups 
providing very effective and general routes for the asymmetric synthesis of isoquinoline alkaloids 
and direct access to natural products. In contrast, imines bearing two aryl on the imine carbon are 
reduced with lower enantioselectivity.[11c] 
2.2.2 Asymmetric transfer hydrogenation of imines in water 
Some studies have achieved the ATH of imines in water, for example, Xiao et al. have shown that 
Ru(II) Ts-DPEN bearing an SO3H is an active water soluble catalyst.[15] Wu et al, using the same 
catalytic system were able to reduce cyclic imines and iminiums in water.[28] A surfactant (CTAB = 
cetyl trimethylammonium bromide) and sodium formate as a hydrogen source were used to 
improve the ee. In the same spirit, Süss-Fink et al. where able to apply cationic arene ruthenium 
complexes containing chiral sulfonated diamine ligands for ketone and imine reduction in water.[29] 
Some other recent developments allowed immobilization of active complexes for ATH of imines in 
water. The system is based on a polymer-immoblized Ru(II) TsDPEN and has the advantage of 
recyclability while giving high ee.[30] 
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Major achievements were obtained by Xiao et al. on ATH of imines in water. He first performed the 
reduction of cyclic imines with a Cp* Rh(III) Ts-DPEN catalyst giving excellent yields and ee.[31] 
The nature of the catalyst conterion played a major role in conversion; SbF6- had the biggest 
influence on the reaction allowing full conversion of the substrate. He later performed ATH of 
quinolines using pH regulation. Excellent ees and conversions were obtained especially for the 
Cp* Rh(III) Ts-DPEN complexes.[32] 
Finally, Pihko et al. reported high enantioselectivities for the preparation of tetrahydroisoquinolines 
and β-carboline alkaloids using Ru(II) Ts-DPEN in water.[33] The anion in this context played a 
determinant role in conversion of substrates. Moreover, lanthanide salts such as La(OTf)3 or 
surfactants such as CTAB improved the conversion of insoluble deactivated substrates.  
It is interesting to mention that, many studies were achieved in the ATH of imines but the 
mechanism of the reaction is still a matter of debate. 
2.2.3 Imine reduction mechanism with Ru(II) Ts-DPEN 
Noyori et al. proposed a widely accepted mechanism for the transfer hydrogenation of ketones 
with Ru(II) Ts-DPEN as catalyst. In contrast, the mechanism of imine reduction is less well 
understood. Generally, cyclic imines are reduced with high enantioselectivity and the rate of the 
reaction is usually higher than that of ketone reduction by asymmetric transfer hydrogenation 
catalysts based on Ts-DPEN. The mechanism of imine reduction has been discussed and different 
modes of reduction have been proposed.[34] 
 
A C-H•••π interaction plays a key role in the mechanism of enantioselective ketone reduction but 
imine reduction seems to proceed via a different mechanism. Bäckvall[26b] has shown that only 
protonated imines are reduced by isolated hydride intermediates. In contrast, Blackmond’s 
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investigations on imine reduction with a Rh(III) catalyst suggested that a deprotonated imine is the 
true substrate (not the corresponding iminium).[35] 
 
The mechanism of ketone reduction cannot be simply superimposed to that of imine reduction as 
shown by the opposite sense of asymmetric induction observed using Noyori’s Ru(II) Ts-DPEN 
complex.[34] Within this context, Wills proposed two alternative mechanisms.[34] The first is the 
reduction of the imine via a six-membered transition state oriented such that the relative positions 
of alkyl and aryl groups are inverted compared to the proposed transition state in Noyori’s 
mechanism (see figure 8). The second one is a reduction through an ionic mechanism where the 
imine  
 
a)     b)           c)    
  
 
Figure 8 Proposed transition states for imine reduction using Noyori’s (R,R)-TsDPEN catalyst (R)-
product predicted by Noyori’s mechanism: Produces incorrect product enantiomer (S) a)(S)-
product predicted by Wills’ mechanism: Produces correct product enantiomer (Wills’ proposed 
mecanism) b) (S)-product predicted by Wills’ mechanism: Produces correct product enantiomer 
(Wills’ proposed mecanism) c) 
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forms an iminium cation without the involvement of a six-membered transition state. It allows the 
formation of C-H•••π interactions and delivers the correct enantiomer. However, Wills’ 
investigations of these mechanisms with Ru(II) N-alkylated Ts-DPEN ligands for ketone and imine 
reduction didn’t give a definitive description of the mechanism of imine reduction. 
2.2.4 Artificial transfer hydrogenases 
Letondor et al.[22] reported, on artificial transfer hydrogenases for the reduction of prochiral 
ketones. The hybrid catalysts were created by combination of various biotinylated metal d6 piano 
stool complexes. In particular, the [η6-(benzene)Ru(Biot-p-L)Cl] and [η6-(p-cymene)Ru(Biot-p-
L)Cl] complexes were combined with a library of Sav isoforms generated by saturation 
mutagenesis at position S112. They provided good (S)-selective respectively (R)-selective 
catalysts. Later on, to get insight into artificial transfer hydrogenases, efforts were invested to 
crystallize the most promising combination of biotinylated d6 piano stool into Sav isoforms. A 
crystal structure of the [η6-(benzene)Ru(Biot-p-L)Cl] ⊂ S112K Sav (In collaboration with Dr. Marc 
Creus, Isolde Letrong and Prof. Ronald Stenkamp from University of Washington). The refined 
structure (1.58 A resolution, PDB code 2QCB) revealed the spatial organization of the active site of 
the (S)-selective metalloenzyme. It is important to mention that the occupancy of the ruthenium 
inside streptavidin is 20% due probably to: 
- Conformational flexibility inside the protein 
- Ruthenium decomplexation during co-crystallization 
- Steric clashes (in the case of simultaneous occupation of the two adjacent binding sites by 
the ruthenium complex). Furthermore, the metal is located near a subunit-subunit interface and 
stands close to the neighboring biotinylated complex (The Ru, Ru distance is about 4.44 Å). In this 
context, incorporation of the bulky biotinylated complex doesn’t generate a structural 
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reorganization of the protein. Compared to the Sav WT, a root mean square (RMS) 0.276 Å for the 
121 Cα atoms was computed (see figure 9). Interestingly, only the (S)-enantiomer of the 
biotinylated complex [η6-(benzene)Ru(Biot-p-L)Cl] was localized in the crystal structure. In 
homogeneous systems, the (S)-Ru configuration is known to generate the (S)-reduction product of 
acetophenone derivatives. Most interestingly, the [η6-(benzene)Ru(Biot-p-L)Cl] was the most (S)-
selective hybrid catalyst identified in previous studies in our group. It renders possible the 
enantioselective discrimination by the protein for one of the two enantiomers of the complex given 
by second coordination sphere interactions. The structure also demonstrated that, S112 position 
lies close to the Ru atom (in accordance with the docked structure[22b]). Additional short contacts 
between the biotinylated catalysts [η6-(benzene)Ru(Biot-p-L)Cl] can be identified: 
- Residues of the L 7,8 (110-124) of both Sav monomer A and B 
- G48 (part of the loop 3,4) of the monomer A 
- H87 (part of the loop 5,6) of the monomer A 
Position 121 is of particular interest since it may interact with the trajectory of the incoming 
substrate (monomer A) or with capping arene (monomer B). Further investigation on the crystal 
structure demonstrated that position 124 may interact with the SO2 moiety of the ligand thus 
influencing the position of the biotinylated complex inside the pocket. 
Even if the structure provides important knowledge about the position of the biotinylated complex 
into Sav, it does not provide any information about the reaction mechanism. As a consequence, 
evolution of the artificial metalloenzyme cannot be based only on rational redesign. It thus required 
mutagenesis and screening experiments to further optimize the artificial enzyme. In order to 
generate highly (R) and (S)-selective artificial metalloenzymes, the most selective biotinylated 
complexes were combined with a designed evolution strategy. Design evolution relied on 
Ketone and Imine reduction 
Chapter 3 
     
109 
saturation mutagenesis at selected close-lying positions identified by X-ray cristallography (see 
figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 X-ray crystal structure of [η6-(benzene)Ru(Biot-p-L)Cl]!⊂ S112K Sav. Close-up view 
(only monomer B (blue) occupied by the biotinylated catalyst (ball-and-stick representation); 
monomers A (green), C (orange), and D (yellow)) a) Highlight of amino acid side-chain residues 
displaying short contacts with Ru. The absolute configuration at ruthenium is (S) b) 
Superimposition of the structure of [η6-(benzene)Ru(Biot-p-L)Cl]!⊂ S112K Sav with the structure 
of biotin!⊂ core streptavidin (PDB reference code 1STP, only monomers A and B displayed for 
clarity; biotin: white stick, core streptavidin: white tube) c) Ru"Cα distances extracted from the X-ray 
structure of [η6-(benzene)Ru(Biot-p-L)Cl]!⊂ S112K Sav; monomers: A black, B blue, C green, and 
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D red d). 
 
For this second round of optimisation, the enantioselective reduction of dialkylketones was 
selected. Dialkylketone substrates are challenging since they don’t exhibit the critical C-H•••π 
interaction with the complex. In natural enzymes (e.g. ADHs), the second coordination sphere 
plays a critical role in the enantiodiscrimination of such substrates. It was reasoned that with this 
artificial system, controlling the second coordination sphere around the catalyst may allow 
exquisite enantiodiscrimination even for challenging substrates. Saturation mutagenesis at 112 did 
not suffice to produce high levels of selectivity for the reduction of dialkyl ketones. Identification of 
residues close to the metal center was of particular interest for two reasons: the first one is an 
interaction with the metal center and the second one is an interaction with the incoming substrate. 
It this context, K121 and L124 positions were selected for saturation mutagenesis. K121 may steer 
the delivery of the substrate while may L124 alter the position of the complex in the binding pocket. 
Since good enantioselectivity was provided by the [η6-(p-cymene)Ru(Biot-p-L)Cl] ⊂ S112A 
towards the (R)-enantiomer and [η6-(benzene)Ru(Biot-p-L)Cl] ⊂ S112K towards the (S)-product, 
saturation mutagenesis was performed at the position 121 and 124 keeping the position S112A 
and S112K thus generating a library of double mutants. A total of 114 Sav mutants were produced 
(K121X, L124X, S112A-K121X, S112K-K121X and S112K-K121X, S112K-K124X) and tested with  
complexes [η6-(p-cymene)Ru(Biot-p-L)Cl] and [η6-(benzene)Ru(Biot-p-L)Cl]). The activated p-
bromoacetophenone and the challenging 4-phenyl-2-butanone were chosen as model aromatic, 
and aliphatic substrates respectively (see figure 9). The acceleration of the screening process was 
achived by immobilization of artificial metallotransferase. Hence, the implemented library allowed 
extending the concept of artificial metallotransferase for the reduction of prochiral cyclic imines. 
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3. Ketone reduction: results and discussion 
3.1 Extraction-Immobilization Protocol: Quick Screening Strategy 
To accelerate the optimization process, a quick screening protocol was implemented. The first 
round of screening for the chemogenetic optimization required the use of milligram quantities (3-4 
mg per catalytic experiment) of the twenty purified Sav mutants to perform the catalytic 
experiments. Since the production and purification of Sav in our laboratory lasts nearly three 
weeks for the production of one mutant (including purification and lyophilisation), an alternative 
technique for testing the 114 new Sav mutants was necessary. 
3.2 Catalysis with Streptavidin-Containing Crude Cell Extracts 
In order to generate a fast screening, a screen method was implemented on cell crude extracts 
produced in small volume culture of E.coli bacteria (50 ml) giving approximatively 1 mg of protein 
(determined by titration using B4F). The cell extracts were treated with DNAase and extracted in 
1.5 ml of water to recover the protein tested in catalysis. The quantification of streptavidin in 
extracts demonstrates that the concentration of the protein is three times lower than the 
concentration of the protein in optimal catalysis conditions. This lead to lower conversions 
compared to standard conditions. The crude extracts were tested in catalysis. However no 
conversion and ee was observed (see table 1). A variety of cell debris are still present (DNA, 
Lipids, Proteins, Sugars, Salts) all of these components may inhibit the catalysis by interaction with 
the metal center. These results suggest that, in contrast to enzyme optimization via evolutionary 
techniques– where screening can be performed on colonies or crude cell extracts –, the presence 
of an exogenous set of molecules inhibit the artificial metalloenzymes. Indeed, to the best of our 
knowledge, all experiments in the area of artificial metalloenzymes have thus far been performed 
with homogeneous purified proteins. This long purification step is the bottleneck for artificial 
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metalloenzyme optimization. 
 
Table 1 Comparison of the results obtained with purified S112Y Sav crude cell extracts containing 
S112Y Sav for the reduction of acetophenone using [η6-(p-cymene)Ru(Biot-p-L)Cl]. 
 
Entry Protein Sav [µM] Conv. (%) ee (%) 
1 pure 251 95 90 (R) 
2 pure 100 59 60 (R) 
3 Cell extract 100 0 - 
4 Pure + cell extract 100 0 - 
 
3.3 Immobilisation process 
To resolve the problem of protein purification, an immobilization protocol was implemented (in 
collaboration with Dr. Anca Pordea) of Sav using iminobiotin sepharose and biotin sepharose 
(commercially available, see figure 10 and 12). Since biotin or imino-biotin has a high affinity for 
streptavidin, it was speculated that immobilisation of Sav directly from the crude cell extracts could 
be possible. In this context, iminobiotin sepharose allows the release of Sav after purification by 
adjusting the pH. When biotin-sepharose is used, one binding site is sacrificed for immobilisation 
thus leaving three free binding sites to incorporate the biotinylated piano stool complex and to 
perform catalysis (see figure 12). Comparison of the two immobilisation techniques showed that 
both methods can be used for rapid purification of Sav but with some loss of conversion and 
enantioselectivity (see table 2). Futhermore some disadvantages are apparent for the 
immobilization techniques. First the affinity of Sav for imino-biotin is lower than the affinity for 
biotin, it is especially problematic for low protein concentration in some cell crude extracts. 
Secondly, for iminobiotin sepharose immobilisation, the pH must be adjusted for the catalysis (form 
pH=2.9 to 6.25) increasing the total volume of the catalysis and generating lower ee and 
conversion. In contrast, immobilization on biotin-sepharose appeared to be a more robust system 
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and was selected for further use for the screening of the 114 Sav mutants (see figure 10 and 11). 
Guanidinium chloride (1 M solution) and the HCOONa/B(OH)3 mixture (the hydrogen source for 
catalysis) were used as washing solutions for the first and the second washing steps, respectively.  
 
Table 2 Comparison of the iminobiotin- and biotin-sepharose extraction and purification techniques 
of streptavidin from crude cell extracts. The catalysis were performed using [η6-(p-
cymene)Ru(Biot-p-L)Cl] ⊂ P64G Sav for the reduction of p-methylacetophenone. The washing 
steps in the case of biotin-sepharose immobilization were realized using H2O / DMF = 50 / 1. 
 
Entry Purification technique Protein Conv(%) ee (%) 
1 - pure 92 94 (R) 
2 biotin pure 92 93 (R) 
3 iminobiotin pure 90 87 (R) 
4 biotin Cell extract 76 73 (R) 
5 iminobiotin Cell extract 57 82 (R) 
 
The immobilization protocol on biotin-sepharose was further tested with various Sav isoforms and 
compared with non-immobilized streptavidin (see table 3). 
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Table 3 Comparison of the results obtained for the transfer hydrogenation of p-
bromoacetophenone (11) using biotin-sepharose immobilized- and purified homogeneous artificial 
metalloenzymes [η6-(arene)Ru(Biot-p-L)Cl] Sav. 
 
   
Pure non-immobilized Sav 
Immobilized Sav 
(from cellular extract) 
Entry η6-(arene) Sav isoforms Conv (%) ee (%) Conv (%) ee (%) 
1 p-cymene Wt Sav 93 87 (R) 81 65 (R) 
2 benzene Wt Sav 43 57 (S) 31 39 (S) 
3 p-cymene S112A Sav 78 87 (R) 57 64 (R) 
4 benzene S112KSav 25 44 (S) 21 38 (S) 
 
Although the purification and immobilization process with biotin sepharose leads to a noticeable 
erosion of the ee and the conversion, the immobilization protocol of biotin-sepharose was used to 
speed up the catalytic rounds thus allowing valuable trends for the catalytic runs. The protocol was 
extensively used to perform round of designed evolution (see figure 10 and 11). 
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a) Immobilisation on iminobiotin-sepharose 
 
 
 
 
 
 
 
 
 
b) Immobilisation on biotin-sepharose 
 
 
 
 
 
 
 
 
 
Figure 10 Rapid techniques for the extraction and purification of streptavidin from crude cell 
extracts. Immobilization on iminobiotin-sepharose, followed by washing (pH = 9.8) and elution (pH 
= 2.9) steps affords pure Sav a) Using biotin-sepharose affords the immobilized artificial 
metalloenzyme after several washing cycles b) 
Washing Complex:5 eq per tetramer
Washingbiotin-
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Figure 11 Catalysis process with immobilization 
Step 1: Cell culture of E.Coli (50 ml) producing Sav isoforms 
Step 2: Centrifugation of the bacteria and freezing of the pellet 
Step 3: Extraction of the protein in water (total volume of 1.5 ml) 
Step 4: Quantification of the crude extracts containing Sav (B4F titration) 
Step 5: Fishing of the protein with biotin-sepharose 
Step 6: Catalysis with immobilized Sav 
Step 7: HPLC analysis of the catalysis 
Step 8: Analysis of the results 
Step 1: Culture
Step 2: Centrifugation
Step 3:Extraction
Step 4: Quantification
Step 5: Fishing
Step 6: Catalysis
Step 7: HPLC
Step 8: Analysis
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Figure 12 Schematic representation of the immobilized artificial metalloenzyme for transfert 
hydrogenation reactions a) Substrates used for transfer hydrogenation of ketones b) 
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3.4 Screening and Trends of the Immobilized Artificial Metalloenzymes 
Catalytic experiments of the screening were performed in collaboration with Dr. Anca Pordea using 
the immobilization strategy described previously. Semi-quantitative trends were obtained out of the 
experiments for both the reduction of 4-phenyl-2-butanone and for p-Bromoacetophenone (see 
figure 12 and 13). The enantioselective trends revealed in a fingerprint display where cherry color 
codes for the (S)-product while green codes for (R)-product. Two substrates are depicted in one 
square for comparison. The fingerprint allows rapid comparison between each combination of 
mutants and complexes thus allowing qualitative analysis of trends. 
 
 
Figure 13 Fingerprint of the results obtained for the ketone reduction catalysez by artificial 
metalloenzymes. 
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3.5 Substrate: aromatic vs. dialkyl ketone 
In general, the two substrates behave similarly in terms of enantioselectivity. It is noteworthy that 
the enantioselectivity obtained for the dialkyl product is greater or opposite to the ee of the 
aromatic product for more than half of the artificial metalloenzymes, reaching a ∆ee (difference in 
enantioselectivity) of up to 64% (Figure 13 and table 4, entries 1 and 2). This suggests that 
protein-substrate interactions, reminiscent of keto-reductases, are intimately involved in the 
enantioselection mechanism, as the classical C-H•••π interaction cannot be invoked for dialkyl 
substrate (12). In most of the experiments, the activated p-bromoacetophenone (11) affords much 
better conversions than the aliphatic substrate (12). The challenging dialkyl ketone gives 
comparable (R)-selectivity to the acetophenone derivative (11), albeit using different biotinylated 
catalyst ⊂ protein combinations (ee’s up to 83 % (R) for (11) and 82% (R) for (12) (see table 4, 
entries 3 and 4). In contrast, with some rare exceptions (Table 4, entry 5), only modest (S)-
selectivities are obtained with substrate (12) (see figure 14). 
 
Table 4 Selected results for the designed evolution of the reduction of ketones (11) and (12) in the 
presence of biotin-sepharose-immobilized artificial metalloenzymes [η6-(arene)Ru(Biot-p-L)Cl] ⊂ 
Sav mutant. Entry η6-(arene) Sav isoform Substrate Conv. (%) ee (%). 
Entry η6-(arene) Sav isoform Substrate Conv. (%) ee (%) 
1 benzene S112A-K121W  11 89 16 (R) 
2 benzene S112A-K121W  12 86 80 (R) 
3 p-cymene  L124V 11 90 83 (R) 
4 p-cymene  S112A-K121T  12 84 82 (R) 
5 benzene S112A-K121N  12 95 62 (S) 
6 p-cymene  S112A-K121N  12 81 58 (R) 
7 benzene S112A-K121N  11 99 55 (S) 
8 p-cymene  S112A-K121N  11 63 50 (R) 
9 p-cymene  S112A-K121F  12 96 73 (R) 
10 p-cymene  S112A-K121V  12 92 68 (R) 
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11 p-cymene  S112A-K121V  12 73 66 (R) 
12 benzene S112A-K121C  12 63 63 (S) 
13 benzene S112K-L124H  12 64 59 (S) 
14 benzene K121R 12 96 64 (S) 
 
3.6 Capping arene: p-cymene versus benzene 
In general the two substrates behave similary in enantioselectivity trends. It is interesting also to 
mention that good (R)-enantioselectivities are given by the p-cymene complex while (S)-
selectivities are obtained by the benzene even if less impressive, respecting the trend observed in 
previous studies.[22c] S112A-K121N illustrate at best the opposite enantioselectivity tendency. 
Interestingly, some deviations are apparent from the (S) trend given by the benzene complex and 
are most often observed with the position S112A. For example with: [η6-(benzene)Ru(Biot-p-L)Cl] 
⊂ S112A-K121W Sav with 80 (R). (Table 4, entry 2) 
 
3.7 Nature of the S112X residues: WT, S112A, S112K 
Some of the best (R)- and (S)-selectivities for both the aromatic and the aliphatic substrates are 
obtained with catalyst variants bearing the S112A mutation (Table 4, entries 4-5 and 9-12). 
Overall, the double mutants are less selective when incorporating S112K mutation, suggesting that 
a small side chain (alanine or serine) at position 112 may increase the influence of beneficial 
K121X or L124X mutations. The best S112K double mutant is [η6-(p-cymene)Ru(Biot-p-L)Cl] ⊂ 
S112K -124H Sav which affords 59% ee (S) for the reduction of substrate (12) (Table 4, entry 13). 
Thus, within this round of designed evolution, the S112K mutation can be regarded as an 
evolutionary dead-end. 
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Figure 14 Enantioselectivity trends of the immobilized artificial transfer hydrogenases. The results 
are arranged from the highest to the lowest ee value, according to: a) the nature of the capping 
arene: p-cymene or benzene b) the nature of the substrate c) the nature of the S112X residue: 
S112A, S112K and S112 d) the position of the site of mutation: K121X and L124X. 
3.8 Evalutation of homogeneous purified Sav Isoforms on representative substrates 
The best results using the immobilized hybrid catalysts were subsequently reproduced using the 
purified Sav mutant in a homogeneous phase. An increase in ee and conversion could be 
observed in almost all cases (Table 5, entries 1-7). An interesting behaviour could be seen in the 
case of some proteins bearing mutations in position 121, which afforded opposite 
enantioselectivities when the pure protein was used instead of the immobilized form. The most 
striking examples are the Sav mutants bearing the K121G mutation (Table 5, entries 8-9), which 
inverted the enantioselectivity in combination with [η6-(p-cymene)Ru(Biot-p-L)Cl]. It is tempting to 
speculate that the presence of the sepharose perturbed the spatial arrangement of the bulky [η6-
(p-cymene)Ru(Biot-p-L)Cl] within these mutants. 
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Table 5 Selected results for the optimization of the reduction of ketones (11) and (12) in the 
presence of immobilized- and purified artificial metalloenzymes [η6-(arene)Ru(Biot-p-L)Cl] Ì Sav 
mutant. 
Entry η6-(arene) Sav isoform substrate Immobilized Sav 
(from cell extract) 
Pure non-
immobilized Sav 
1 p-cymene   L124V 11 83 (90)  91 (96) 
2 benzene S112A-K121N  11 -55 (99) -75 (98) 
3 benzene S112K-L124H  11 -59 (64) -65 (94) 
4 benzene K121R 11 -64 (96) -68 (95) 
5 p-cymene  S112A-K121T  12 82 (84) 88 (99) 
6 benzene S112A-K121W  12 80 (86) 84 (99) 
7 benzene S112A-K121N 12 -62 (95) -72 (100) 
8 p-cymene  S112A-K121G 11 -43 (97) 38 (66) 
9 p-cymene  K121G 12 -31 (73) 23 (20) 
10 p-cymene  S112K-K121C 11 -11 (91) 41 (68) 
 
 
The reconstructed evolutionary path of the best (R)- and (S)-selective hybrid catalysts for the 
reduction of 4-phenyl-2-butanone (12) is depicted in figure 15. It is interesting to note that the most 
selective artificial enzymes identified for the dialkyl ketone substrate ([η6-(p-cymene)Ru(Biot-p-
L)Cl] ⊂ S112A-K121T Sav and ([η6-(benzene)Ru(Biot-p-L)Cl] ⊂ S112A-K121N Sav) are reached 
by an evolutionary path involving a combination of two poorly adapted mutations that would not 
normally be selected individually. Screening for enantioselectivity likely optimizes second 
coordination sphere interactions between substrate and protein, exerting an evolutionary pressure 
toward substrate specialization. 
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Figure 15 Reconstructed evolutionary path of the best (R)- and (S)-selective immobilized hybrid 
catalysts for the reduction of 4-phenyl-2-butanone (12).  
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4. Ketone reduction: conclusion 
In summary, identification of (R)- and (S)-selective artificial metalloenzymes by a chemogenetic 
optimization procedure and the information provided by the structural characterization of [η6-
(benzene)Ru(Biot-p-L)Cl] ⊂ S112K Sav has allowed us to implement a designed evolution 
protocol for the optimization of artificial transfer hydrogenases. The method is based on the 
combination between rational and combinatorial modifications, i.e. the mutation sites were 
identified from the X-ray structure and the most efficient residues were selected after screening of 
the enzyme variants obtained by saturation mutagenesis. A straightforward screening step, 
performed on crude cellular extracts, allowed the identification of [η6-(p-cymene)Ru(Biot-p-L)Cl] ⊂ 
S112A-K121T Sav for the enantioselective reduction of dialkyl ketones. While a single point 
mutation was sufficient to generate selective catalysts for the aromatic ketones (>90% ee), double 
mutants obtained by the designed evolution protocol were required to identify best hybrid catalysts 
for the reduction of dialkyl substrates. 
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5. Imine reduction: results and discussion 
5.1 Screening Strategy 
In our previous study on artificial metalloenzymes for the hydrogenation of ketones, it was 
established that chemical optimization brings more diversity than the genetic counterpart.[22c] To 
reduce the number of screening experiments, a representational search strategy was applied to 
optimize conversion and selectivity of the artificial metalloenzymes (see figure 16). In a first 
screening round, all 18 catalysts precursors were evaluated in combination with one streptavidin 
isoform (WT) (see table 6). For the second round, the most promising biotinylated catalysts were 
screened with 19 streptavidin isoforms derived from saturation mutagenesis at position S112 (see 
figure 17). Finally, the best catalyst ⊂ protein combinations (hybrid catalyst) were optimized with 
regard to reaction conditions (pH, Temp, Conc,...).  
Concept 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Schematic representation of the artificial metalloenzyme bearing a biotinylated d6 piano 
stool complex for the reduction of the salsolidine precursor. The host protein (streptavidin, black) 
displays a high affinity for the anchor (biotin, green); introduction of a spacer (blue) and variation of 
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the metal (red) and the ηn-bonded arene (orange) allows one to chemically optimize the activity 
and the selectivity of the catalyst. Saturation mutagenesis (magenta) allows genetic optimization of 
the host protein. 
5.2 Chemical diversity 
Chemical diversity is provided using three different biotinylated ligands (ortho, meta or para 
position of the biotin anchor), 5 different capping arenes and the metal (Ru, Rh, Ir). For the first 
optimization step, the catalysts precursors were screened in the presence of WT Sav. The results 
of the screening experiments are summarized in table 6 for each substrate-protein-ligand 
combination (experiments were performed in collaboration with Annette Mutschler and Karoline 
Kersten). 
Table 6 Complexes optimization for salsolidine production. 
 
Entry Complexes Loading (%) Protein Conversion (%) ee (%) 
1 [η5-(Cp*)Ir(Biot-o-L)Cl] 1 WT 21 31 (S) 
2 [η5-(Cp*)Rh(Biot-o-L)Cl] 1 WT 98 10 (S) 
3 [η6-(p-cymene)Ru(Biot-o-L)Cl] 1 WT 63 8 (S) 
4 [η6-(mesitylene)Ru(Biot-o-L)Cl] 1 WT 99 3 (S) 
5 [η6-(benzene)Ru(Biot-m-L)Cl] 1 WT 19 0 (R) 
6 [η6-(C6Me6)Ru(Biot-m-L)Cl] 1 WT 19 0 (R) 
7 [η5-(Cp*)Rh(Biot-m-L)Cl] 1 WT 61 2 (R) 
8 [η6-(benzene)Ru(Biot-o-L)Cl] 1 WT 29 3 (R) 
9 [η6-(C6Me6)Ru(Biot-o-L)Cl] 1 WT 29 3 (R) 
10 [η5-(Cp*)Ir(Biot-m-L)Cl] 1 WT 100 4 (R) 
11 [η6-(mesitylene)Ru(Biot-m-L)Cl] 1 WT 49 5 (R) 
12 [η6-(p-cymeme)Ru(Biot-m-L)Cl] 1 WT 53 11 (R) 
13 [η6-(mesitylene)Ru(Biot-p-L)Cl] 1 WT 76 12 (R) 
14 [η6-(cymene)Ru(Biot-p-L)Cl] 1 WT 81 18 (R) 
15 [η6-(benzene)Ru(Biot-p-L)Cl] 1 WT 30 23 (R) 
16 [η6-(C6Me6)Ru(Biot-p-L)Cl] 1 WT 77 36 (R) 
17 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 WT 98 36 (R) 
18 [η5-(Cp*)Rh(Biot-p-L)Cl] 1 WT 97 69 (R) 
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Catalysis conditions: [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ Sav (0.69 mM) , Sodium formate (3.65 M) , MOPS 
(1.46 M ), pHinitial = 7.25, Salsolidine precusor (69 mM), 55°C, 5 h. 
 
Of a library of 18 complexes tested, it appeared that the orientation of the spacer and the capping 
arene played an important role in both the conversion and enantioselectivity (Table 6). 
Futhermore, iridium and rhodium in conjugation with Cp* gave the best enantioselectivities ((R) 
and (S), (table 6, entries 1 and 18) with the Biot-p-L ligand (R) respectively the Biot-o-L (S). 
5.3 Genetic diversity 
Improvements of the ee and conversion for the reduction of salsolidine precursor were achieved. 
Table 7 summarizes the best catalytic results obtained for 19 Sav variants at position S112X 
(S112P not included due difficult production of the protein). The best ee in favor of the (R)-
enantiomer was obtained with S112A allowing 85% (R) ee and complete conversion (Table 7, 
entry 1 and figure 17). This mutant was therefore selected for further investigations. In contrast, 
the best ee in favor of the (S)-enantiomer was obtained with S112K affording 57% (S) ee and 83% 
conversion (Table 7, entry 19) 
 
Table 7 Catalysis optimization through saturation mutagenesis at the S112 position 
 
Entry Complexes Loading (%) Protein Conversion (%) ee (%) 
1 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A Sav 100 85 (R) 
2 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112G Sav 100 60 (R) 
3 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 WT Sav 100 57 (R) 
4 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112Y Sav 100 50 (R) 
5 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112T Sav 15 46 (R) 
6 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112F Sav 100 37 (R) 
7 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112D Sav 100 29 (R) 
8 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112C Sav 75 20 (R) 
9 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112N Sav 87 19 (R) 
10 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112V Sav 100 19 (R) 
11 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112L Sav 91 15 (R) 
12 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112H Sav 13 9 (R) 
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13 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112W Sav 100 7 (R) 
14 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112E Sav 80 5 (R) 
15 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112I Sav 75 5 (S) 
16 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112Q Sav 47 16 (S) 
17 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112R Sav 100 19 (S) 
18 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112M Sav 26 19 (S) 
19 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112K Sav 83 57 (S) 
 
Catalysis conditions: [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ Sav (0.69 mM, metal complex) , Sodium formate 
(3.65 M) , MOPS (1.46 M ), pHinitial = 7.25, Salsolidine precursor (69 mM), 55 °C, 1 h. 
 
 
 
 
 
 
ee (%) 
 
 
 
 
 
 
 
Figure 17 Enantiomeric excess and conversion as a function of the Sav isoform used in catalysis. 
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Referring to table 7, the only clear trend that can be observed is the following: 
 
- The small hydrophobic residues gave the best enantioselectivities and conversions towards 
the (R)-product and in particular the [η5-(Cp*)Ir(Biot-p-L)Cl ⊂ S112A] (Table 7, entry 1). 
Assuming that the ligand is the most important factor in determining ee, then a small (or 
absent) side-chain may allow best placement of the metal, without steric hindrance. 
- Aromatic residues gave good enantioselectivities and good conversion highlighted by the 
[η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ S112Y (Table 7, entry 4). 
- Negatively charged residues gave poor enantioselectivities but excellent conversions. 
(Table 7, entry 7 and 14) 
- Positively charged aminoacids gave the best enantioselectivities and conversion in favor of 
the (S)-product. In particular the [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ S112K (Table 7, entry 19).  
 
5.4 Loading optimisation 
In order to study the catalyst performance, the loading of the catalyst was varied by increasing the 
concentration of the salsolidine precursor. This allowed determining the TON of the artificial 
metalloenzyme at a fixed concentration (0.69 mM) of the catalyst precursor. Despite loss of 
enantioselectivity at lower loadings, the complex showed an excellent activity up to 1000 turnovers 
(Table 8, entry 5).  
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Table 8 Loading optimization. 
Entry Complexes Loading
(%) 
Protein Temp. 
(°C) 
Time 
(h) 
Conversion 
(%) 
ee 
1 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 25 5 100 92 (R) 
2 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 55 1 100 83 (R) 
3 [η5-(Cp*)Ir(Biot-p-L)Cl] 0.10 S112A 25 6 63 92 (R) 
4 [η5-(Cp*)Ir(Biot-p-L)Cl] 0.10 S112A 25 26 99 91 (R) 
5 [η5-(Cp*)Ir(Biot-p-L)Cl] 0.10 S112A 55 120 100 82 (R) 
 
Catalysis conditions: [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ Sav (0.69 mM, metal complex), formate (3.65 M), 
MOPS (1.46 M), pHinitial = 7.25, Salsolidine precursor (69 mM, 1% loading), (690 mM, 0.1 % 
loading), (6900 mM, 0.01% loading), 25 °C. 
5.5 Temperature optimisation 
As shown previously (Table 8, entries 1 and 2), temperature played a major role in the outcome of 
the catalysis. In order to determine the best ee, the catalysis temperature was decreased from 
55°C to 0°C. 
Table 9 Temperature optimization using the S112A mutant. 
 
Entry Complexes Loading 
(%) 
Protein Temp. 
(°C) 
Time 
(h) 
Conversion 
(%) 
ee 
1 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 55 1 100 85 (R) 
2 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 25 5 90 87 (R) 
3 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 25 1 100 89 (R) 
4 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 4 5 100 92 (R) 
5 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 0 5 42 93 (R) 
 
Catalysis conditions: [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ Sav (0.69 mM, metal complex) , Sodium formate 
(3.65 M) , MOPS (1.46 M ), pHinitial = 7.25, Salsolidine precursor (69 mM). 
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The enantioselectivity increased from 85 % (R) up to 93 % (R) going from 55 °C to 0 °C thus 
demonstrating that temperature has a significant influence on the enantioselectivity of the reaction 
(Table 9, entries 4 and 5). 
5.6 Michaelis-Menten kinetics 
In order to assess the kinetic behaviour of imine reduction, Michaelis-Menten saturation kinetics 
was measured and the substrate concentration versus initial rate was plotted.(see figure 18). 
 
Table 10 Kinetic parameters. 
 
Entry  kcat 
 (h-1) 
Km 
(mM) 
Vmax  
(mM h-1) 
kcat/Km  
(h-1mM) 
1 [η5-(Cp*)Ir(Biot-p-L)Cl] 64.2 0.18 15.6  356  
2 [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ 
S112A 138.2 0.47 40.8 
294 
 
 
a)         b) 
 
 
 
 
 
 
 
 
 
Figure 18 Saturation kinetics plot for the ATH catalyzed by [Cp*Ir(Biot-p-L)Cl] (square) and 
[Cp*Ir(Biot-p-L)Cl] ⊂ S112A Sav (triangles). The solid lines correspond to the Michaelis-Menten fit 
using the KM and kcat displayed above a) simplified model to rationalize the correlation between KM 
and kcat b) 
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The imine reduction using the [η5-(Cp*)Ir(Biot-p-L)Cl] anchored to S112A streptavidin showed a 
kcat of 138.2 h-1 (see table 10). This is 2.71 times faster than the free complex (kcat = 64.2 h-1). The 
KM of the artificial metalloenzyme (KM = 0.47 mM) is higher than that for the complex alone (KM = 
0.18 mM). This correlation may be rationalized by assuming that the decrease in affinity raises the 
energy of the enzyme·substrate intermediate, which in turn leads to a decrease in the activation 
barrier, (see figure 18 b). Compared to other artificial metalloenzymes formed using biotin-
streptavidin technology, this system is the fastest and the most efficient to date (see table 11). 
 
Table 11 Michaelis-Menten comparison of the imine reductase with a hydrogenase. 
 
Entry System  kcat 
 (h-1) 
KM 
(mM) 
Vmax  
(mM h-1) 
kcat/Km  
(h-1 mM) 
Ref. 
1 Imine reductase Complex alone 64.2
 0.18 15.6 356 This work 
2 Imine reductase 
Complex ⊂ 
protein 138.2
 0.47 40.8 294 This work 
3 Hydrogenase Complex alone 180 7.38 10.38 24.39 Ref.[37] 
4 Hydrogenase Complex ⊂ protein 269 3.18 15.24 84.59 
Ref.[37] 
 
5.7 Immobilisation of the catalyst 
 
In order to immobilize the artificial enzymes two approaches were used. The first is immobilization 
via iminobiotin-sepharose previously developped for transfer hydrogenation reactions of 
ketones[22c], giving the opportunity to use cell extracts containing streptavidin isoforms.  
The second approach was to use cross linked streptavidin. Glutaraldehyde, polyethylene imine 
(PEI) or activated dextrans were used as cross linking-agents. The resulting cross-linked enzyme 
aggregates called CLEAs (see figure 19) were developed by Sheldon et al.[36] This allowed 
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formation of insoluble protein polymers in catalytic conditions but that conserved the binding 
properties for B4F (Biotin-4-fluoresceine) and therefore for the biotinylated complex. Table 12 
summarizes the catalytic results obtained with CLEAs in same experimental conditions as those 
used for the non-immobilized catalysts. 
 
 
Figure 19 Schematic representation of the CLEAs formation with cross-linker agents. 
 
Table 12 Selected results for transfer hydrogenation of imines using CLEA immobilized artificial 
metalloenzymes. 
Entry Complexes Loading 
(%) 
Protein Conversion 
(%) 
ee 
1 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A Cleas Glu 87 49 (R) 
2 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A Cleas PEI 100 18 (R) 
3 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A Cleas Dex 72 43 (R) 
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4 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 Wt Cleas Glu 93 39 (R) 
5 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 Wt Cleas PEI 97 22 (R) 
6 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 Wt Cleas Dex 72 34 (R) 
7 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A immobilized 74 14 (R) 
8 [η5-(Cp*)Ir(Biot-p-L)Cl] 1 S112A 100 93 (R) 
 
Catalysis conditions: [η5-(cp*)Ir(Biot-p-L)Cl] ⊂ Sav (0.69 mM, metal complex) , Sodium formate 
(3.65 M) , MOPS (1.46 M ), pHinitial=7.25, Salsolidine precursor (69 mM), 25 °C, 5 h. Glu = 
Glutaraldehyde, PEI = Polyethylene imines, Dex = Dextrans, Immobilised = immobilized with 
biotin-sepharose. 
 
From the table 12, it appeared that the best system for immobilization of S112A is based on 
glutaraldehyde as a cross-linker agent (Table 12, entry 1). However, the ee is lower than for the 
non-immobilized enzyme (Table 12 entry 8). Polyethylene imine cross-linkers were, in contrast, 
less efficient (Table 12, entry.2). Furthermore, immobilized streptavidin on iminobiotin sepharose 
was least efficient (Table 12, entry 7). 
5.8 CLEAs gels 
To determine the size and the binding capacity of the CLEAs, SDS-PAGE analysis were 
performed. The SDS-page in figure 20 shows the migration of the cross-linked streptavidin. S112A 
Sav cross-linked with glutaraldehyde didn’t migrate through the stacking gel. This may be due to 
the size of the CLEAs or to the low solubility of the polymer. The same trend was observed with 
the PEI cross-linker. In contrast, the S112A isoform cross-linked with activated dextrans 
demonstrates migration abilities into the SDS-page. This could be explained by lower cross-linking, 
allowing migration throught the acrylamide gel. Moreover, the gel shows a plethora of bands 
suggesting different populations of polymers with different sizes. In this context, it is interesting to 
mention that the polymer formed with activated dextrans is more a gel-like than an insoluble 
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precipitate as in the case of S112A Sav cross-linked with glutaraldehyde. The same trend was 
observed with the WT streptavidin except that the PEI cross-linked streptavidin presented similar 
pattern of bands as for the activated dextrans with S112A. Finally, the ability to detect the CLEAs 
using B4F showed that the polymer binds this modified biotin and suggest that biotinylated 
complexes do bind to the polymer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 SDS-page of the Cross-linked Streptavidin with Glutaraldehyde, PEI or Dex 
5.9 Crystal structure of the [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂  S112A 
 
In order to get insight into artificial transfer hydrogenase, efforts were invested to crystallize the 
most promising combination for the reduction of imines which consist of the [η5-(Cp*)Ir(Biot-p-
L)Cl] ⊂ S112A (see figure 21). Crystals of the [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ S112A were obtained 
(Crystal structure determined by Tillmann Heinisch in collaboration with Prof. Tilman Schirmer, 
Biozentrum). The refined structure (1.9 Å resolution) allowed the identification of the environment 
of surrounding the active site of the artificial metalloenzyme. The occupancy of the [η5-
(Cp*)Ir(Biot-p-L)Cl] into streptavidin S112A Sav isoform was of 50% with soaking methods 
compared to the [η6-(benzene)Ru(Biot-p-L)Cl] into S112K Sav isoform (20% occupancy, 1.58 Å 
W
t S
av
W
t S
av
 G
lu
W
t S
av
 PE
I
W
t S
av
 D
ex
S1
12
A 
Sa
v
S1
12
A 
Sa
v G
lu
S1
12
A 
Sa
v P
EI
S1
12
A 
Sa
v D
ex
Cleas 
Cleas 
W
t S
av
W
t S
av
 G
lu
W
t S
av
 PE
I
W
t S
av
 D
ex
S1
12
A 
Sa
v
S1
12
A 
Sa
v G
lu
S1
12
A 
Sa
v P
EI
S1
12
A 
Sa
v D
ex
La
dd
er
B4F gel Coomassie blue gel
Ketone and Imine reduction 
Chapter 3 
     
136 
resolution, PDB code 2QCB) with cocrystallization. Comparing the structure of the [η5-(Cp*)Ir(Biot-
p-L)Cl] ⊂ S112A with [η6-(benzene)Ru(Biot-p-L)Cl] ⊂ S112K[22c] allows some interesting 
observations: The absolute configuration of the metal in the biotinylated complex is conserved in 
the two structures and is (S). The spatial organization markedly differs, a rotation of 150° around 
the S-N axes allows superimposition of the two different complexes. In this context, the position of 
the [η6-(benzene)Ru(Biot-p-L)Cl] ⊂ S112K it not really perturbed by the mutation. In contrary, the 
position 121 is close to the [η6-(benzene)Ru(Biot-p-L)Cl] ⊂ S112K while not to the [η5-
(Cp*)Ir(Biot-p-L)Cl] ⊂ S112A. It demonstrates that positions 112, 121 and 124 are closest one to 
the metal center, depending on the nature of the complex, each one would have their own effect 
on the position of the metal center in the protein. Furthermore, the position of the sulfonamide is 
not changed for each complexes suggesting that only a rotation around the S-N bond is required to 
adapt the position of the complexes into the protein. 
 
Ketone and Imine reduction 
Chapter 3 
     
137 
 
 
Figure 21 Crystal structure of the [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ S112A. Figure of two adjacent 
monomers of streptavidin bearing each one an [η5-(cp*)Ir(Biot-p-L)Cl] a) View of one complex 
bound to streptavidin with close lying residues highlighted (A is for the monomer A, B is for the 
monomer B) b) 
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Superposition of two crystal structures, the first one for ketone reduction bearing an [η5-
(benzene)Ru(Biot-p-L)Cl] ⊂ S112K and the second one bearing a [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ 
S112A c) Close-up view of the two superimposed structures with close lying aminoacids d) 
6. Imine reduction: mechanistic discussion 
Comparison of Noyori’s Ru(II) Ts-DPEN catalyst with [η5-(Cp*)Ir(Biot-p-L)Cl] biotinylated complex 
(see figure 22), suggests that the chirality at the metal in the protein may be determinant for the 
enantioselection mechanism. For both the Ru(II) Ts-DPEN and the biotinylated piano stool with the 
same configuration at the metal, the chirality of the product should be maintained if C-H•••π 
interactions occur (see figure 22). 
 
By extension, for the reduction of imines, the (R)-product should be produced with a six-membered 
transition state via a C-H•••π interactions. In fact, for the imine reduction with Noyori’s system, the 
opposite enantiomer is produced suggesting that another mechanism is involved (see 
introduction).[11d] This contrast with (η5-(Cp*)Ir(Biot-p-L)Cl ⊂ S112A which generates the (R)-
product both for ketone and imine reduction. 
 
The crystal structure depicted in the previous paragraph demonstrated that only one of the two 
enantiomers (the S one) of the biotinylated complex (bearing a chloride) is preferred by the protein 
during the crystallization process. In this context, it is speculated that Sav selects one of the two 
enantiomers of the complex. If the chloride is replaced by a hydride to generate the active catalyst, 
it would mean that the preferred active complex is (R). In this situation the substrate can be 
presented in four different orientations (see figure 22) to the metal generating four different 
possible mechanisms for the reduction. Two of them are non-concerted mechanisms and two of 
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them are non C-H•••π mechanisms (Figure 22). Since the (R) product is generated with the 
S112A hybrid catalyst (η5-(Cp*)Ir(Biot-p-L)Cl ⊂ S112A) it could be could argued that only two 
mechanisms are possible. The first one is a mechanism with a C-H•••π interaction but non-
concerted and the second one is a non C-H•••π mechanism but concerted. It is interesting to 
mention that these possibilities are in agreement with the alternative mechanism proposed by Wills 
for the imine reduction by Ru(II) Ts-DPEN. 
 
 
Figure 22 Four different possible transition states for ketone and imine reduction. 
 
The replacement of the S112A with S112K affords the (S) product. It suggest a concerted 
mechanism with C-H•••π interaction or a non-concerted without C-H•••π interactions (see figure 
22). 
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7. Imine reduction: conclusion 
In conclusion, the first highly efficient artificial metalloenzyme, based on biotin-avidin technology, 
for the ATH of cyclic imines (salsolidine) in water was created. The conjugation of the biotinylated 
catalyst with streptavidin showed an acceleration of the reaction when compared to the free 
complex, as well as Michaelis-Menten kinetics, thus efficiently mimicking natural enzymes. 
Positional scanning[22b] was highly efficient for the improvement of artificial imine reductases 
reaching ee up to 93% with 100% conversion. A new protocol for the immobilization of these 
artificial metalloenzymes, based on the formation of streptavidin polymers called CLEAs (cross-
linked enzymes aggregates) was implemented and suggested the potential for future practical 
applications. Finally, the crystal structure of this new imine reductase and its comparison with a 
ketone reductase provided valuable insights on catalytic results and on possible mechanisms for 
ATH of cyclic imines. 
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8. Experimental part 
8.1 Ketone reduction 
8.1.1 Catalysis : standard conditions 
All experiments were carried out using standard Schlenk techniques, with thoroughly degassed 
solutions (nitrogen-flushed). 
8.1.2 Description of the catalytic runs 
Boric Acid - Sodium Formate Mixture. Boric acid (2.10 g, 34 mmol) and sodium formate (2.72 g, 40 
mmol) were dissolved in water (40 ml). The pH was adjusted to 6.25 with NaOH pellets and the 
solution was thoroughly degassed. The concentration of the final stock-solution was: [B(OH)3] = 
0.85M, [HCOONa] = 1M. 
d-Biotin – Sepharose : The beads of biotin – sepharose (2350 µl wet beads; Affiland, Belgium) 
were washed with water and then resuspended in water in a total volume of 4000 µl. The binding 
capacity of the beads was 40 mg of avidin per ml of wet beads. 
General Procedure for the Transfer Hydrogenation with Immobilized Protein. To a solution of cell 
extract containing the streptavidin (0.15 µmol) was added the suspension of biotin – sepharose 
(215 µl containing 125 µl wet beads; the solution contained a two-fold excess of protein with 
respect to the beads). The resulting suspension was vigorously stirred at room temperature for 60 
min. The beads containing the immobilized protein (0.075 µmol) were centrifuged in 1.5 ml 
eppendorf tubes and washed three times with 400 µl of a 1M guanidinium chloride solution and 
one time with 400 µl of water, then resuspended in degassed water in a total volume of 750 µl. The 
suspension was thoroughly degassed (nitrogen flushed). The degassed immobilized protein (337 
µl suspension, 0.0337 µmol) was mixed in an eppendorf tube with the precursor complex [η6-
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(arene)RuCl(Biot–p-L)] (4.27 µL of a 0.0395 M stock-solution in DMF, 0.169 µmol Ru) and shaked 
at room temperature for 10 min. The beads were centrifuged in 1.5 ml eppendorf tubes, washed 
three times with 200 µL boric acid - formate mixture, one time with 200 µL water and then 
resuspended in degassed water in a total volume of 340 µL. The boric acid - formate mixture (405 
µl) and the MOPS buffer (135 µL of a 1M stock-solution, pH adjusted to 6.25) were added. The 
resulting suspension was divided in two different test tubes (400 µL per test tube, containing 0.015 
µmol protein, 0.045 µmol Ru, 180 µmol HCOONa) and the corresponding substrate (para-
bromoacetophenone (11) or 4- phenyl-2-butanone (12), 4.5 µmol) was added to each tube. 
The test tubes were placed in a magnetically-stirred multireactor, purged several times with 
nitrogen and heated at 55°C for 64 hours. After completion, the reaction mixture was extracted 
with Et2O (4 ×  0.5 mL) and dried over Na2SO4. The organic solution was filtered through a short 
silicagel plug that was thoroughly washed with Et2O, concentrated and subjected to HPLC 
analysis. 
Catalysis with purified protein: The lyophilized streptavidin was dissolved in mQ (100 µM solution). 
The solution was thoroughly degassed (nitrogen flushed). The degassed protein (150 µL solution, 
0.015 µmol) was mixed in a test tube with the precursor complex [η6-(arene)RuCl(Biot–p-L)] (1.27 
µL of a 0.0395 M stock- solution in DMF, 0.05 µmol Ru) and stirred at room temperature for 10 
min. The boric acid - formate mixture (200 µL) and the MOPS buffer (67 µL of a 1M stock-solution, 
pH adjusted to 6.25) were added and the corresponding substrate was added to each tube. The 
test tubes were placed in a magnetically stirred multireactor, purged several times with nitrogen 
and heated at 55 °C for 64 hours. After completion, the reaction mixture was extracted with Et2O (4 
× 0.5 mL) and dried over Na2SO4. The organic solution was filtered through a short silicagel plug 
that was thoroughly washed with Et2O, concentrated and subjected to HPLC analysis. 
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8.1.3 HPLC analysis 
Table 13 HPLC conditions, retention times and absolut configurations for the reduction products.a 
 
Alcohol Column Conditions t1 t2 Detection 
 
OD-H 
Hexane / i-PrOH 95 / 5 
flow 0.7 mL / min 
17.8 
(R) 
22.7 
(S) 
215 nm 
 
OD-H 
Hexane / i-PrOH 95 / 5 
flow 0.7 mL / min 
11.6 
(S) 
12.9 
(R) 
225 nm 
 
(S,S)-ULMO 
Hexane / DME 100 / 1.5 
Flow 1 mL / min 
16.6 
(R) 
19.5 
(S) 
215 nm 
 
OD-H 
Hexane / i-PrOH 95 / 5 
Flow 0.7 mL / min 
13.9b 
(R) 
20.6b 
(S) 
215 nm 
 
a The absolute configuration was assigned by comparison with published results. 
b The absolute configuration was asseigned by comparison with enantiopure sample. 
8.2 Imine reduction 
8.2.1 Catalysis: standard conditions 
All experiments were carried out using standard Schlenk techniques, with thoroughly degassed 
solutions (nitrogen-flushed). 
OH
Br
OH
OH
OH
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8.2.2 Preparation of stock solutions 
Formate, 4.0 M / MOPS, 1.6 M: 3.4 g of sodium formate and 4.20 g of MOPS were dissolved in 
12.5 mL of Milli-Q water and the pH was adjusted to 7.25, using solid NaOH. Metal complex, 
0.0395 M: [η6-(arene)Ru(Biot-p-L)Cl] resp. [η5-(Cp*)M(Biot-p-L)Cl] were dissolved in degassed 
DMF and kept under nitrogen at 4°C prior to use. Substrate, 1.0 M: 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline was dissolved in degassed Milli-Q water. 
8.2.3 General Procedure for Asymmetric Transfer Hydrogenation (ATH) 
Streptavidin was directly weighed into the reaction tubes*, (0.206 mM tetramer concentration) 
having been calculated 1.2 equivalents of as binding sites with respect to the quantity of metal 
complex used in catalysis. The tubes were carefully flushed with nitrogen and 200 µL of degassed 
formate/MOPS stock solution was added. The mixture was stirred for 5-10 min until the protein 
was completely dissolved. 3.8 µL of precursor complex stock solution was added and again the 
reaction mixture was stirred for 10 min. Finally, 15 µL of substrate stock solution was added. The 
test tube was placed in a magnetically stirred multireactor, purged several times with nitrogen and 
heated to the appropriated temperature and time. *Alternatively, the appropriate quantity of 
Streptavidin was dissolved in formate/MOPS stock solution and degassed. Both methods 
produced the same results. 
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Table 14 Conditions used per reaction tube. 
 
Entry Stock 
solution 
Concentration of stock 
[M] 
Volume applied 
[µL] 
Concentration in assay 
[mM] 
1 HCOONa 4.0 3650 
2 MOPS 1.6 200 1460 
3 Streptavidin - - 0.206 (tetrameric) 
4 Metal 
complex 0.0395 3.8 0.69 
5 Substrate 1 15 69 
 
For higher catalyst loadings, the concentration of the catalyst was kept constant and substrate 
concentration was increased 10 times (0.1%) and 100 times for (0.01%). To test the effect of 
Lanthanum triflate (La(OTf)3), a 1 to 1 mixture of the substrate with the salt was prepared in 
degassed water before adding it to the reaction. Preparation of complexes and immobilization of 
the protein was set up according to literature descriptions.[22b, 22c, 37] 
8.2.4 Sample workup 
After completion, 500 µL of Milli-Q water was added to the reaction mixture, and the pH was 
adjusted to approximatively 12, adding a 20 % NaOH solution. The reaction mixture was extracted 
with 4 x 1 mL of CH2Cl2, dried over Na2SO4, concentrated and subjected to HPLC analysis. 
8.2.5 Analytical data 
The conversion and the ee of the reduction products were determined by chiral HPLC, using a 
Chiracel OD-H column (5 µm, 250 x 4.6 mm, Daicel Chemical Industries, Tokyo). A 
hexane/isopropanol/diethylamine (90/10/0.1) mixture was used as eluent with a flow of 1mL / min. 
The retention times for the amines and the imine are (UV-detection at 280 nm): 
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(R)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, t = 15.8 min  
(S)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, t = 13.6 min 
6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline, t = 9.2 min 
 
The absolute configurations of the enantiomers were assigned by comparison with the commercial 
reference substance (S)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline. To determine the 
conversion, a response factor was determined, taking into account the different UV responses for 
the imine and the amine. Therefore, 2.30 mg of commercial 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline imine substrate (solution 1) and 2.20 mg of commercial (S)-6,7-dimethoxy-1-
methyl-1,2,3,4-tetrahydroisoquinoline ((S)-Salsolidine, solution 2) were dissolved in 3 mL of 
CH2Cl2 each. Different molar ratios of imine and amine were prepared and subjected to HPLC 
analysis. The ratio of the peak areas imine/amine was plotted against the molar ratio imine/amine. 
The slope of the regression line indicated the response factor. 
Table 15 Conditions used per reaction tube 
 
Entry Solution 1 [µL] Solution 2 [µL] 
1 900 100 
2 700 300 
3 500 500 
4 300 700 
5 100 900 
 
Linear regression of the points gave the following equation: 
   
 
where    
 
A1 = HPLC area of the substrate 
A2 = HPLC area of the product (R+S enantiomer) 
S/P = substrate/product (corrected conversion) 
! 
A1
A2
= 3.6 SP
! 
S
P =
A2 " 3.6
A1
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8.2.4 Michaelis Menten experiments[37] 
Michaelis-Menten experiments were performed using the same catalysis procedure described 
above. Substrate concentration was varied keeping constant the complex concentration (0.69 
mM). The conversion was determined after 20 minutes of reaction using HPLC as described 
previously. 
 
Table 16 Conditions used per reaction tube. 
 
Entry Substrate concentration [mM] Ratio substrate/complex 
1 4.31 6.25 
2 8.62 12.5 
3 17.25 25 
4 34.50 50 
5 69 100 
6 138 200 
7 276 400 
8 552 800 
9 1104 1600 
10 2208 3200 
 
The observed initial rate is described as: 
 
Calculated from the Michaelis-Menten equation: 
 
 
The fitting of the conversions obtained with a Michaelis-Menten equation was done using a fitting 
program: GraphPad Prism version 5.02 for Windows, GraphPad Software, San Diego California 
USA, www.graphpad.com. 
The following kinetic parameters were obtained: 
! 
" =
substrate[ ]0 • conversion( )
t
! 
" =
Vmax S[ ]
Km + S[ ]
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Table 17 Kinetic parameters for artificial imine reductase. 
 
Michaelis-Menten [η5-(Cp*)Ir(Biot-p-L)Cl] [η5-(Cp*)Ir(Biot-p-L)Cl] ⊂ S112A 
Best-fit values   
Vmax 0.1814 0.4720 
Km 64.22 138.2 
Std. Error   
Vmax 0.007429 0.02177 
Km 11.05 23.24 
95% Confidence Intervals   
Vmax 0.1643 to 0.1985 0.4218 to 0.5222 
Km 38.73 to 89.70 84.63 to 191.8 
Goodness of Fit   
Degrees of Freedom 8 8 
R² 0.9759 0.9811 
Absolute Sum of Squares 0.0009774 0.005085 
Sy.x 0.01105 0.02521 
Constraints   
Km Km > 0.0 Km > 0.0 
Number of points   
Analyzed 10 10 
 
kcat values were are calculated using the following equation: 
 
Entry System kcat 
1 [η5-(Cp*)M(Biot-p-L)Cl] 15.6 h-1  
2 [η5-(Cp*)M(Biot-p-L)Cl] ⊂ S112A 40.8 h-1 
 
! 
Vmax = kcat • E[ ]0
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8.1.5 Gels 
Analysis of the Sav proteins polymers (CLEAs) was performed by SDS-PAGE prepared as follows: 
 
Table 18 Preparation of the SDS-Page. 
 
Entry SDS loading gel (12%) SDS stacking gel (5%) 
1 5 mL of dd H2O 3.4 mL of dd H2O 
2 6 mL of 30% acrylamide 1 mL of 30% acrylamide 
3 3.8 mL of Tris pH=8.8 1.5 mL of Tris pH=6.8 
4 75 µL of 20% SDS 30 µL of 20% SDS 
5 100 µL of 15% APS 40 µL of 15% APS 
6 6 µL of TEMED 6 µL of TEMED 
 
Samples were loaded on a gel as follows: 
 
Entry Protein 
1 BenchMark Ladder (Invitrogen) 
2 S112A (2 µL) 
3 S11A Glu CLEAs 
4 S11A PEI CLEAs 
5 S11A Dex CLEAs 
6 Wt 
7 Wt Glu CLEAs 
8 Wt PEI CLEAs 
9 Wt Dex CLEAs 
Each sample contains a 6X loading buffer (6 µL) and biotin-4-fluorescein (2 µL) to reveal the Sav 
protein on the gel. Gels were analysed using a Biorad camera system. 
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8.2.6 Cleas[38] 
 
To form CLEAs, the following protocol is used : 
1) 100 mg of Sav S112A and Sav Wt are dissolved in 3 ml of H2O mQ 
2) 7 ml of dimethoxyethane are added until precipitation 
3) The reaction tubes are stirred on ice 
4) Polyethylene imine (PEI) (250 µL of a solution 25%), glutaraldehyde (250 µL of a solution 
25%) or activated dextrans (250 µL of a solution 25%) are added to the solutions at 4°C. 
5) NaBH4 was added to the reaction at rt and stirred 1h (2 fold excess compared to the 
concentration of cross-linker) 
6) The reactions are stirred 16h 
7)  Insoluble polymers are centrifuged and lyophilized 
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«La grandeur des actions humaines se mesure à l'inspiration qui les fait naître» 
 
        Louis Pasteur 
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Chapter 4: General conclusion and perspectives 
Natural enzymes are divided in six different classes according to the chemical transformation they 
catalyze (see figure 1). By extension artificial metalloenzymes were extensively studied in order to 
mimick and understand these chemical transformations classes found in natural enzymes. In the 
six classes, no example of artificial metallohydrolases based on supramolecular anchoring was 
described in litterature.  
 
 
 
 
 
 
 
 
 
Figure 1 Six enzymes classes’ 
This thesis focused on two different classes of artificial metalloenzymes: phosphate transferases 
(hydrolases, EC 3) and transfer hydrogenases (oxidoreductases, EC 1). 
 
The first part of the chapter presented the first example of a selective artificial hydrolase (EC 3) 
based on biotin-streptavidin. The introduction of biotinylated Ce(IV) complexes afforded an artificial 
metallohydrolase. The substrate of choice was a chiral phosphodiester mimicking RNA. The 
chemogenetic optimisation allowed to identify the best hybrid catalysts for the transformation thus 
1. OxIdoreductases
5. Isomerases 3. Hydrolases
2. Transferases6. Ligases
Enzymes
4. Lyases
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mimicking alkaline phosphatase or purple acid phosphatase. The second coordination sphere 
arround the artificial metalloenzyme allowed improvements of the activity and selectivity. Hence, 
the high throughput screening methods based on colorimetric assays have proven their efficiency 
for the identification of best hybrid catalysts. 
 
The second part of this thesis dealed with artificial transfer hydrogenases (EC 1). The best (R) and 
(S)-selective streptavidin-based artificial transfer hydrogenases were described in our laboratory 
for the enantioselective reduction of acetophenone derivatives. The X-ray structure of the best (S)-
selective hybrid catalyst was the starting point of a directed evolution protocol that allowed to 
futher optimize the reduction of dialkylketones (see figure 2). The choice of the chemical fragment 
in the fisrt screening round have proven efficiency to ameliorate the activity and the selectivity 
towards challenging substrates. Several interactions are involved in the enantioselection 
mechanism. Rounds of mutagenesis at selected positions allowed fine-tuning the environnement 
around the organometallic catalyst to improve interactions with the substrate. These specialized 
enzymes were obtained with a modest screening effort and based on a protein immobilisation 
protocol performed on cellular crude extracts. The concept of artificial transfer hydrogenase was 
extended to the reduction of cyclic imines using saturation mutagenesis at position 112. Some 
variants of the produced library of artificial metalloenzymes showed high activity and selectivity 
toward the reduction of a salsolidine precursor. The crystal structure of the first artificial imine 
reductase allowed speculations on the mechanism of both reduction of aryl ketones and cyclic 
imines. 
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Figure 2 Designed evolution protocol 
 
Artificial metalloenzymes enzymes currently suffer from low activity (few turnovers) and high cost 
of production. The challenge remains in the developpement of highly active hybrid catalysts. 
Therefore, the efficient optimisation of artificial metalloenzymes needs a robust high troughput 
screening method e.g. based on colorimetric assays. For the moment, the hybrid catalysts are 
produced with pure protein or immobilized proteins. The challenge therefore remains in the 
identification of a robust system that can be evolved on cellular crude extracts. This would 
accelerate the process of “designed evolution” and would therefore allow a quick identification of 
highly active and selective hybrid catalysts for a given reaction opening new routes for the effective 
synthesis of enantiopure chemicals. 
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Annex 
Part 1: Artificial phospholipases 
9.1 Introduction 
The interest in new phospholipids and phospholipid analogs stems from their potential use as 
biodegradable surfactants, carriers of drugs or genes or as biologically active compounds in 
medicine and agriculture. However, the synthesis of these substances is difficult by chemical 
means since control of regio- and stereoselectivity must be ensured.[1] 
Four types of phospholipases (A,B,C,D) which hydrolyze phospholipids with different 
regioselectivities, have been identified.[1] The cleavage sites for phosphatidyl choline are depicted 
in figure 1. The physiological role of phospholipases is believed to be the degradation of 
phospholipid components of cell membranes and the digestion of phospholipid-containing fats in 
food. They ensure regulation of membrane vesicule trafficking, cytosqueletal reorganisation, cell 
proliferation and survival signalling.[2] Dysfunctions of phospholipases are known to generate 
inflammations and phagocytosis, diabetes, neuronal and cardiac stimulation, oncogenesis and 
metastasis.[2-3] 
 
 
PLA = Phospholipase A (A1 + A2) 
PLC = Phospholipase C 
PLD = Phospholipase D 
 
 
P OO
O O
NMe3
O
O
O
R1
O
PLC PLD
PLA2
PLA1
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Figure 1 Reaction site of each class of phospholipases. Phospholipase B is a combinaition  of 
both PLA1 and PLA2 activities. 
Most of the time, insoluble phospholipids form bilayers, micelles or liposomes in water[4] (see figure 
2). Natural enzymes have adapted the environment of the active site to favour interactions of the 
amino acids around the catalytic center with the charged part of the phospholipids.[3] It leads to 
close contact between the enzyme and the substrate favouring the reaction.[5] 
 
 
 
 
 
 
 
 
 
 
Figure 2 Three possible layouts of phospholipids 
 
Classical phospholipase D (PLD) is a phosphodiesterase that catalyzes the hydrolysis of 
phosphatidylcholine, the most abundant membrane phospholipid, to form the free base (choline) 
and phosphatidic acid. Of the four classes, phospholipase D is the only phosphodiesterase that 
catalyzes the hydrolysis of a non-water miscible to substrate to generate a phospholipid and an 
alcohol. Futhermore, phospholipase D is the most commonly used phospholipase in organic 
syntheses. Hydrolysis with PLD leads to phosphatidic acids, but in the presence of suitable 
alcohols, e.g. ethanolamine, glycerol, serine, PLD also catalyzes an efficient head group 
exchange. These reactions are usually performed in a biphasic mixture in order to ensure high 
enzymatic activity.[1] 
liposome micelle bilayer sheet
Annex 
 
     
161 
 
Phosphodiesterases activities of natural enzymes are widely discussed in literature and many 
examples cite purple acid phosphatase and alkaline phosphatase for the hydrolysis of 
phosphodiesters.[6] Trying to mimic these enzymes has also been investigated with a large variety 
of artificial systems containing an active site bearing Lewis acids (Mg(II), Mn(II), Ce(IV), Zn(II), 
Cu(II), Fe(III)).[7] However, all of these systems use a soluble substrate. To our knowledge, no 
artificial phospholipases for non-miscible substrates has been described in literature to date. 
 
Based on the biotin-streptavidin technology previously reported by Whitesides et al.[8], artificial 
phospholipases are presented herein. The idea was to incorporate the catalyst inside a pocket 
using supramolecular anchoring via the biotin-(strept)avidin couple. Increasing kinetic parameters 
of the catalyst and generation of enantioselective discrimination towards non-miscible to water 
substrates was expected. The biotinylated complex of choice was a dinuclear cerium based 
catalyst described by Que et al.[9] The catalyst is known to have a good hydrolytic acceleration rate 
towards the substrate bisnitrophenylphosphate (BNPP) and is also capable of cleaving double 
stranded DNA (ds-DNA).[10] 
 
Previous reports in our group showed that incorporation of biotinylated complexes into streptavidin 
leads to active and enantioselective artificial metalloenzymes for various reactions.[11] Both 
chemical diversity of the ligand scaffold and genetic diversity, for fine tuning, were exploited with 
success.[11e] 
 
Annex 
 
     
162 
Herein, it is shown that artificial phospholipases (see figure 3) based on biotin-streptavidin 
technology can be chemo-genetically optimized to improve characteristics such as selectivity and 
conversion towards phospholipids. 
9.2 Results and discussion 
To generate diversity, both chemical and genetic optimization strategies were combined. 
Combining m streptavidin isoforms with n biotinylated catalyst precursors yields a two-dimensional 
diversity matrix of n‚m combinations. A screening method was established in 96 well plates by 
following the nitrophenolate absorbance at 405 nm (hydrolysis of the substrate). A total of six 
complexes were formed in situ in the plate by mixing the ligand dissolved in HEPES, 100 mM 
pH=8 and cerium ammonium nitrate (CAN). After 15 minutes of incubation at 37 °C, streptavidin 
isoforms (8 per plate) in HEPES buffer solution were directly added in separate wells to the 
complexes and incubated for 15 minutes at 37 °C to form the hybrid catalyst. Both enantiomers of 
the substrate were added prior reading in the spectrometer (37 °C). A total of 276 possibilities 
were screened. After 3 h reaction, a workup protocol was established in order to dissolve the 
suspensions. DMSO was added to each well and mixed. Plates were centrifuged at 4400 rpm 
during 10 minutes and a carbonate buffer at pH = 9 was added to enhance the intensity of the 
yellow colour. The conversion was determined by measuring the absorbance at 405 nm. Previous 
work showed that 3 positions in loop 7,8 of streptavidin S112, K121, L124 were close to the 
biotinylated complex and that these may influence both conversion and enantioselectivity of the 
catalyst.  
Based on these observations, representative mutations at these three positions were selected 
including: aromatic, polar, non-polar and charged amino acids residues. The conversions were 
determined after 3 hours (end-point assay). 
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Concept 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Schematic representation of the artificial phospholipase based on the biotin-streptavidin 
technology. The anionic substrate forms micelles in water which interact with the cationic artificial 
metalloenzyme 
Substrate
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Sav monomer
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Biotin
Spacer
Artificial
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9.2.1 Substrates 
 
Three amphiphylic substrates were synthesised in enantiopure form according to the literature. All 
of the substrates were insoluble in water thus forming micelles (see figure 4). 
 
 
 
Figure 4  Synthesis of enantiopure phosphodiesters. 
7.2.2 Genetic Diversity 
 
The mutant library presented in chapter 2 for HPNP hydrolysis was used for this study. 
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9.2.3 Chemical Diversity 
 
A total of three biotinylated cerium complexes; {(Biot-HXTA)Ce2}3+ , {(Biot-2-IDA)Ce}2+ , {(Biot-3-
IDA)Ce}2+, were prepared in situ by reaction of the appropriate ligand dissolved in HEPES buffer 
(100 mM, pH=8) with cerium ammonium nitrate (CAN). For the first optimization step, the three 
catalysts precursors were screened in the presence of WT Sav. The substrate was dissolved in 
acetonitrile and added to the reaction wells prior to reading. The results of the conversion (TON) 
are summarized using a fingerprint display for each substrate-protein-ligand combination. The 
conversion is color-coded from white (no conversion) to red (best conversion). The display shows 
the best combination of complex/mutant/substrate under the screening conditions (see figure 5) 
Interesting features are apparent from figure 5: 
Turnover number (see figure 5): 
 
i) The dinuclear cerium complexes presented a higher hydrolytic activity against 
the phosphodiester substrates compared to the mononuclear complexes, especially 
for substrate 1 and 2. 
ii) Of all the mutants tested, only mutations at positions K121R & K121N 
increased the TON, while mutations at positions 112 and 124 showed almost no 
improvement. 
 
Of all the complexes used, {(Biot-HXTA)Ce2}3+ gave the best conversions for the hydrolysis of the 
substrate probably due to the cooperativity between the two metals. It is especially true for 
substrate (1) that presents a non-aromatic side chain. The increased activity observed for this 
substrate, in combination with S112R or S112N (Table.1, entry 1 and 2) could be due to a higher 
accessibility of the substrate to the active site.  
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Enantioselectivity (see figure 6): 
i) Both chemical and genetic diversity can lead to an increase in the 
enantioselectivity. 
ii) The IDA ligand gaves better estimated E values than the HXTA scaffold. 
iii) The best estimated E values of the catalytic runs is 13.15 for {(Biot-2-
IDA)Ce}2+ ⊂ 112F. 
iv) Most of the mutants that lead to enantioselectivity are aromatic or negatively 
charged amino acid. 
 
{(Biot-2-IDA)Ce}2+ and {(Biot-HXTA)Ce2}3+ were more efficient at discriminating enantiomers of 
substrate 1 (see table.2). Aromatic residues with the mentioned complexes improve 
enantiodiscrimination. In addition, some of the mutants with the same complex yielded the 
opposite enantiomer for the hydrolysis and best examples are given for substrate 3 (Table 2, entry 
1 compared 10). Interestingly, aromatic residues gave best enantiodiscriminations while best 
activities were obtained with non-aromatic substrates.  
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Figure 5 Mapping of the TON (turnover number) of the catalyst for phosphodiester hydrolysis of 
substrate 1, 2 and 3 after 3 h of reaction. The R and S substrates were tested with Sav mutants 
without complexes to establish the background reaction. The background reaction was subtracted 
to the catalytic runs performed with the artificial metalloenzymes. 
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Table 1: Selected best TON of the screening 
 
Entry Complex Substrate Enantiomer Mutant TON 
1 {(Biot-HXTA)Ce2}3+  1 S K121R 2.09 
2 {(Biot-HXTA)Ce2}3+  1 S K121N 1.84 
3 {(Biot-HXTA)Ce2}3+  1 S V47G 1.37 
4 {(Biot-HXTA)Ce2}3+  1 S K121G 1.24 
5 {(Biot-HXTA)Ce2}3+  1 S P64G 1.22 
6 {(Biot-HXTA)Ce2}3+  2 S S112R 1.14 
7 {(Biot-HXTA)Ce2}3+  1 S L124Y 1.13 
8 {(Biot-HXTA)Ce2}3+  1 R L124A 1.1 
9 {(Biot-HXTA)Ce2}3+  1 S L124G 1.06 
10 {(Biot-HXTA)Ce2}3+  2 R S112A 0.89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Chart of the estimated E for phosphodiester hydrolysis of substrate (1), (2) and (3) after 3 
h reaction time. The background reactions were substracted from the data obtained with artificial 
metalloenzymes. 
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Table 2: Selected best estimated E values from the screening 
 
Entry Complex Mutant Substrate estimated E 
value 
1 {(Biot-2-IDA)Ce}2+ S112D 3 16.5 
2 {(Biot-2-IDA)Ce}2+ S112F 3 13.2 
3 {(Biot-HXTA)Ce2}3+  S112D 2 9.3 
4 {(Biot-HXTA)Ce2}3+  Wt 2 8.6 
5 {(Biot-2-IDA)Ce}2+ K121F 1 7.8 
6 {(Biot-2-IDA)Ce}2+ L124F 2 6.7 
7 {(Biot-2-IDA)Ce}2+ L124Y 2 5.3 
8 {(Biot-2-IDA)Ce}2+ V47G 3 5.0 
9 {(Biot-2-IDA)Ce}2+ S112E 3 -4.2 
10 {(Biot-2-IDA)Ce}2+ K121A 3 -7.2 
 
9.2.4 Substrate-protein interactions 
 
In order to determine if streptavidin interacts with the substrate, immobilization experiments of the 
protein on the substrate were performed (see figure 7). The substrate was added to water to form 
micelles and a solution of streptavidin was added on it. The biphasic mixture was shaken for 30 
minutes and the reaction centrifuged to separate the precipitate from the supernatant. The pellet 
and supernatant were loaded into a 12% SDS-PAGE gel to determine whether the protein 
interacts strongly with the micelles formed by the substrate. (B4F was added to reveal the 
presence of streptavidin) 
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Pellet: 
                               1   2    3    4    5    6 
 
 
 
 
 
 
 
 
1 = S112K pellet with (R)-4-nitrophenyl (4-phenylbutan-2-yl) hydrogen phosphate 
2 = S112K pellet with (S)-4-nitrophenyl (4-phenylbutan-2-yl) hydrogen phosphate 
3 = S112K pellet with (R)-4-nitrophenyl (2-phenylpropyl) hydrogen phosphate 
4 = S112K pellet with (S)-4-nitrophenyl (2-phenylpropyl) hydrogen phosphate 
5 = positive control with Wt 
6 = positive control with S112K 
 
Supernatant : 
                              1     2      3     4     5    6 
 
 
 
 
 
 
 
 
1 = S112K pellet with (R)-4-nitrophenyl (4-phenylbutan-2-yl) hydrogen phosphate 
2 = S112K pellet with (S)-4-nitrophenyl (4-phenylbutan-2-yl) hydrogen phosphate 
3 = S112K pellet with (R)-4-nitrophenyl (2-phenylpropyl) hydrogen phosphate 
4 = S112k pellet with (S)-4-nitrophenyl (2-phenylpropyl) hydrogen phosphate 
5 = positive control with Wt 
6 = positive control with S112K 
 
 
Figure 7 Immobilization of streptavidin on different substrates forming micelles indicating that 
streptavidin strongly interacts with the anionic substrate. 
Annex 
 
     
171 
 
In nature, phospholipases adhere to the substrate to react with the substrate. SDS-PAGE shows 
that streptavidin interacts with the micelles and mimics the phospholipases binding to the insoluble 
substrate. When complexes are added to streptavidin, the global positive charge of the 
metalloenzyme increases further which could give rise to Coulomb interactions with the phosphate 
moiety of the phospholipidic substrate. In this context, ionic interaction of the catalyst directly with 
the substrate significantly increases the effective molarity. 
9.3 Conclusion 
The screening of the 207 metal ⊂ protein combinations using a 96 well plate format allowed to 
chemo-genetically optimize a heterogeneous hydrolytic reaction. The position and nature of the 
mutations around the catalyst-binding pocket were crucial for the optimization of the artificial 
phospholipase and to enantioselectivity. As in the active site of natural enzymes, tuning the 
environment of the catalyst improved the overall kinetic characteristics of the system. Furthermore, 
interactions of the streptavidin with the insoluble substrates allowed its “immobilization” of an 
artificial enzyme on substrates. 
Part 2: Artificial restriction enzymes 
9.4 Introduction 
{(Biot-HXTA)Ce2}3+ has been reported in literature to cleave phosphosdiesters such as the model 
substrate BNPP (2).[9] In the first part of the research, efforts were devoted to phosphodiester 
hydrolysis to create artificial phosphodiesterase. A model substrate for RNA (HPNP, 1) was used 
to investigate the kinetic properties of the hybrid catalyst.[10] One of the major challenges in this 
field is to create highly active and selective artificial phosphodiesterases in order to create artificial 
restriction enzymes for medical applications such as cancer therapeutics.[7] Such artificial catalysts 
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may be able to recognize a specific DNA or RNA target and cleave it. Both DNA and RNA can be 
found in a single strand form[12] and are a potential target for artificial restriction enzymes. 
Designing an active site of such an enzyme is particularly challenging and many artificial catalysts 
have been tailored to improve their activity by chemical means.[13] Streptavidin presents the 
advantage to offer both a defined active site in the vicinity of the anchored complex and an 
enormous potential for amino acid shuffling as a protein.  
 
Tailoring the active site is of interest to improve specific interactions of the complex to the 
substrate. It would be a first step towards the development of a new generation of artificial 
phosphatases for gene silencing, cancer treatments or new biotechnological applications.[13b] 
9.5 Results and discussion 
In order to investigate the cleavage of single stranded DNA, a biotinylated single stranded DNA, 
containing six nucleotides (poly A) was designed, and a fluorescent tag (FAM) added. The 
biotinylated substrate was added to WT streptavidin. The presence of a biotin anchor ensured its 
localization within streptavidin.  
Thanks to the dimer of dimer nature of Sav with close lying biotin binding sites, it was anticipated 
that, in the presence of both Biot-AAAAAA-FAM and {(Biot-HXTA)Ce2}3+, the polyA substrate may 
be bought in close proximity to the biotinylated Lewis acid. This could thus improve the hydrolytic 
efficiency, to liberate FAM which could be detected by fluorescence (see figure 8). 
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General concept of a artificial restriction pseudoenzyme 
 
 
 
 
Figure 8 A biotinylated single stranded DNA, composed of 6 adenosines bases and bearing at the 
end an FAM, was designed. This substrate was anchored into WT streptavidin. Upon addition of 
{(Biot-HXTA)Ce2}3+, cleavage occurs and liberates the FAM moiety. 
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Figure 9 Cleavage of the Biot-AAAAAA-FAM with {(Biot-HXTA)Ce2}3+ in the presence of WT 
streptavidin. 
 
1) Gel 1 (see figure 9) demonstrates that Sav binds to the biotinylated nucleotide. Futhermore 
cleavage occured with {(Biot-HXTA)Ce2}3+ and with {(HXTA)Ce2}3+ (spiking of the substrate with 
Wt Sav after 3h) but not with CAN alone, it demonstrated that a dinuclear complex is necessary for 
cleavage.  
 
2) Gel 2 (see figure 9) demonstrates that Sav Wt prevents the cleavage of the biotinylated 
nucleotide from {(HXTA)Ce2}3+ but not for {(Biot-HXTA)Ce2}3+ . Avidin, which is positively charged 
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at pH = 8 and adheres to DNA, shows the same activity for the cleavage of biotinylated single 
stranded DNA.  
 
3) Gel 3 (see figure 9) demonstrates that the reaction occurs quickly, within 30 min. 
 
Only close contact between the catalytic center and the single stranded DNA leads to cleavage: no 
cleavage occurs with CAN or with {(HXTA)Ce2}3+, it demonstrates that the biotinylated DNA is 
protected against hydrolysis by streptavidin. With {(Biot-HXTA)Ce2}3+, cleavage occurs due to the 
close proximity of the metal center to single stranded DNA. It permits the hydrolysis of the 
polynucleotide with high efficiency thus liberating the fluorophore. 
9.6 Conclusion 
A new method for selective single stranded DNA cleavage has been developed with a pseudo 
artificial metalloenzyme. The active site of the artificial metalloenzyme can be modulated in order 
to provide specific interactions and cleavage of the substrate. 
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